
<html lang="en"     class="pb-page"  data-request-id="878588cd-704e-4ab1-81f3-86aa4df6185e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.7b00174;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-10;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists" /></meta><meta name="dc.Creator" content="Andreas  Evers" /></meta><meta name="dc.Creator" content="Torsten  Haack" /></meta><meta name="dc.Creator" content="Martin  Lorenz" /></meta><meta name="dc.Creator" content="Martin  Bossart" /></meta><meta name="dc.Creator" content="Ralf  Elvert" /></meta><meta name="dc.Creator" content="Bernd  Henkel" /></meta><meta name="dc.Creator" content="Siegfried  Stengelin" /></meta><meta name="dc.Creator" content="Michael  Kurz" /></meta><meta name="dc.Creator" content="Maike  Glien" /></meta><meta name="dc.Creator" content="Angela  Dudda" /></meta><meta name="dc.Creator" content="Katrin  Lorenz" /></meta><meta name="dc.Creator" content="Dieter  Kadereit" /></meta><meta name="dc.Creator" content="Michael  Wagner" /></meta><meta name="dc.Description" content="Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel..." /></meta><meta name="Description" content="Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 5, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00174" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00174" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00174" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00174" /></link>
        
    
    

<title>Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00174" /></meta><meta property="og:title" content="Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0011.jpeg" /></meta><meta property="og:description" content="Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure–activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chemical and physical stability." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00174"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00174">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00174&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00174&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00174&amp;href=/doi/10.1021/acs.jmedchem.7b00174" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4293-4303</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00182" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00247" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.7b00887"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Evers">Andreas Evers</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-4643-1941" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Torsten++Haack">Torsten Haack</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Lorenz">Martin Lorenz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Bossart">Martin Bossart</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ralf++Elvert">Ralf Elvert</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bernd++Henkel">Bernd Henkel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Siegfried++Stengelin">Siegfried Stengelin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Kurz">Michael Kurz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maike++Glien">Maike Glien</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Dudda">Angela Dudda</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katrin++Lorenz">Katrin Lorenz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dieter++Kadereit">Dieter Kadereit</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Wagner">Michael Wagner</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building G838, D-65926 Frankfurt am Main, Germany</span></div><div class="corresp-info"><strong>*</strong>A.E.: phone, +49 305 12636; e-mail, <a href="/cdn-cgi/l/email-protection#3e7f505a4c5b5f4d107b485b4c4d7e4d5f50515857105d5153"><span class="__cf_email__" data-cfemail="9adbf4fee8fffbe9b4dfecffe8e9dae9fbf4f5fcf3b4f9f5f7">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>M.W.: phone, +49 305 46875; e-mail, <a href="/cdn-cgi/l/email-protection#0845616b60696d64265f696f666d7a487b6966676e61266b6765"><span class="__cf_email__" data-cfemail="c38eaaa0aba2a6afed94a2a4ada6b183b0a2adaca5aaeda0acae">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00174&amp;href=/doi/10.1021%2Facs.jmedchem.7b00174" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4293–4303</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 27, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 February 2017</li><li><span class="item_label"><b>Published</b> online</span>5 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 May 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00174" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00174</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4293%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndreas%2BEvers%252C%2BTorsten%2BHaack%252C%2BMartin%2BLorenz%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D10%26contentID%3Dacs.jmedchem.7b00174%26title%3DDesign%2Bof%2BNovel%2BExendin-Based%2BDual%2BGlucagon-like%2BPeptide%2B1%2B%2528GLP-1%2529%252FGlucagon%2BReceptor%2BAgonists%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4303%26publicationDate%3DMay%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00174"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2873</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">60</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00174" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Evers&quot;},{&quot;first_name&quot;:&quot;Torsten&quot;,&quot;last_name&quot;:&quot;Haack&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Lorenz&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Bossart&quot;},{&quot;first_name&quot;:&quot;Ralf&quot;,&quot;last_name&quot;:&quot;Elvert&quot;},{&quot;first_name&quot;:&quot;Bernd&quot;,&quot;last_name&quot;:&quot;Henkel&quot;},{&quot;first_name&quot;:&quot;Siegfried&quot;,&quot;last_name&quot;:&quot;Stengelin&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Kurz&quot;},{&quot;first_name&quot;:&quot;Maike&quot;,&quot;last_name&quot;:&quot;Glien&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Dudda&quot;},{&quot;first_name&quot;:&quot;Katrin&quot;,&quot;last_name&quot;:&quot;Lorenz&quot;},{&quot;first_name&quot;:&quot;Dieter&quot;,&quot;last_name&quot;:&quot;Kadereit&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Wagner&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4293-4303&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00174&quot;},&quot;abstract&quot;:&quot;Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure–activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00174&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00174" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00174&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00174" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00174&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00174" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00174&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00174&amp;href=/doi/10.1021/acs.jmedchem.7b00174" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00174" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00174" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00174%26sid%3Dliteratum%253Aachs%26pmid%3D28448133%26genre%3Darticle%26aulast%3DEvers%26date%3D2017%26atitle%3DDesign%2Bof%2BNovel%2BExendin-Based%2BDual%2BGlucagon-like%2BPeptide%2B1%2B%2528GLP-1%2529%252FGlucagon%2BReceptor%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D10%26spage%3D4293%26epage%3D4303%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/jmcmar.2017.60.issue-10/20170525/jmcmar.2017.60.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure–activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chemical and physical stability.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The dramatic rise of the twin epidemics, type 2 diabetes and obesity collectively referred to as “diabesity”, is associated with increased mortality and morbidity worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> On the basis of this global development, there is clinical need for antidiabetic therapies with accompanied weight reduction. Already a modest reduction in body weight (∼4–5 kg) is an effective means of managing diabesity, resulting in highly beneficial effects on glycemic control as well as reduced morbidity and mortality.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> From the approved antidiabetic therapies, sodium–glucose co-transporter 2 inhibitors (SGLT2-I) and the injectable glucagon-like peptide-1 (GLP-1) receptor agonists are the only classes of agents that are associated with such a modest weight reduction. Physiological effects of the gastrointestinal hormone GLP-1 are improvement of glycemic control as well as a reduction in appetite and food intake. The body weight reduction which can be achieved with synthetic GLP-1 analogs is in the range of 3–6%. A high dose variant of liraglutide (3 mg) was approved in 2014 for the treatment of obese adults with weight related health conditions. In that target population liraglutide has shown a body weight reduction of 5–6% over 56 weeks in late stage clinical trials.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a></div><div class="NLM_p">Beyond the currently approved GLP-1 receptor agonists, the next generation of peptidic agonists could combine the activity of GLP-1 and additional gastrointestinal hormones in one molecule, leading to superior therapeutic benefits. For example, the native gastrointestinal hormone oxyntomodulin (OXM), a 37 amino acid peptide (comprising the entire 29 amino acid sequence from glucagon plus a C-terminal extension of 8 residues) secreted by intestinal L-cells (together with GLP-1 and PYY) following meal ingestion, is such an endogenous dual agonist for the GLP-1 and glucagon receptor. Its activity is weaker for the GLP-1 and glucagon receptors when compared to the cognate native ligands GLP-1 and glucagon (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Amino Acid Sequences of Glucagon, Oxyntomodulin (OXM), Exendin-4, Native GLP-1, and Liraglutide and Respective Activities (and SEM Values) at the GLP-1 Receptor and Glucagon Receptor (GCGR) As Measured in a cAMP Assay Overexpressing HEK-293 Cell Lines<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0007.gif" alt="" id="GRAPHIC-d7e249-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>Table a</sup><p class="last">In all cases, three replicates were measured. Amino acids, which are identical among glucagon/oxyntomodulin and exendin-4, are colored green. Residues unique to glucagon/oxyntomodulin are shown in yellow. Residues unique to exendin-4 are colored gray. Residues unique to GLP-1 are white, and further modifications are shown in orange. Residue 20 in liraglutide is modified by addition of a C16 fatty acid (palmitic acid) at the ε-amino group of lysine using a γ-glutamic acid spacer.</p></div></div><div></div></div><div class="NLM_p">Glucagon is an insulin counter-regulatory hormone secreted by the α-cells of the pancreas that raises blood glucose levels by stimulating gluconeogenesis and glycogenolysis, thus circumventing a hypoglycemic state. More recent data in rodents and humans reveal that glucagon could have beneficial effects on energy balance, body fat mass, and nutrient intake, although the first observation that glucagon reduces food intake was already made 50 years ago.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These effects seem to be mediated at least in part by FGF21-dependent pathways, a protein acting at the level of the brain, liver, and adipose tissue to reduce body weight.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> In overweight and obese people the endogenous dual GLP-1/glucagon agonist oxyntomodulin was shown to significantly reduce body weight by ∼1.7 kg vs placebo following 3 times daily subcutaneous administration (to compensate for the short half-life of the native peptide) after 4 weeks.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Furthermore, oxyntomodulin was mechanistically proven to reduce food intake after an ad libitum test meal and increase energy expenditure in humans.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therapeutic utility of natural gastrointestinal hormones like GLP-1, glucagon, or oxyntomodulin is limited by its rapid degradation by serum proteases, predominantly dipeptidyl peptidase IV (DPPIV) but also other enzymes such as neutral endopeptidase (NEP), plasma kallikrein, or plasmin.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Therefore, such native peptides have a very short half-life of a few minutes following intravenous administration. One strategy to stabilize peptides against DPPIV cleavage is to exchange amino acid sequences which are prone to enzymatic degradation. Another approach for peptide stabilization is chemical modification, e.g., by conjugation to a fatty acid side chain or cholesterol derivatives for reversible binding to plasma albumin or to large hydrophilic polymers such as polyethylene glycol (PEG) to reduce renal clearance.</div><div class="NLM_p">Such dual GLP-1/glucagon receptor agonists that are additionally stabilized by chemical modifications have been described, for example, by Pocai et al.,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Flatt et al.,<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13-16)</a> Day et al.,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and most recently by Henderson et al. (MedImmune).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">For example, Lys(yE-C16)<sup>10</sup>Glu<sup>12</sup>Glu<sup>17</sup>Arg<sup>20</sup>Ala<sup>24</sup>Glu<sup>27</sup>Ala<sup>28</sup>Gly<sup>29</sup>Gly<sup>30</sup>-glucagon (MEDI0382)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> is a once-daily administered glucagon analog with dual GLP-1 and glucagon receptor activity, which is modified with a fatty acid side chain in position 10. It is currently evaluated in a phase 1/2 study in patients with type 2 diabetes mellitus (T2DM). Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 38,39-diether with <span class="smallcaps smallerCapital">l</span>-histidyl-2-methylalanyl-<span class="smallcaps smallerCapital">l</span>-glutaminylglycyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-phenylalanyl-<span class="smallcaps smallerCapital">l</span>-threonyl-<span class="smallcaps smallerCapital">l</span>-seryl-<span class="smallcaps smallerCapital">l</span>-α-aspartyl-<span class="smallcaps smallerCapital">l</span>-tyrosyl-<span class="smallcaps smallerCapital">l</span>-seryl-<span class="smallcaps smallerCapital">l</span>-lysyl-<span class="smallcaps smallerCapital">l</span>-tyrosyl-<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-α-aspartyl-<span class="smallcaps smallerCapital">l</span>-seryl-<span class="smallcaps smallerCapital">l</span>-lysyl-<span class="smallcaps smallerCapital">l</span>-lysyl-<span class="smallcaps smallerCapital">l</span>-alanyl-<span class="smallcaps smallerCapital">l</span>-glutaminyl-<span class="smallcaps smallerCapital">l</span>-α-glutamyl-<span class="smallcaps smallerCapital">l</span>-phenylalanyl-<span class="smallcaps smallerCapital">l</span>-valyl-<span class="smallcaps smallerCapital">l</span>-glutaminyl-<span class="smallcaps smallerCapital">l</span>-tryptophyl-<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-asparaginyl-2-methylalanylglycyl-<span class="smallcaps smallerCapital">l</span>-arginyl-<span class="smallcaps smallerCapital">l</span>-asparaginyl-<span class="smallcaps smallerCapital">l</span>-arginyl-<span class="smallcaps smallerCapital">l</span>-asparaginyl-<span class="smallcaps smallerCapital">l</span>-asparaginyl-<span class="smallcaps smallerCapital">l</span>-isoleucyl-<span class="smallcaps smallerCapital">l</span>-alanyl-<i>S</i>-(1-(3-((3-hydroxypropyl)amino)-3-oxopropyl)-2,5-dioxo-3-pyrrolidinyl)-<span class="smallcaps smallerCapital">l</span>-cysteinyl-<i>S</i>-(1-(3-((3-hydroxypropyl)amino)-3-oxopropyl)-2,5-dioxo-3-pyrrolidinyl)-<span class="smallcaps smallerCapital">l</span>-cysteinamide (pegapamodutide)<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> from Transition Therapeutics, which is a PEGylated dual agonist for once-weekly dosing, is another dual agonist that has been evaluated in phase 2 studies in patients with T2DM. An extensive review that includes dual GLP-1/glucagon agonists in discovery, preclinical validation, and first clinical examination has recently been published by Tschöp et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Exendin-4 is a 39 amino acid peptide that is produced by the salivary glands of the Gila monster (<i>Heloderma suspectrum</i>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Exendin-4 is an activator of the GLP-1 receptor; however it does not activate the glucagon receptor (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Clinical and nonclinical studies have shown that exendin-4 has several beneficial antidiabetic properties including an increase in β cell mass and markers of β cell function, a glucose dependent enhancement in insulin synthesis and secretion, glucose dependent suppression of glucagon secretion, slowing of gastric emptying, thereby reducing postprandial glucose absorption, and reduced food intake resulting in a reduction in body weight.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> Exenatide BID, a synthetic version of exendin-4, represents the first GLP-1 receptor agonist approved in 2005 (at the time by Amylin/Eli Lilly, now marketed by AstraZeneca) as antidiabetic therapy for the treatment of T2DM. It has a terminal half-life of ∼2.4 h after subcutaneous administration and is applied twice daily (10 μg).</div><div class="NLM_p">In contrast, liraglutide developed by Novo Nordisk is a marketed chemically modified GLP-1 analog. In position 20, a fatty acid is linked to a lysine leading to a half-life of 13 h in humans following subcutaneous injection via oligomerization and reversible albumin binding, suitable for once-daily administration (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div><div class="NLM_p">Compared to GLP-1, glucagon, and oxyntomodulin, exendin-4 has improved physicochemical properties, such as solubility and stability in both solution and under physiological conditions: the Leu21-Ser39 span of exendin-4 forms a compact tertiary fold (termed as tryptophan cage or Trp cage), which is one of the smallest protein folds.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The Trp cage shields the side chain of Trp25 from solvent exposure and enhances helicity and stability of the peptide by intramolecular interactions (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> DiMarchi and co-workers have shown that C-terminal addition of the exendin-4 tail, e.g., residues 31–39, to the glucagon sequence resulted in an analogue with significantly improved solubility and chemical stability compared to glucagon itself, probably by shielding hydrophobic and chemically labile surface motifs of the glucagon C-terminus.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 3D structures of exendin-4 (derived from a NMR structure in solution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>), glucagon (derived from an X-ray structure, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1gcn">1gcn</a>), and binding hypotheses for these peptides to the extracellular domain (ECD) of the GLP-1 receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>) and glucagon receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>). The color coding of peptide residues is equivalent to the sequence color coding outlined in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Residue Trp25, which is exposed to the solvent in glucagon and shielded from the solvent by the Trp cage motif in exendin-4, is shown in spacefill representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, exendin-4 shows an enhanced metabolic stability compared to GLP-1, glucagon, and oxyntomodulin. This improved stability is partially due to the introduction of a Gly residue at position 2, which renders it resistant to DPPIV mediated degradation. In addition, due to the formation of the Trp cage, exendin-4 shows an increased helicity<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> that might also prevent structural unwinding and enzymatic digestion by other proteases. Indeed, it was shown that the C-terminal exendin-4 extension, which is responsible for the formation of the Trp cage, provides additional metabolic stability and prolonged in vivo potency.<a onclick="showRef(event, 'ref14 ref32'); return false;" href="javascript:void(0);" class="ref ref14 ref32">(14, 32)</a> Finally, it was shown that exendin-4 forms specific oligomers in solution<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> that increase particle size and might, thus reducing renal clearance.</div><div class="NLM_p">Due to these favorable properties, we considered exendin-4 as an attractive scaffold for the development of exendin-4 analogues with dual activities for the GLP-1 and glucagon receptor. Many of the so far described GLP-1/glucagon agonists are based on the glucagon or oxyntomodulin structure, resulting in a considerable challenge to optimize and tune the structural and physicochemical properties. Although glucagon and oxyntomodulin already show considerable activity at the GLP-1 and glucagon receptor, exendin-4 is a highly selective GLP-1 receptor agonist (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p last">Here, we report our efforts to identify such novel dual agonistic peptides, aiming to introduce significant activity at the glucagon receptor into exendin-4 while preserving its favorable structure-stabilizing and solubility-enhancing fold. Relevant pharmacophoric features for dual activity were identified by sequence and structure-based comparison of exendin-4 and glucagon and their interactions with the extracellular domains of the respective receptors (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). On the basis of this analysis, sequence stretches from glucagon were systematically introduced into exendin-4 to obtain a potent dual agonist. Additional chemical modifications resulted in a further improved metabolic stability. Structural analysis of the most promising peptide by NMR spectroscopy revealed that (in agreement with the design rationales) the resulting peptide indeed shows an exendin-like fold. This peptide was then pharmacologically assessed in rodent models of diabetes and obesity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structural Analysis of Peptides and Binding Hypotheses to the GLP-1 and Glucagon Receptor</h3><div class="NLM_p">The GLP-1 and glucagon receptors both belong to the class B G-protein-coupled receptors (GPCRs), sharing 47% sequence identity and adopting a similar fold. At the time of peptide design and synthesis, X-ray structures were available only for the extracellular domain (ECD) of the GLP-1 receptor (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3iol">3iol</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c5t">3c5t</a>).<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> Therefore, a structural hypothesis for the ECD of the glucagon receptor was generated by homology modeling. Consistent with a recently published crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> a high structural similarity to the ECD of the GLP-1 receptor is observed (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Structural data for the peptides were obtained from solution-state NMR of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and X-ray data of glucagon (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1gcn">1gcn</a>)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> or exendin(9–39) in the receptor-bound conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Binding models of exendin-4 and glucagon to their respective receptors were generated after 3D alignment of the receptor structures and subsequent structure-based alignments of the peptides to receptor-bound exendin(9–39), followed by energy minimization of receptor–peptide complexes. The resulting 3D alignments were then analyzed. Although exendin-4 and glucagon share only 13 identical residues, they show similar helical conformations in the receptor-bound state and establish several similar key interactions to their target receptors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Interestingly, several differences were found in the structural regions of the GLP-1 receptor and glucagon receptor that interact with residues 15–21 from exendin-4 and glucagon, respectively. The C-terminal exendin-4 tail, which is responsible for the formation of the Trp cage, does not establish relevant interactions with the receptors, suggesting that this motif does not significantly impact activation of the glucagon receptor. In contrast, it is well-known that the interaction of the N-terminal part of the peptides with the transmembrane domains of the receptors is essential for receptor activity. However, at the time of design and synthesis, structural data about the full-length sequences or the transmembrane domain of the receptors were not available. In the meantime, an X-ray structure of the transmembrane domain and a structural model for full-length glucagon receptor have been published.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A peptide binding hypothesis in this full-length model of the glucagon receptor is provided below.</div><div class="NLM_p last">In summary, structure- and sequence-based analysis suggests that transfer of N-terminal and “central” sequence stretches of glucagon into exendin-4 might result in exendin-4 analogues with dual GLP-1/glucagon receptor activity.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Peptide Design and Optimization</h3><div class="NLM_p">As outlined above, peptide sequences were designed by sequence- and structure-based analysis. Following synthesis of these peptides, their potency on the GLP-1 and glucagon receptors was tested in a cAMP assay in receptor overexpressing HEK-293 cells.</div><div class="NLM_p">In the first optimization cycle (peptides <b>1</b>–<b>5</b>), sequence stretches from positions 15–33 of the exendin-4 sequence were replaced by the corresponding glucagon/oxyntomodulin stretches (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Potency at the GLP-1 receptor was only affected to a low extent for most analogues, while activity at the glucagon receptor could not be significantly increased. At least, peptide <b>2</b> (containing residues 15–21 from glucagon) showed a very modest activity (EC<sub>50</sub> = 565 nM) at the glucagon receptor and was used as a starting point for further optimization. It was found that introduction of solely Ser2 and Gln3 from the glucagon sequence into exendin-4 resulted in a peptide (peptide <b>6</b>) that maintained high potency at the GLP-1R (EC<sub>50</sub> = 0.7 pM) and showed one-digit nanomolar activity at the glucagon receptor (EC<sub>50</sub> = 1.12 nM). Finally, combination of sequence motifs of peptides <b>2</b> and <b>6</b> resulted in peptide <b>7</b>, which shows potent dual activity at the GLP-1 and glucagon receptor (EC<sub>50</sub>(GLP-1R) = 22.2 pM, EC<sub>50</sub>(GCGR) = 26.4 pM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. EC<sub>50</sub> Values (plus SEM Values, Measured in pM in a cAMP Assay in Overexpressing HEK-293 Cell Lines) of Peptide Sequences Derived from Grafting Glucagon/Oxyntomodulin Sequence Stretches into Exendin-4<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0008.gif" alt="" id="GRAPHIC-d7e651-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>Table a</sup><p class="last">In all cases, three replicates were measured.</p></div></div><div></div></div><div class="NLM_p">In order to identify the importance of specific mutations for relative activity at both receptors, several variants of peptide <b>7</b> were synthesized and tested (see <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, peptides <b>8</b>–<b>13</b>). According to our structural analysis (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), the C-terminal tail of exendin-4 that cages residue Trp25 does not show significant interactions with the GLP-1 or glucagon receptor. Therefore, modifications in this region were not expected to have a significant impact on receptor in vitro activities. Peptides <b>8</b>–<b>10</b> reveal that the C-terminal tail derived from exendin-4 can be modified or shortened, resulting in similar or even higher in vitro activity at both receptors. Since this Trp-cage motif is known to significantly enhance solubility and stability,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> this motif was retained for further peptide optimization, and therefore, peptide <b>7</b> was chosen as starting point for additional modifications (see below).</div><div class="NLM_p">One of the most relevant requirements for dual activity at the GLP-1 and glucagon receptor is the presence of Ser2 and Gln3. Reverse mutation of one of these residues into exendin-4 (i.e., Ser2Gly or Gln3Glu) results in a significant activity loss at the glucagon receptor (compare peptides <b>11</b> and <b>12</b> vs peptides <b>6</b> and <b>7</b>). Activity data for peptide <b>13</b> in comparison to peptides <b>6</b> and <b>7</b> reveal that in addition residues 15–21 are important for activity at the glucagon receptor.</div><div class="NLM_p">In summary, the combination of amino acids from the exendin-4 and glucagon sequence as realized in peptide <b>7</b> results in a peptide with a balanced GLP-1/glucagon in vitro activity ratio of 1:1. The in vitro activity data in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> show that adjustment for another activity ratio toward the one or other receptor might be achieved by specific amino acid exchange. This is further supported by the in vitro activity data that have been reported by Chabenne et al.:<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> in their study, glucagon shows an EC<sub>50</sub> value of 3.74 nM at the GLP-1 receptor and of 0.06 nM at the glucagon receptor, respectively, which translates into a GLP-1R/glucagon activity ratio of 1:62. Addition of the exendin-4(30–39) sequence stretch to glucagon, resulting in glucagonCex (see <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), switches the GLP-1R/glucagon selectivity ratio from 1:62 to 1:14.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This peptide still differs in seven positions from peptide <b>7</b>, indicating that a further stepwise adjustment toward the GLP-1/glucagon activity ratio of 1:1 can be achieved by systematic mutation of the glucagon-originating residues into the corresponding exendin-4 variants.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Amino Acid Sequences of Glucagon and GlucagonCex, a Glucagon Variant That Carries the C-Terminal Exendin-4(30–39) Sequence Stretch, and Peptide <b>7</b><a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0009.gif" alt="" id="GRAPHIC-d7e746-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are taken from ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>. Absolute EC<sub>50</sub> values for glucagon differ from measurements of this study, presumably due to different assay settings.</p></div></div><div></div></div><div class="NLM_p">While peptide <b>7</b> shows potent dual activity at both the GLP-1 and glucagon receptors, it is thought to be cleared by renal filtration and/or enzymatic digestion, e.g., by DPPIV.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We used the following strategies in order to improve metabolic stability: (1) modification of the serine residue in position 2 to avoid DPPIV-mediated degradation and (2) addition of a palmitic acid at the ε-amino group of a lysine residue using a γ-glutamic acid spacer, a strategy that has been successfully proven in the case of liraglutide.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> On the basis of the peptide-receptor binding models in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, several positions were identified where the modified Lys residue could be introduced without perturbing receptor binding interactions (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). While the position of the fatty acid substituent in peptides <b>14</b> vs <b>15</b> and <b>16</b> are distant in the sequence positions (14 vs 39 and 40), they are spatially similar. In all cases, the modified peptides show even enhanced activation at both receptors compared to the nonacylated peptides (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). This observation was also described by DiMarchi et al. for glucagon analogues.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Experimental data based on different biophysical and structural characterization techniques suggest that in these particular cases, lipidation enhances receptor activity by stabilizing relevant bioactive conformations. Further studies addressing other peptide targets also demonstrated that lipid conjugation can increase the functional activity of peptides.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40-42)</a> However, the molecular basis for the activity increase is not clear due to lack of experimental evidence. It was hypothesized that additional hydrophobic interactions between the lipid side chain and hydrophobic regions of the target receptor might be responsible.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Another theory that is potentially relevant for the GLP-1 and glucagon receptor is that lipidation fosters membrane association and thereby increases the local peptide concentration in the proximity of membrane-bound receptors.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> In the present context, the fatty acid side chain might simultaneously establish hydrophobic interactions with the receptor(s) and the surrounding membrane. Inspection of the binding hypothesis of peptide <b>14</b> to the full-length glucagon receptor indicates that this might be possible (see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). However, for a final conclusion about the molecular mechanism, further experimental data are required, for example, experimental (crystal) structural data of a lipidated peptide in complex with the full-length GLP-1 or glucagon receptor.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Full Amino Acid Sequences and EC<sub>50</sub> Values (plus SEM Values) of <span class="smallcaps smallerCapital">d</span>-Ser2 Variants of Peptide <b>7</b> Containing an Additional Lysine Residue, Which Is Modified by Addition of a Palmitic Acid at the ε-Amino Group Using a γ-Glutamic Acid Spacer in Positions Expected Not To Disturb Receptor Binding/Activation<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0010.gif" alt="" id="GRAPHIC-d7e834-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>Table a</sup><p class="last">In all cases, three replicates were measured.</p></div></div><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeling hypotheses of <span class="smallcaps smallerCapital">d</span>-Ser2 variants containing an additional lysine residue, which is modified by addition of a palmitic acid at the ε-amino group using a γ-glutamic acid spacer in positions expected not to disturb receptor binding/activation. Full amino acid sequences and EC<sub>50</sub> values (in pM) of the corresponding peptides are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> NMR Structure of Peptide <b>14</b> in Solution</h3><div class="NLM_p">The 3D structure of peptide <b>14</b> was determined by restrained molecular dynamics (MD) calculations and energy minimization, imposing distance constraints obtained from NOESY spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S2 in Supporting Information</a>). In total, 455 distance constraints were obtained from analysis of the NOESY spectra and used for the MD simulation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S3</a>). <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a shows a superposition of 10 representative snapshots from a 2 ns restrained MD simulation. Though a certain degree of structural flexibility is observed in the N-terminal region (residues 1–8), the upper part of the helix (i.e., residues 9–28) and in particular the Trp cage motif show very high structural stability. A very high degree of flexibility is observed for the palmitic acid substituted at position 14. No NOEs were observed between the fatty acid side chain and any other amino acid of the peptide.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NMR structure of peptide <b>14</b> in solution. For structural clarity, only heavy atoms are depicted. (a) Superposition of 10 structures derived from a 2 ns restrained MD simulation “in water”. All backbone atoms of residues 9–37 were used for fitting. (b) Individual structure with the lowest constraint violation compared to the NMR structure of exendin-4 (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>). The secondary structure is shown in ribbon presentation, the palmitic acids side chain of peptide <b>14</b> is shown as spacefill.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, peptide <b>14</b> displays high structural similarity to exendin-4 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b), although both peptides differ in 10 positions from each other. Of particular note, the Trp cage, which is a hydrophobic cluster surrounding Trp25, shows a highly similar conformation to exendin-4 and a similar low degree of structural fluctuation.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Binding Hypothesis of Peptide <b>14</b> to Full-Length Glucagon Receptor</h3><div class="NLM_p">The X-ray crystal structure of the seven transmembrane (TM) domain of the human glucagon receptor, together with a full-length homology model of the glucagon bound-receptor complex, has been reported.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> We used this structure prediction to model glucagon receptor binding of peptide <b>14</b>, including the interactions with the TM region of the receptor (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Importantly, several key interactions that have been reported for glucagon, and/or related (such as GLP-1) receptors, are also observed in our model including (1) a salt bridge between the peptidic N-terminal amino group of His1 and the carboxy side chain of Asp195 of the receptor, (2) a second salt bridge between Asp9 of the peptide and Arg378 of the receptor, and (3) hydrogen bonding between the amide side chain of Gln3 and the hydroxyl side chain of Tyr149 of the receptor.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Predicted binding mode of peptide <b>14</b> (color) to the full-length homology model of the glucagon receptor (orange), shown in ribbon representation.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The palmitic acid side chain of peptide <b>14</b> is shown in spacefill representation. (b) Key interactions of the N-terminal domain of the peptide with specific regions in the transmembrane domain of the receptor are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">According to the binding model, the palmitic acid side chain projects into the solvent space. As shown above, our NMR studies reveal a high structural flexibility of this side chain in solution. It is unclear whether this flexibility is maintained in the receptor-bound state or if hydrophobic interactions with the receptor or the membrane are established.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Studies</h3><div class="NLM_p">The in vivo assessment of above-described peptidic dual GLP-1/glucagon receptor agonists comprised evaluation of the pharmacokinetic (PK) properties as well as pharmacodynamic characterization in diabetic and obese mice. Subcutaneous administration of peptide <b>14</b> (1 mg/kg) in healthy mice showed a long half-life of 3.2 h (similar to liraglutide but with a lower exposure), whereas peptide <b>15</b> showed a somewhat shorter half-life. Nevertheless, exposure for peptide <b>15</b> was higher than for peptide <b>14</b>.</div><div class="NLM_p"><a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> summarizes the pharmacokinetic properties of peptides <b>14</b> and <b>15</b> in comparison to liraglutide in healthy mice dosed at 1 mg/kg subcutaneously.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters for Peptides <b>14</b>, <b>15</b> and Liraglutide after sc Administration to Mice<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC (ng h/mL)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1930</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">11000</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">3450</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">17000</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">7700</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">80300</td><td class="colsep0 rowsep0" align="left">3.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">Data represent average data calculated from mean plasma concentrations at different time points. The respective raw data including SD values can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S4</a>.</p></div></div></div><div class="NLM_p">The pharmacological activity of the dual GLP-1/glucagon agonist peptide <b>14</b> was assessed in a variety of chronic mouse studies, among those studies in db/db mice as well as studies in diet induced obese (DIO) mice. In all studies the selective GLP-1 receptor agonist liraglutide was used as reference compound. As mentioned in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, liraglutide carries (as peptide <b>14</b>) a fatty acid side chain, leading to a significantly prolonged exposure and duration of action when compared with the natural hormones GLP-1, glucagon, oxyntomodulin, or exendin-4. For pharmacological interpretation respective receptor activation (measured in a cAMP assay in overexpressing HEK-293 cell lines) in mice was the following: peptide <b>14</b> activated the murine GLP-1 receptor with an EC<sub>50</sub> of 2.3 pM and the glucagon receptor with an EC<sub>50</sub> of 25 pM. In comparison, liraglutide activated murine GLP-1 receptor with an EC<sub>50</sub> of 4.4 pM (see <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. EC<sub>50</sub> Values (Measured in pM in a cAMP Assay in Overexpressing HEK-293 Cell Lines) of Peptides at the Murine GLP-1 and Glucagon Receptors<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">EC<sub>50</sub> (pM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">mGLP-1R</th><th class="colsep0 rowsep0" align="center">SEM</th><th class="colsep0 rowsep0" align="center">mGCGR</th><th class="colsep0 rowsep0" align="center">SEM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">25.0</td><td class="colsep0 rowsep0" align="left">10.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">>10 000 000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exendin-4</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">>10 000 000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GLP-1</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">>10 000 000</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glucagon</td><td class="colsep0 rowsep0" align="left">43.5</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">In all cases, three replicates were measured.</p></div></div></div><div class="NLM_p">The antiobese activity of peptide <b>14</b> and liraglutide was tested in diet induced obese (DIO) mice. Liraglutide as well as peptide <b>14</b> were dosed at 50 μg/kg twice daily to ensure sufficient and approximately continuous 24 h plasma levels repeatedly over 33 days. For both peptides a significant decrease in body weight was observed compared to baseline values as well as to high fat diet (HFD) controls (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). A significant decrease of 29.1% (±2.2%, <i>p</i> < 0.001) in relative body weight loss for peptide <b>14</b> and 13.6% (±2.2%, <i>p</i> < 0.001) for liraglutide compared to baseline values prior to start of treatment was observed. This strong reduction in body weight coincided with a marked reduction in body fat mass, as determined by NMR spectroscopy before the start of treatment and after 33 days. While the high fat diet control group maintained body fat content over the study period, treatment with peptide <b>14</b> led to a significant reduction of 57.3% (±3.8%) and liraglutide of 31.2% (±2.5%); see <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. As discussed earlier, body weight reduction for GLP-1/glucagon agonists is caused by inhibition of food intake but also increased energy expenditure (details of such studies will be published elsewhere in due time<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Overall Body Weight and Body Fat Change (%) versus Baseline Values Prior Start of Treatment over a Treatment Period of 33 Days<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">overall weight change</th><th class="colsep0 rowsep0" align="center">body fat change</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control standard diet</td><td class="colsep0 rowsep0" align="left">+1.5% (±0.9%)</td><td class="colsep0 rowsep0" align="left">+6.4% (±3.5%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">control high-fat diet</td><td class="colsep0 rowsep0" align="left">+0.2% (±0.7%)</td><td class="colsep0 rowsep0" align="left">+2.5% (±1.4%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">–29.1% (±2.2%)<sup>*,#</sup></td><td class="colsep0 rowsep0" align="left">–57.3% (±3.8%)<sup>*,#</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="left">–13.6% (±2.2%)<sup>*,#</sup></td><td class="colsep0 rowsep0" align="left">–31.2% (±2.5%)<sup>*,#</sup></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Female C57BL/6N mice are fed with standard diet (SD control), with high fat diet (HFD control), and HFD plus treatment with peptide <b>14</b> and liraglutide. Both control groups were treated with vehicle. All mice were treated twice daily (b.i.d.). Data are shown as the mean ± SEM, <i>n</i> = 8 per group: (∗) <i>p</i> < 0.001 vs baseline and (#) vs HFD controls, one-way ANOVA with Dunnett’s post hoc test.</p></div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Relative body weight change (%) versus baseline values on day 0 prior to start of treatment. Female diet-induced obese (DIO) C57BL/6N mice are fed with standard diet (SD control), with high fat diet (HFD control) and HFD plus treatment with peptide <b>14</b> and liraglutide. Both control groups were treated with vehicle. All mice were treated twice daily with 50 μg/kg (b.i.d.). An oral glucose tolerance test (oGTT) was performed on day 21 of chronic treatment (data not shown), with an overnight starvation prior to glucose load. Relative weight loss is shown as mean values ± SEM, <i>n</i> = 8 per group. Black bar indicates statistically different body weight change from day 1 to day 33 of treatment for both peptides: (∗) <i>p</i> < 0.001 vs baseline and (#) vs HFD controls, one-way ANOVA with Dunnett’s post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antidiabetic activity of peptide <b>14</b> was studied in diabetic db/db mice. Liraglutide and peptide <b>14</b> were administered twice daily at 50 μg/kg over 32 days. Compared to the diabetic control group at day 32, treatment with peptide <b>14</b> prohibited worsening of the long-term glucose marker HbA1c and led to a significantly lower value of approximately 1.5%, very similar to liraglutide. Although the dual acting peptide <b>14</b> stimulates the glucagon receptor, no evidence for an increase in HbA1c indicating an elevation of blood glucose compared to liraglutide was seen (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Chronic activation of the glucagon receptor to a certain amount does not seem to limit the glucose lowering potential of a dual GLP-1/glucagon coagonist.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HbA1c (%), start vs end of study after 32 days. Female diabetic (db/db) mice were treated with vehicle or peptide <b>14</b> or liraglutide with 50 μg/kg twice daily. Data are shown as mean values ± SEM, <i>n</i> = 8 per group: (∗) <i>p</i> < 0.001 vs baseline and (#) vs db/db controls, one-way ANOVA with Dunnett’s post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of preclinical and exploratory human data for the native gut hormone oxyntomodulin, the combined activation of the GLP-1 and glucagon receptors could simultaneously improve blood glucose and reduce body weight. If the short half-life of this native peptide could be significantly improved, dual GLP-1 and glucagon receptor agonists represent a very promising therapeutic principle for the chronic treatment of diabesity. On the basis of the exceptional physiochemical properties, in vivo stability, and prolonged pharmacokinetic profile of the selective GLP-1 receptor agonist exendin-4, we have re-engineered the exendin-4 sequence to (i) include glucagon receptor agonistic activity while (ii) maintaining the potent GLP-1 receptor activity and (iii) achieving sufficient in vivo stability for a therapeutic evaluation in preclinical models of diabetes and obesity.</div><div class="NLM_p">We have described a series of novel peptides with dual activity on these GLP-1 and glucagon receptors that were discovered by rational design, utilizing sequence and structural information from X-ray and NMR structures as well as molecular models for peptide optimization and structure–activity rationalization. On the basis of this strategy, structural elements of glucagon/oxyntomodulin were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in a hybrid peptide (<b>7</b>) with potent and balanced dual GLP-1/glucagon receptor activity. New structure–activity relationships demonstrate where specific mutations of exendin-4-originating residues into the corresponding glucagon variants or vice versa can be introduced to switch the GLP-1/glucagon receptor activity ratio toward the one or other receptor. Importantly, the innovative challenge for such a dual coagonist design is to identify the optimal balance of the relative GLP-1/glucagon receptor activity ratio. GLP-1 receptor activation could lead to glucose lowering, in conjunction with moderate body weight reduction, whereas an additional enhancement of the glucagon receptor activity provides more significant weight loss, however, at the risk of glucose elevation. This concept is in line with findings from Day et al. that the GLP-1/glucagon activity ratio needs to be carefully evaluated and could be different for different species.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Introduction of a <span class="smallcaps smallerCapital">d</span>-serine in position 2 of peptide <b>7</b> and a lysine residue in position 14 modified by addition of a palmitic acid at the ε-amino group using a γ-glutamic acid spacer provided the dual GLP-1/glucagon receptor agonist peptide <b>14</b>. Although this peptide differs in 10 (out of 39) residues from exendin-4, the structural fold of both peptides is (in agreement with our design rationales) highly similar, as demonstrated by NMR structure determination in solution. In particular, the stability- and solubility-enhancing Trp cage motif was structurally maintained.</div><div class="NLM_p">Peptide <b>14</b> showed significant glucose lowering effects associated with body weight reduction in murine models of diabetes and obesity. The observed weight loss in DIO mice was significantly greater compared to the selective GLP-1 receptor agonist liraglutide, while glycaemic control was similar to liraglutide when assessed in diabetic db/db mice.</div><div class="NLM_p">Overall, these beneficial preclinical data seen with peptide <b>14</b> support the hypothesis that dual GLP-1/glucagon receptor agonists have the potential to lead to significantly higher body weight reduction (due to reduced food intake and increased energy expenditure) compared to pure GLP-1 receptor agonists but similar glucose control. Due to lipidation, the pharmacokinetic properties of peptide <b>14</b> are comparable to liraglutide, showing that the half-life in comparison to exendin-4 could be improved pointing toward a suitability for once-daily administration in humans.</div><div class="NLM_p last">The therapeutic potential of dual GLP-1/glucagon receptor agonists as antidiabetic therapy will certainly depend on the question of how far the efficacy, especially with respect to body weight reduction, exceeds the benefits of marketed GLP-1 receptor agonists without impacting glucoregulatory effects. Currently, there are a number of dual GLP-1/glucagon coagonists undergoing clinical testing,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the confirmation of their potential in human POC studies is urgently awaited.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Molecular Modeling</h3><div class="NLM_p last">For binding mode generation of peptide <b>14</b> in full-length homology model of the glucagon receptor, the full-length glucagon receptor homology model in complex with glucagon<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> was used as starting point. Peptide <b>14</b> was aligned to the 3D structure of receptor-bound glucagon. Subsequently, a conformational search of the N-terminal peptide residues 1–9 was performed in the presence of the glucagon receptor using Schrodinger’s loop refinement routine.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The top-ranked solutions were minimized in the presence of the glucagon receptor, allowing all peptide and receptor atoms to move. After minimization, the different binding poses were analyzed and we selected the pose that showed the best agreement with available mutagenesis data.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Peptides</h3><div class="NLM_p last">Solid phase synthesis was carried out on Rink resin with a loading of 0.38 mmol/g, 75–150 μm from Agilent Technologies. The Fmoc synthesis strategy was applied with HBTU/DIPEA activation. The peptide was cleaved from the resin with King’s cocktail.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The crude product was purified via preparative HPLC on a Waters column (XBridge, BEH130, Prep C18, 5 μm) using an acetonitrile/water gradient (both buffers with 0.1% TFA). For analogs with fatty acid side chain Fmoc-Lys(ivDde)-OH and in position 1, Boc-His(Boc)-OH was used in the solid phase synthesis protocol. The ivDde group was cleaved from the peptide on resin using hydrazine in DMF according to literature.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Hereafter Palm(γOSu)(αO<sup><i>t</i></sup>Bu)Glu was coupled to the liberated amino group. Peptides were purified by RP-HPLC on a C18-column in acetonitrile/TFA, and purity and identity of the product were established by UPLC and LC–MS (for details see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S1</a>). Chemical identity and purity of the peptides were assessed by LC–MS and confirmed to have ≥95% purity for all key compounds.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> In Vitro Cellular Assays for GLP-1 Receptor and Glucagon Receptor Efficacy</h3><div class="NLM_p last">Agonism of compounds for the two receptors was determined by functional assays measuring cAMP response of HEK-293 cell lines stably expressing human or murine GLP-1 or glucagon receptor. cAMP content of cells was determined using a kit from Cisbio Corp. (catalog no. 62AM4PEC) based on HTRF (homogeneous time resolved fluorescence). For preparation, cells were split into T175 culture flasks and grown overnight to near confluence in medium (DMEM/10% FBS). Medium was then removed, and cells were washed with PBS lacking calcium and magnesium, followed by proteinase treatment with accutase (Sigma-Aldrich catalog no. A6964). Detached cells were washed and resuspended in assay buffer (1× HBSS; 20 mM HEPES, 0.1% BSA, 2 mM IBMX), and cellular density was determined. They were then diluted to 400 000 cells/mL, and 25 μL aliquots were dispensed into the wells of 96-well plates. For measurement, 25 μL of test compound in assay buffer was added to the wells, followed by incubation for 30 min at room temperature. After addition of HTRF reagents diluted in lysis buffer (kit components), the plates were incubated for 1 h, followed by measurement of the fluorescence ratio at 665/620 nm. In vitro potency of agonists was quantified by determining the concentrations that caused 50% activation of maximal response (EC<sub>50</sub>). By default, three replicates were measured. Data are provided as the mean ± SEM.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> NMR</h3><div class="NLM_p last">The 3D structure of peptide <b>14</b> has been determined by restrained molecular dynamics calculations and energy minimization. Molecular dynamics (MD) simulations and interactive modeling were performed using the software package SYBYL, version 2.1.1. All energy calculations were based on the Tripos force field. For energy minimizations the Powell method was used. The analysis of the NMR-derived distance restraints was carried out with SPL (Sybyl programming language) scripts. The experimental data set used as input for the MD calculations included 455 distance constraints obtained from NOESY spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S2</a>) recorded in a mixture of 350 μL of H<sub>2</sub>O/D<sub>2</sub>O (9:1), 50 mM phosphate buffer, pH 5.0, and 150 μL of trifluoroethanol at 310 K (mixing time was 200 ms) and from a NOESY spectrum recorded in a mixture of 350 μL of D<sub>2</sub>O, 50 mM phosphate buffer, pH 5.0, and 150 μL of trifluoroethanol at 310 K (mixing time was 200 ms). The 455 constraints included 83 intraresidual distances, 155 sequential distances, 147 medium distances (2–4 amino acids apart), and 70 long-range distances (>4 amino acids apart). The NOE between Trp25-H1 and H7 has been used as reference integral (2.9 Å). Upper and lower distance limits were set to ±10% of the calculated (experimental) distances, respectively. For nondiastereotopically assigned methylene protons and methyl groups, 0.9 and 1.0 Å were added to the upper bounds as pseudo atom corrections, respectively. The set of utilized distance constraints is summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">Table S3</a>. Dihedral angle constraints and hydrogen bond constraints have not been used. A homology model derived from the NMR structure of exendin-4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>) was used as starting structure. The NOE derived distance constraints were applied with a force constant of 41.9 kJ mol<sup>–1</sup> Å<sup>–2</sup>. The MD simulation was performed in a water box using 7133 explicit water molecules. In the production run at 300 K, conformers were sampled every 100 ps for a duration of 2000 ps yielding a total of 20 structures. The obtained structures were energy-minimized (2000 steps). The 10 structures with the lowest constraint violation were used for further analyses. The average constraint violation is 0.10 Å. Only 9 constraints are violated by more than 0.6 Å; the largest violation is 0.87 Å. Considering only residues 9–37, the rmsd over all backbone atoms (N, NH, Cα, Hα, C′, O) is 0.698 Å with a standard deviation of 0.148 Å. For the same residues (residue 14 has been excluded) the rmsd over all heavy atoms is 1.068 Å with a standard deviation of 0.157 Å.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Pharmacokinetics in Mice</h3><div class="NLM_p last">Female C57/Bl6 mice were dosed 1 mg/kg subcutaneously (sc). The mice were sacrificed, and blood samples were collected after 0.083, 0.25, 1, 2, 4, 8, 16, and 24 h after application. Plasma samples were analyzed after protein precipitation via liquid chromatography–mass spectrometry (LC–MS/MS). Pharmacokinetic parameters and half-life were calculated using WinonLin, version 5.2.1 (noncompartment model).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Pharmacodynamics. Acute and Subchronic Effects on Body Weight in Female Diet-Induced Obese (DIO) C57BL/6NCrl Mice</h3><div class="NLM_p">All mouse related experimental procedures were conducted in accordance with the German Animal Protection Law, as well as according to international animal welfare legislation and rules.</div><div class="NLM_p last">Female C57BL/6N mice (Charles River) were housed in groups with <i>n</i> = 8 mice per cage in a specific pathogen-free barrier facility on a 12 h light/dark cycle with free access to water and high-fat diet. Mice were prefed for 18 weeks on high-fat diet (Ssniff adjusted to Teklad diet, TD.97366) and reached a plateau in body weight before start of the study. Mice were stratified at an age of approximately 24 weeks to treatment groups (<i>n</i> = 8) so that each group had similar mean body weight (HFD controls, 43.7 ± 0.93g; peptide <b>14</b>, 43.9 ± 0.4 g; liraglutide, 43.5 ± 0.5 g). Individual values for body fat content varied between 16.9 and 21.3 g. An aged-matched group with ad libitum access to standard chow (Ssniff E15769-04 EF) was included as standard control group (SD controls: 24.4 ± 0.3 g). Before the experiment, mice were subcutaneously (sc) injected with vehicle solution (PBS, Gibco) and weighed for 3 days for acclimation. All animals were treated twice daily sc with an application volume of 5 mL/kg in the morning at the beginning of the light phase (12 h lights on) and in the evening prior lights off for 33 days with vehicle or compound, respectively, to ensure bioavailability of compound levels. Body weight was recorded daily. Two days before start of treatment and on day 32, total fat mass was measured by nuclear magnetic resonance (NMR) using a Bruker minispec (Ettlingen, Germany). Statistical analyses were performed with Everstat 6.0 by one-way ANOVA, followed by Dunnetts post hoc test for body weight and body fat compared to baseline values as well as to HFD controls. Differences were considered statistically significant at the <i>p</i> < 0.05 level.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chronic Treatment Effects on HbA1c in Female Leptin-Receptor Deficient Diabetic db/db Mice</h3><div class="NLM_p">Female BKS.Cg-m +/+ Leprdb/J (db/db) and BKS.Cg-m +/+ Leprdb/+ (lean control) mice were obtained from Charles River Laboratories, Germany, at an age of 9–10 weeks. The animals were housed in groups of <i>n</i> = 8 mice per cage in a specific pathogen-free barrier facility on a 12 h light/dark cycle with free access to water and rodent standard chow (see above). After 1 week of acclimatization, blood samples were drawn from the tail without anesthesia and HbA1c level (method, hemolysate, Cobas6000 c501, Roche Diagnostics, Germany) was determined. HbA1c is a glycosylated form of hemoglobin whose level reflects the average level of glucose to which the erythrocyte has been exposed during its lifetime. In mice, HbA1c is a relevant biomarker for the average blood glucose level during the preceding 4 weeks (erythrocyte life span in mouse ∼47 days). Db/db mice were stratified to treatment groups (<i>n</i> = 8) so that each group had similar baseline blood glucose and HbA1c levels (blood glucose, 20.7 ± 1.0 mmol/L (db/db controls), 20.5 ± 0.8 mmol/L (peptide <b>14</b>), and 20.8 ± 0.6 mmol/L (liraglutide); HbA1c, 5.3 ± 0.2% (db/db controls), 5.3 ± 0.2% (peptide <b>14</b>), and 5.3 ± 0.1% (liraglutide). An aged-matched lean and healthy littermate group was included as lean control (7.2 ± 0.1 mmol/L blood glucose and 3.8 ± 0.03% for HbA1c).</div><div class="NLM_p last">For chronic effect on HbA1c, all animals were treated twice daily sc for 32 days. At the end of the study, blood samples (tail, no anesthesia) were analyzed for HbA1c. Statistical analyses were performed with Everstat 6.0 by repeated measures by one-way ANOVA and Dunnetts post hoc analyses. Differences versus baseline and vehicle-treated db/db control mice were considered statistically significant at the <i>p</i> < 0.05 level.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00174">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00174" class="ext-link">10.1021/acs.jmedchem.7b00174</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data with RP-HPLC retention times and molecular masses of the synthesized peptides, <sup>1</sup>H chemical shifts of peptide <b>14</b>, distance constraints used for the MD simulation obtained from NOESY spectra, and tabular results of pharmacokinetic data not shown in the manuscript (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf">jm7b00174_si_001.pdf (256.72 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for peptide <b>14</b> can be accessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIQ">5NIQ</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00174" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Evers</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4643-1941" title="Orcid link">http://orcid.org/0000-0003-4643-1941</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1958777d6b7c786a375c6f7c6b6a596a7877767f70377a7674"><span class="__cf_email__" data-cfemail="cc8da2a8bea9adbfe289baa9bebf8cbfada2a3aaa5e2afa3a1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Wagner</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#733e1a101b12161f5d2412141d16013300121d1c151a5d101c1e"><span class="__cf_email__" data-cfemail="45082c262d2420296b1224222b20370536242b2a232c6b262a28">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Torsten Haack</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Lorenz</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Bossart</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ralf Elvert</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernd Henkel</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siegfried Stengelin</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Kurz</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maike Glien</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Dudda</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katrin Lorenz</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dieter Kadereit</span> - <span class="hlFld-Affiliation affiliation">R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst Building
G838, D-65926 Frankfurt
am Main, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1703-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Ray C. Stevens and Chris de Graaf for providing us the coordinates of their full-length homology model of the glucagon receptor. We thank Melissa Besenius and Garima Tiwari for reading the manuscript and providing valuable comments.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i28" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i28"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i29" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i29"> Abbreviations Used</h2><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">analysis of variance</p></td></tr><tr><td class="NLM_term">GCGR</td><td class="NLM_def"><p class="first last">glucagon receptor</p></td></tr><tr><td class="NLM_term">DPPIV</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase IV</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">extracellular domain</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">HbA1c</td><td class="NLM_def"><p class="first last">hemoglobin A1c</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks’ balanced salt solution</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HFD</td><td class="NLM_def"><p class="first last">high-fat diet</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time resolved fluorescence</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">isobutylmethylxanthine</p></td></tr><tr><td class="NLM_term">NEP</td><td class="NLM_def"><p class="first last">neutral endopeptidase</p></td></tr><tr><td class="NLM_term">OXM</td><td class="NLM_def"><p class="first last">oxyntomodulin</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">proof of concept</p></td></tr><tr><td class="NLM_term">PYY</td><td class="NLM_def"><p class="first last">peptide tyrosine tyrosine</p></td></tr><tr><td class="NLM_term">RPC</td><td class="NLM_def"><p class="first last">reversed phase chromatography</p></td></tr><tr><td class="NLM_term">SGLT2-I</td><td class="NLM_def"><p class="first last">sodium–glucose co-transporter 2 inhibitor</p></td></tr><tr><td class="NLM_term">SPL</td><td class="NLM_def"><p class="first last">Sybyl programming language</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Farag, Y. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaballa, M. R.</span><span> </span><span class="NLM_article-title">Diabesity: An Overview of a Rising Epidemic</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1093/ndt/gfq576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1093%2Fndt%2Fgfq576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21045078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FlvFSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=28-35&issue=1&author=Y.+M.+K.+Faragauthor=M.+R.+Gaballa&title=Diabesity%3A+An+Overview+of+a+Rising+Epidemic&doi=10.1093%2Fndt%2Fgfq576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Diabesity: an overview of a rising epidemic</span></div><div class="casAuthors">Farag Youssef M K; Gaballa Mahmoud R</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">'Diabesity' is the term for diabetes occurring in the context of obesity.  In this review, we will overview the latest epidemiological data available describing the rising prevalence, health impact and economic impact of diabesity.  We will also outline the measures required to slowdown this newly evolving epidemic.  The global prevalence of diabetes in 2010 was 284 million people worldwide constituting around 6.4% of the world population, which is higher than was projected in earlier studies.  Furthermore, the projections for 2030 show the prevalence to reach 439 million individuals comprising ~7.7% of the world population.  The burden of diabetes on the world economy has been rising steadily in the last decade to reach $376 billion in 2010 and is expected to reach $490 billion in 2030.  Diabesity represents a substantial economic burden as reflected by diabetes and obesity consuming 14 and 5.7% of the USA's total health expenditure, respectively, representing the highest known expenditure on diabesity worldwide.  When costs associated with being overweight were also included, the upper limit of obesity expenditure rises to 9.1% of the USA's total healthcare expenditure.  The highest recorded expenditure on diabetes alone was in Saudi Arabia consuming 21% of the country's total health expenditure, with no data available about the health expenditure on obesity.  The health impact of diabesity is substantial to include long-term diabetic complications, reduction in health-related functioning, reduction of quality of life and reduced overall life expectancy.  Long-term complications include myocardial infarction, cerebrovascular stroke and end-stage renal disease.  Also recent advances have found that there is an association between chronic stress, depression and sleeping troubles to both diabetes and obesity.  This century is the unprecedented diabetogenic era in human history.  It is thus urgent to take steps including screening, prevention and early management in an attempt to control this evolving epidemic of diabesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSum7uGROUeDX6HPRus0rAafW6udTcc2eZ_nXmJqh4G1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FlvFSgsw%253D%253D&md5=9188f8aa4eef047545c181eff170b42f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfq576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfq576%26sid%3Dliteratum%253Aachs%26aulast%3DFarag%26aufirst%3DY.%2BM.%2BK.%26aulast%3DGaballa%26aufirst%3DM.%2BR.%26atitle%3DDiabesity%253A%2520An%2520Overview%2520of%2520a%2520Rising%2520Epidemic%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2011%26volume%3D26%26issue%3D1%26spage%3D28%26epage%3D35%26doi%3D10.1093%2Fndt%2Fgfq576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ross, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzida, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khunti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligthelm, R. J.</span><span> </span><span class="NLM_article-title">Impact of Weight Gain on Outcomes in Type 2 Diabetes</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1185/03007995.2011.585396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1185%2F03007995.2011.585396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21599553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3MngvVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=1431-1438&issue=7&author=S.+A.+Rossauthor=G.+Dzidaauthor=J.+Voraauthor=K.+Khuntiauthor=M.+Kaiserauthor=R.+J.+Ligthelm&title=Impact+of+Weight+Gain+on+Outcomes+in+Type+2+Diabetes&doi=10.1185%2F03007995.2011.585396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of weight gain on outcomes in type 2 diabetes</span></div><div class="casAuthors">Ross Stuart A; Dzida Grzegorz; Vora Jiten; Khunti Kamlesh; Kaiser Marcel; Ligthelm Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Current medical research and opinion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1431-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The majority of patients with type 2 diabetes mellitus (T2DM) are overweight or obese.  Obesity is a significant risk factor for increased morbidity and mortality in people with T2DM, and increased weight has been shown to worsen glycemic control and increase the risk of diabetes progression.  METHODS:  A search was conducted of the National Library of Medicine (PubMed) for articles published from 1990 to 2009 about the treatments of T2DM, relationship between T2DM and weight gain, obesity-related comorbidities of T2DM, and T2DM therapies associated with increased weight.  Reference lists of retrieved articles were reviewed for additional publications.  FINDINGS:  Results from large, prospective clinical trials have shown that weight reduction significantly improves glycemic control and blood pressure in T2DM patients and lowers the risk of progression of T2DM as well as CV disease and cancer.  Treatment-related weight gain is a side effect of many oral antidiabetes agents and insulin.  The thiazolidinediones (TZD), sulfonylureas, and glinides are associated with weight gain.  Despite the weight gain, TZDs also redistribute fat from the central to peripheral compartments, which may lead to a beneficial effect on insulin resistance.  Among insulin products, the basal insulin analog detemir is typically associated with a smaller weight increase than human insulin and insulin analog preparations, including glargine, biphasic, and prandial insulin regimens.  Alpha-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors are weight neutral, whereas glucagon-like peptide1-R agonists and metformin are associated with weight loss.  DISCUSSION:  An effective approach to management of the obese patient with diabetes is to communicate the significant benefits of a 1 kg reduction in body weight or prevention of weight gain on glycemic control and reduced morbidity and mortality.  LIMITATION:  This article is based on an extensive literature review rather than the prospective studies needed to define further the effect of weight gain on the management of T2DM.  CONCLUSION:  Weight management should be an integral part of a T2DM treatment strategy that includes selecting oral antidiabetes medications and insulin products that are weight beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGUU-12gBb3252AMpI4GK2fW6udTcc2eZ_nXmJqh4G1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MngvVSquw%253D%253D&md5=0d8d603e4c20a738023b77b59a66f33d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1185%2F03007995.2011.585396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2011.585396%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DS.%2BA.%26aulast%3DDzida%26aufirst%3DG.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DKhunti%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DLigthelm%26aufirst%3DR.%2BJ.%26atitle%3DImpact%2520of%2520Weight%2520Gain%2520on%2520Outcomes%2520in%2520Type%25202%2520Diabetes%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2011%26volume%3D27%26issue%3D7%26spage%3D1431%26epage%3D1438%26doi%3D10.1185%2F03007995.2011.585396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Wadden, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronne, L.</span><span> </span><span class="NLM_article-title">NN8022–1923 Investigators. Weight Maintenance and Additional Weight Loss with Liraglutide after Low-Calorie-Diet-Induced Weight Loss: The SCALE Maintenance Randomized Study</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/ijo.2013.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fijo.2013.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslynsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=1443-1451&issue=11&author=T.+A.+Waddenauthor=P.+Hollanderauthor=S.+Kleinauthor=K.+Niswenderauthor=V.+Wooauthor=P.+M.+Haleauthor=L.+Aronne&title=NN8022%E2%80%931923+Investigators.+Weight+Maintenance+and+Additional+Weight+Loss+with+Liraglutide+after+Low-Calorie-Diet-Induced+Weight+Loss%3A+The+SCALE+Maintenance+Randomized+Study&doi=10.1038%2Fijo.2013.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study</span></div><div class="casAuthors">Wadden, T. A.; Hollander, P.; Klein, S.; Niswender, K.; Woo, V.; Hale, P. M.; Aronne, L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1443-1451</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced clin. meaningful wt. loss in a phase 2 study in obese individuals without diabetes.  The present randomized phase 3 trial assessed the efficacy of liraglutide in maintaining wt. loss achieved with a low-calorie diet (LCD).  Methods: Obese/overweight participants (≥18 years, body mass index ≥30 kg m-2 or ≥27 kg m-2 with comorbidities) who lost ≥5% of initial wt. during a LCD run-in were randomly assigned to liraglutide 3.0 mg per day or placebo (s.c. administration) for 56 wk.  Diet and exercise counseling were provided throughout the trial.  Co-primary end points were percentage wt. change from randomization, the proportion of participants that maintained the initial ≥5% wt. loss, and the proportion that lost ≥5% of randomization wt. (intention-to-treat anal.).  ClinicalTrials.gov identifier: NCT00781937.  Results: Participants (n=422) lost a mean 6.0% (s.d. 0.9) of screening wt. during run-in.  From randomization to week 56, wt. decreased an addnl. mean 6.2% (s.d. 7.3) with liraglutide and 0.2% (s.d. 7.0) with placebo (estd. difference -6.1% (95% class intervals -7.5 to -4.6), P<0.0001).  More participants receiving liraglutide (81.4%) maintained the ≥5% run-in wt. loss, compared with those receiving placebo (48.9%) (estd. odds ratio 4.8 (3.0; 7.7), P<0.0001), and 50.5% vs. 21.8% of participants lost ≥5% of randomization wt. (estd. odds ratio 3.9 (2.4; 6.1), P<0.0001).  Liraglutide produced small but statistically significant improvements in several cardiometabolic risk factors compared with placebo.  Gastrointestinal (GI) disorders were reported more frequently with liraglutide than placebo, but most events were transient, and mild or moderate in severity.  Conclusion: Liraglutide, with diet and exercise, maintained wt. loss achieved by caloric restriction and induced further wt. loss over 56 wk.  Improvements in some cardiovascular disease-risk factors were also obsd.  Liraglutide, prescribed as 3.0 mg per day, holds promise for improving the maintenance of lost wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqTz_P82QSLVg90H21EOLACvtfcHk0lg621rCiRNSwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslynsr3I&md5=bf1f08f83e6edc6c5003697d3eb405ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fijo.2013.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2013.120%26sid%3Dliteratum%253Aachs%26aulast%3DWadden%26aufirst%3DT.%2BA.%26aulast%3DHollander%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DNiswender%26aufirst%3DK.%26aulast%3DWoo%26aufirst%3DV.%26aulast%3DHale%26aufirst%3DP.%2BM.%26aulast%3DAronne%26aufirst%3DL.%26atitle%3DNN8022%25E2%2580%25931923%2520Investigators.%2520Weight%2520Maintenance%2520and%2520Additional%2520Weight%2520Loss%2520with%2520Liraglutide%2520after%2520Low-Calorie-Diet-Induced%2520Weight%2520Loss%253A%2520The%2520SCALE%2520Maintenance%2520Randomized%2520Study%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2013%26volume%3D37%26issue%3D11%26spage%3D1443%26epage%3D1451%26doi%3D10.1038%2Fijo.2013.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pi-Sunyer, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujioka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenway, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpern, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krempf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, D. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">le Roux, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violante Ortiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, J. P. H.</span><span> </span><span class="NLM_article-title">SCALE Obesity and Prediabetes NN8022–1839 Study Group. A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1056%2FNEJMoa1411892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=26132939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbps1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=11-22&issue=1&author=X.+Pi-Sunyerauthor=A.+Astrupauthor=K.+Fujiokaauthor=F.+Greenwayauthor=A.+Halpernauthor=M.+Krempfauthor=D.+C.+W.+Lauauthor=C.+W.+le+Rouxauthor=R.+Violante+Ortizauthor=C.+B.+Jensenauthor=J.+P.+H.+Wilding&title=SCALE+Obesity+and+Prediabetes+NN8022%E2%80%931839+Study+Group.+A+Randomized%2C+Controlled+Trial+of+3.0+Mg+of+Liraglutide+in+Weight+Management&doi=10.1056%2FNEJMoa1411892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management</span></div><div class="casAuthors">Pi-Sunyer Xavier; Astrup Arne; Fujioka Ken; Greenway Frank; Halpern Alfredo; Krempf Michel; Lau David C W; le Roux Carel W; Violante Ortiz Rafael; Jensen Christine Bjorn; Wilding John P H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone.  Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.  METHODS:  We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension.  We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification.  The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight.  RESULTS:  At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes.  At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).  A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001).  The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea.  Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group.  CONCLUSIONS:  In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOB_K8FQ7n-bqxQ2mb9Pu8fW6udTcc2ebSH5Lng7XoaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbps1GrsQ%253D%253D&md5=6ab59797f31ac5a44c9335007c96c211</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411892%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DGreenway%26aufirst%3DF.%26aulast%3DHalpern%26aufirst%3DA.%26aulast%3DKrempf%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DD.%2BC.%2BW.%26aulast%3Dle%2BRoux%26aufirst%3DC.%2BW.%26aulast%3DViolante%2BOrtiz%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DC.%2BB.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DSCALE%2520Obesity%2520and%2520Prediabetes%2520NN8022%25E2%2580%25931839%2520Study%2520Group.%2520A%2520Randomized%252C%2520Controlled%2520Trial%2520of%25203.0%2520Mg%2520of%2520Liraglutide%2520in%2520Weight%2520Management%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1056%2FNEJMoa1411892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Schulman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carleton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehorn, J. C.</span><span> </span><span class="NLM_article-title">Effect of Glucagon on Food Intake and Body Weight in Man</span> <span class="citation_source-journal">J. Appl. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1957</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1957&pages=419-421&issue=3&author=J.+L.+Schulmanauthor=J.+L.+Carletonauthor=G.+Whitneyauthor=J.+C.+Whitehorn&title=Effect+of+Glucagon+on+Food+Intake+and+Body+Weight+in+Man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchulman%26aufirst%3DJ.%2BL.%26aulast%3DCarleton%26aufirst%3DJ.%2BL.%26aulast%3DWhitney%26aufirst%3DG.%26aulast%3DWhitehorn%26aufirst%3DJ.%2BC.%26atitle%3DEffect%2520of%2520Glucagon%2520on%2520Food%2520Intake%2520and%2520Body%2520Weight%2520in%2520Man%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D1957%26volume%3D11%26issue%3D3%26spage%3D419%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartness, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">The Metabolic Actions of Glucagon Revisited</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">697</span><span class="refDoi"> DOI: 10.1038/nrendo.2010.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnrendo.2010.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=20957001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=689-697&issue=12&author=K.+M.+Habeggerauthor=K.+M.+Heppnerauthor=N.+Gearyauthor=T.+J.+Bartnessauthor=R.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=The+Metabolic+Actions+of+Glucagon+Revisited&doi=10.1038%2Fnrendo.2010.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic actions of glucagon revisited</span></div><div class="casAuthors">Habegger, Kirk M.; Heppner, Kristy M.; Geary, Nori; Bartness, Timothy J.; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The diabetogenic effect of glucagon has long overshadowed the potential of this pancreatic hormone as an endogenous satiety and anti-obesity factor.  This Review discusses the role of glucagon as a beneficial endocrine factor in lipid and energy metab. and its potential as a therapeutic agent on the basis of studies that combine the agonism of glucagon receptor and glucagon-like peptide 1 receptor.  The initial identification of glucagon as a counter-regulatory hormone to insulin revealed this hormone to be of largely singular physiol. and pharmacol. purpose.  Glucagon agonism, however, has also been shown to exert effects on lipid metab., energy balance, body adipose tissue mass and food intake.  The ability of glucagon to stimulate energy expenditure, along with its hypolipidemic and satiating effects, in particular, make this hormone an attractive pharmaceutical agent for the treatment of dyslipidemia and obesity.  Studies that describe novel preclin. applications of glucagon, alone and in concert with glucagon-like peptide 1 agonism, have revealed potential benefits of glucagon agonism in the treatment of the metabolic syndrome.  Collectively, these observations challenge us to thoroughly investigate the physiol. and therapeutic potential of insulin's long-known opponent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOL0wBOH5c17Vg90H21EOLACvtfcHk0lgrNZxndtHf9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsL%252FE&md5=e9654fcb821e11f5388ef74e95513bc0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.187%26sid%3Dliteratum%253Aachs%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DHeppner%26aufirst%3DK.%2BM.%26aulast%3DGeary%26aufirst%3DN.%26aulast%3DBartness%26aufirst%3DT.%2BJ.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Metabolic%2520Actions%2520of%2520Glucagon%2520Revisited%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2010%26volume%3D6%26issue%3D12%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fnrendo.2010.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arafat, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alessio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharitonenkov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spranger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1453</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span><span class="refDoi"> DOI: 10.2337/db12-1116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdb12-1116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=1453-1463&issue=5&author=K.+M.+Habeggerauthor=K.+Stemmerauthor=C.+Chengauthor=T.+D.+M%C3%BCllerauthor=K.+M.+Heppnerauthor=N.+Ottawayauthor=J.+Hollandauthor=J.+L.+Hembreeauthor=D.+Smileyauthor=V.+Gelfanovauthor=R.+Krishnaauthor=A.+M.+Arafatauthor=A.+Konkarauthor=S.+Belliauthor=M.+Kappsauthor=S.+C.+Woodsauthor=S.+M.+Hofmannauthor=D.+D%E2%80%99Alessioauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+J.+Seeleyauthor=M.+Konishiauthor=N.+Itohauthor=A.+Kharitonenkovauthor=J.+Sprangerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=Fibroblast+Growth+Factor+21+Mediates+Specific+Glucagon+Actions&doi=10.2337%2Fdb12-1116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2337%2Fdb12-1116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb12-1116%26sid%3Dliteratum%253Aachs%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DHeppner%26aufirst%3DK.%2BM.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%2BL.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DArafat%26aufirst%3DA.%2BM.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DKapps%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DHofmann%26aufirst%3DS.%2BM.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DN.%26aulast%3DKharitonenkov%26aufirst%3DA.%26aulast%3DSpranger%26aufirst%3DJ.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DFibroblast%2520Growth%2520Factor%252021%2520Mediates%2520Specific%2520Glucagon%2520Actions%26jtitle%3DDiabetes%26date%3D2013%26volume%3D62%26issue%3D5%26spage%3D1453%26epage%3D1463%26doi%3D10.2337%2Fdb12-1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wynne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wren, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2390</span><span class="NLM_x">–</span> <span class="NLM_lpage">2395</span><span class="refDoi"> DOI: 10.2337/diabetes.54.8.2390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdiabetes.54.8.2390" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2390-2395&issue=8&author=K.+Wynneauthor=A.+J.+Parkauthor=C.+J.+Smallauthor=M.+Pattersonauthor=S.+M.+Ellisauthor=K.+G.+Murphyauthor=A.+M.+Wrenauthor=G.+S.+Frostauthor=K.+Meeranauthor=M.+A.+Ghateiauthor=S.+R.+Bloom&title=Subcutaneous+Oxyntomodulin+Reduces+Body+Weight+in+Overweight+and+Obese+Subjects%3A+A+Double-Blind%2C+Randomized%2C+Controlled+Trial&doi=10.2337%2Fdiabetes.54.8.2390"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.8.2390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.8.2390%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DPatterson%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DS.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BG.%26aulast%3DWren%26aufirst%3DA.%2BM.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DMeeran%26aufirst%3DK.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DSubcutaneous%2520Oxyntomodulin%2520Reduces%2520Body%2520Weight%2520in%2520Overweight%2520and%2520Obese%2520Subjects%253A%2520A%2520Double-Blind%252C%2520Randomized%252C%2520Controlled%2520Trial%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26issue%3D8%26spage%3D2390%26epage%3D2395%26doi%3D10.2337%2Fdiabetes.54.8.2390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Wynne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Oxyntomodulin Increases Energy Expenditure in Addition to Decreasing Energy Intake in Overweight and Obese Humans: A Randomised Controlled Trial</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1729</span><span class="NLM_x">–</span> <span class="NLM_lpage">1736</span><span class="refDoi"> DOI: 10.1038/sj.ijo.0803344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fsj.ijo.0803344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ClsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=1729-1736&issue=12&author=K.+Wynneauthor=A.+J.+Parkauthor=C.+J.+Smallauthor=K.+Meeranauthor=M.+A.+Ghateiauthor=G.+S.+Frostauthor=S.+R.+Bloom&title=Oxyntomodulin+Increases+Energy+Expenditure+in+Addition+to+Decreasing+Energy+Intake+in+Overweight+and+Obese+Humans%3A+A+Randomised+Controlled+Trial&doi=10.1038%2Fsj.ijo.0803344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial</span></div><div class="casAuthors">Wynne, K.; Park, A. J.; Small, C. J.; Meeran, K.; Ghatei, M. A.; Frost, G. S.; Bloom, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1729-1736</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Oxyntomodulin has recently been found to decrease body-wt. in obese humans and may be a potential anti-obesity therapy.  Objective:To det. whether oxyntomodulin alters energy expenditure, in addn. to reducing energy intake, in free-living' overweight and obese volunteers.  Design:Randomized double-blind controlled cross-over trial.  Setting:Community and hospital-based.  Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m2).  All volunteers completed the study protocol.Interventions:Four-day s.c. self-administration of pre-prandial oxyntomodulin, three times daily.  Participants were advised to maintain their normal dietary and exercise regimen.  Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.  Results: Oxyntomodulin administration reduced energy intake at the study meal by 128±29 kcal (P=0.0006) or 17.3±5.5% (P=0.0071), with no change in meal palatability.  Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143±109 kcal/day or 26.2±9.9% (P=0.0221); total energy expenditure by 9.4±4.8% (P=0.0454) and phys. activity level by 9.5±4.6% (P=0.0495).  A redn. in body wt. of 0.5±0.2% was obsd. during the oxyntomodulin administration period (P=0.0232).  Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in neg. energy balance.  This data supports the role of oxyntomodulin as a potential anti-obesity therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUKdXvSPC2VLVg90H21EOLACvtfcHk0lgrNZxndtHf9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ClsL%252FO&md5=ca668aed35743288fdff04e49b6d11a6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803344%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DMeeran%26aufirst%3DK.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DOxyntomodulin%2520Increases%2520Energy%2520Expenditure%2520in%2520Addition%2520to%2520Decreasing%2520Energy%2520Intake%2520in%2520Overweight%2520and%2520Obese%2520Humans%253A%2520A%2520Randomised%2520Controlled%2520Trial%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2006%26volume%3D30%26issue%3D12%26spage%3D1729%26epage%3D1736%26doi%3D10.1038%2Fsj.ijo.0803344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauck, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft-Nielsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willms, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Both Subcutaneously and Intravenously Administered Glucagon-like Peptide I Are Rapidly Degraded from the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1126</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.2337/diab.44.9.1126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdiab.44.9.1126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=7657039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK2MXotVGhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1995&pages=1126-1131&issue=9&author=C.+F.+Deaconauthor=M.+A.+Nauckauthor=M.+Toft-Nielsenauthor=L.+Pridalauthor=B.+Willmsauthor=J.+J.+Holst&title=Both+Subcutaneously+and+Intravenously+Administered+Glucagon-like+Peptide+I+Are+Rapidly+Degraded+from+the+NH2-Terminus+in+Type+II+Diabetic+Patients+and+in+Healthy+Subjects&doi=10.2337%2Fdiab.44.9.1126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects</span></div><div class="casAuthors">Deacon, Carolyn F.; Nauck, Michael A.; Toft-Nielsen, Maibritt; Pridal, Lone; Willms, Berend; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1126-31</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">The fate of exogenous glucagon-like peptide I (GLP-I)(7-36) amide was studied in nondiabetic and type II diabetic subjects using a combination of HPLC, specific RIAs, and a sensitive ELISA, whereby intact biol. active GLP-I and its metabolites could be detd.  After GLP-I administration, the intact peptide could be measured using an N-terminally direct RIA or ELISA, while the difference in concn. between these assays and a C-terminal-specific RIA allowed detn. of N-terminally truncated metabolites.  S.c. GLP-I was rapidly degraded in a time-dependent manner, forming a metabolite, which coeluted on HPLC with GLP-I(9-36) amide and had the same immunoreactive profile.  Thirty minutes after s.c. GLP-I administration to diabetic patients, the metabolite accounted for 88.5% of the increase in plasma immunoreactivity detd. by the C-terminal RIA, which was higher than the levels measured in healthy subjects (78.4%).  I.v. infused GLP-I was also extensively degraded, but no significant differences were seen between the 2 groups.  Intact GLP-I accounted for only 19.9% of the increase in immunoreactivity measured with the C-terminal RIA in normal subjects and 25.0% of the increase in diabetic subjects, the remainder being the N-terminally truncated metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4B-dpZvjbLVg90H21EOLACvtfcHk0lhlcaT46eVq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotVGhu7c%253D&md5=f8a989897d4e40a0662d51cb89aba34f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2337%2Fdiab.44.9.1126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.44.9.1126%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DToft-Nielsen%26aufirst%3DM.%26aulast%3DPridal%26aufirst%3DL.%26aulast%3DWillms%26aufirst%3DB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DBoth%2520Subcutaneously%2520and%2520Intravenously%2520Administered%2520Glucagon-like%2520Peptide%2520I%2520Are%2520Rapidly%2520Degraded%2520from%2520the%2520NH2-Terminus%2520in%2520Type%2520II%2520Diabetic%2520Patients%2520and%2520in%2520Healthy%2520Subjects%26jtitle%3DDiabetes%26date%3D1995%26volume%3D44%26issue%3D9%26spage%3D1126%26epage%3D1131%26doi%3D10.2337%2Fdiab.44.9.1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sountis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capito’, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2258</span><span class="NLM_x">–</span> <span class="NLM_lpage">2266</span><span class="refDoi"> DOI: 10.2337/db09-0278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdb09-0278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19602537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&issue=10&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiangauthor=F.+Liuauthor=C.+Millerauthor=L.+M.+Totaauthor=G.+Zhouauthor=X.+Zhangauthor=M.+M.+Sountisauthor=A.+Santopreteauthor=E.+Capito%E2%80%99author=G.+G.+Chicchiauthor=N.+Thornberryauthor=E.+Bianchiauthor=A.+Pessiauthor=D.+J.+Marshauthor=R.+SinhaRoy&title=Glucagon-Like+Peptide+1%2FGlucagon+Receptor+Dual+Agonism+Reverses+Obesity+in+Mice&doi=10.2337%2Fdb09-0278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span></div><div class="casAuthors">Pocai, Alessandro; Carrington, Paul E.; Adams, Jennifer R.; Wright, Michael; Eiermann, George; Zhu, Lan; Du, Xiaobing; Petrov, Aleksandr; Lassman, Michael E.; Jiang, Guoqiang; Liu, Franklin; Miller, Corey; Tota, Laurie M.; Zhou, Gaochao; Zhang, Xiaoping; Sountis, Michael M.; Santoprete, Alessia; Capito, Elena; Chicchi, Gary G.; Thornberry, Nancy; Bianchi, Elisabetta; Pessi, Antonello; Marsh, Donald J.; Sinha Roy, Ranabir</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2258-2266</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body wt. in obese subjects through increased energy expenditure and decreased energy intake.  The metabolic effects of OXM have been attributed primarily to GLP1R agonism.  We examd. whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist.  Research Design and Methods-We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics.  The metabolic effects of these two peptides with respect to wt. loss, caloric redn., glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice.  Acute studies in DIO mice revealed metabolic pathways that were modulated independent of wt. loss.  Studies in Glp1r-/- and Gcgr-/- mice enabled delineation of the contribution of GLP1R vs. GCGR activation to the pharmacol. of DualAG.  Results-Peptide DualAG exhibits superior wt. loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG.  Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG.  Dual receptor agonism also increased fatty acid oxidn. and reduced hepatic steatosis in DIO mice.  The antiobesity effects of DualAG require activation of both GLP1R and GCGR.  Conclusions-Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX2C2QNX0zG7Vg90H21EOLACvtfcHk0lhlcaT46eVq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK&md5=412b04ba021de2fdfb2c6b011c289eeb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2337%2Fdb09-0278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-0278%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DTota%26aufirst%3DL.%2BM.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSountis%26aufirst%3DM.%2BM.%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapito%25E2%2580%2599%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26atitle%3DGlucagon-Like%2520Peptide%25201%252FGlucagon%2520Receptor%2520Dual%2520Agonism%2520Reverses%2520Obesity%2520in%2520Mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26issue%3D10%26spage%3D2258%26epage%3D2266%26doi%3D10.2337%2Fdb09-0278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capitò, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finotto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingallinella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zytko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veneziano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">DPP-IV-Resistant, Long-Acting Oxyntomodulin Derivatives</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/psc.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fpsc.1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21294225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVGis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=270-280&issue=4&author=A.+Santopreteauthor=E.+Capit%C3%B2author=P.+E.+Carringtonauthor=A.+Pocaiauthor=M.+Finottoauthor=A.+Langellaauthor=P.+Ingallinellaauthor=K.+Zytkoauthor=S.+Bufaliauthor=S.+Cianettiauthor=M.+Venezianoauthor=F.+Bonelliauthor=L.+Zhuauthor=E.+Monteagudoauthor=D.+J.+Marshauthor=R.+SinhaRoyauthor=E.+Bianchiauthor=A.+Pessi&title=DPP-IV-Resistant%2C+Long-Acting+Oxyntomodulin+Derivatives&doi=10.1002%2Fpsc.1328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">DPP-IV-resistant, long-acting oxyntomodulin derivatives</span></div><div class="casAuthors">Santoprete, Alessia; Capito, Elena; Carrington, Paul E.; Pocai, Alessandro; Finotto, Marco; Langella, Annunziata; Ingallinella, Paolo; Zytko, Karolina; Bufali, Simone; Cianetti, Simona; Veneziano, Maria; Bonelli, Fabio; Zhu, Lan; Monteagudo, Edith; Marsh, Donald J.; Sinha Roy, Ranabir; Bianchi, Elisabetta; Pessi, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-280</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Obesity is one of the major risk factors for type 2 diabetes, and the development of agents, that can simultaneously achieve glucose control and wt. loss, is being actively pursued.  Therapies based on peptide mimetics of the gut hormone glucagon-like peptide 1 (GLP-1) are rapidly gaining favor, due to their ability to increase insulin secretion in a strictly glucose-dependent manner, with little or no risk of hypoglycemia, and to their addnl. benefit of causing a modest, but durable wt. loss.  Oxyntomodulin (OXM), a 37-amino acid peptide hormone of the glucagon (GCG) family with dual agonistic activity on both the GLP-1 (GLP1R) and the GCG (GCGR) receptors, has been shown to reduce food intake and body wt. in humans, with a lower incidence of treatment-assocd. nausea than GLP-1 mimetics.  As for other peptide hormones, its clin. application is limited by the short circulatory half-life, a major component of which is cleavage by the enzyme dipeptidyl peptidase IV (DPP-IV).  SAR studies on OXM, described herein, led to the identification of mols. resistant to DPP-IV degrdn., with increased potency as compared to the natural hormone.  Analogs derivatized with a cholesterol moiety display increased duration of action in vivo.  Moreover, the authors identified a single substitution which can change the OXM pharmacol. profile from a dual GLP1R/GCGR agonist to a selective GLP1R agonist.  The latter finding enabled studies, described in detail in a sep. study, which highlight the potential of GLP1R/GCGR dual agonists as a potentially superior class of therapeutics over the pure GLP1R agonists currently in clin. use.  Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0kcyP1jgOzbVg90H21EOLACvtfcHk0lja-z8kQmNMHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVGis7o%253D&md5=e0197f794ec64e967c06081058f0b423</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1328%26sid%3Dliteratum%253Aachs%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapit%25C3%25B2%26aufirst%3DE.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DFinotto%26aufirst%3DM.%26aulast%3DLangella%26aufirst%3DA.%26aulast%3DIngallinella%26aufirst%3DP.%26aulast%3DZytko%26aufirst%3DK.%26aulast%3DBufali%26aufirst%3DS.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DVeneziano%26aufirst%3DM.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DDPP-IV-Resistant%252C%2520Long-Acting%2520Oxyntomodulin%2520Derivatives%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D270%26epage%3D280%26doi%3D10.1002%2Fpsc.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">D-Ser2)Oxm[mPEG-PAL]: A Novel Chemically Modified Analogue of Oxyntomodulin with Antihyperglycaemic, Insulinotropic and Anorexigenic Actions</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1735</span><span class="refDoi"> DOI: 10.1016/j.bcp.2010.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bcp.2010.08.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=1727-1735&issue=11&author=B.+D.+Kerrauthor=P.+R.+Flattauthor=V.+A.+Gault&title=D-Ser2%29Oxm%5BmPEG-PAL%5D%3A+A+Novel+Chemically+Modified+Analogue+of+Oxyntomodulin+with+Antihyperglycaemic%2C+Insulinotropic+and+Anorexigenic+Actions&doi=10.1016%2Fj.bcp.2010.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DD-Ser2%2529Oxm%255BmPEG-PAL%255D%253A%2520A%2520Novel%2520Chemically%2520Modified%2520Analogue%2520of%2520Oxyntomodulin%2520with%2520Antihyperglycaemic%252C%2520Insulinotropic%2520and%2520Anorexigenic%2520Actions%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26issue%3D11%26spage%3D1727%26epage%3D1735%26doi%3D10.1016%2Fj.bcp.2010.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A Novel DPP IV-Resistant C-Terminally Extended Glucagon Analogue Exhibits Weight-Lowering and Diabetes-Protective Effects in High-Fat-Fed Mice Mediated through Glucagon and GLP-1 Receptor Activation</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1927</span><span class="NLM_x">–</span> <span class="NLM_lpage">1936</span><span class="refDoi"> DOI: 10.1007/s00125-014-3296-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1007%2Fs00125-014-3296-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1927-1936&issue=9&author=A.+M.+Lynchauthor=N.+Pathakauthor=V.+Pathakauthor=F.+P.+M.+O%E2%80%99Harteauthor=P.+R.+Flattauthor=N.+Irwinauthor=V.+A.+Gault&title=A+Novel+DPP+IV-Resistant+C-Terminally+Extended+Glucagon+Analogue+Exhibits+Weight-Lowering+and+Diabetes-Protective+Effects+in+High-Fat-Fed+Mice+Mediated+through+Glucagon+and+GLP-1+Receptor+Activation&doi=10.1007%2Fs00125-014-3296-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3296-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3296-7%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DPathak%26aufirst%3DN.%26aulast%3DPathak%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520Novel%2520DPP%2520IV-Resistant%2520C-Terminally%2520Extended%2520Glucagon%2520Analogue%2520Exhibits%2520Weight-Lowering%2520and%2520Diabetes-Protective%2520Effects%2520in%2520High-Fat-Fed%2520Mice%2520Mediated%2520through%2520Glucagon%2520and%2520GLP-1%2520Receptor%2520Activation%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D1927%26epage%3D1936%26doi%3D10.1007%2Fs00125-014-3296-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Novel Dual Agonist Peptide Analogues Derived from Dogfish Glucagon Show Promising in Vitro Insulin Releasing Actions and Antihyperglycaemic Activity in Mice</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1016/j.mce.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.mce.2016.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27179756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2016&pages=133-144&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Novel+Dual+Agonist+Peptide+Analogues+Derived+from+Dogfish+Glucagon+Show+Promising+in+Vitro+Insulin+Releasing+Actions+and+Antihyperglycaemic+Activity+in+Mice&doi=10.1016%2Fj.mce.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The antidiabetic potential of thirteen novel dogfish glucagon derived analogs were assessed in vitro and in acute in vivo studies.  Stable peptide analogs enhanced insulin secretion from BRIN-BD11 β-cells (p < 0.001) and reduced acute glycemic responses following i.p. glucose (25 nmol/kg) in healthy NIH Swiss mice (p < 0.05-p<0.001).  The in vitro insulinotropic actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL, were blocked (p < 0.05-p<0.001) by the specific GLP-1 and glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by (Pro3)GIP, indicating lack of GIP receptor involvement.  These analogs dose-dependently stimulated cAMP prodn. in GLP-1 and glucagon (p < 0.05-p<0.001) but not GIP-receptor transfected cells.  They improved acute glycemic and insulinotropic responses in high-fat fed diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p < 0.05-p<0.001), but not GLP-1R-KO mice, confirming action on GLP-1 but not GIP receptors.  Overall, dogfish glucagon analogs have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 and glucagon receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYMG0tNkdC2LVg90H21EOLACvtfcHk0lja-z8kQmNMHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D&md5=50d438aaa6ea3d9910faa9063c66f441</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Dual%2520Agonist%2520Peptide%2520Analogues%2520Derived%2520from%2520Dogfish%2520Glucagon%2520Show%2520Promising%2520in%2520Vitro%2520Insulin%2520Releasing%2520Actions%2520and%2520Antihyperglycaemic%2520Activity%2520in%2520Mice%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2016%26volume%3D431%26spage%3D133%26epage%3D144%26doi%3D10.1016%2Fj.mce.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Dogfish Glucagon Analogues Counter Hyperglycaemia and Enhance Both Insulin Secretion and Action in Diet-Induced Obese Diabetic Mice</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span><span class="refDoi"> DOI: 10.1111/dom.12713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fdom.12713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27357054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1013-1024&issue=10&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Dogfish+Glucagon+Analogues+Counter+Hyperglycaemia+and+Enhance+Both+Insulin+Secretion+and+Action+in+Diet-Induced+Obese+Diabetic+Mice&doi=10.1111%2Fdom.12713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To investigate the antidiabetic actions of three dogfish glucagon peptide analogs [known glucagon-like peptide-1 and glucagon receptor co-agonists] after chronic administration in diet-induced high-fat-diet-fed diabetic mice.  Materials and methods : National Institutes of Health Swiss mice were pre-conditioned to a high-fat diet (45% fat) for 100 days, and control mice were fed a normal diet (10% fat).  Normal diet control and high-fat-fed control mice received twice-daily i.p. (i.p.) saline injections, while the high-fat-fed treatment groups (n = 8) received twice-daily injections of exendin-4(1-39), [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (25 nmol/kg body wt.) for 51 days.  Results : After dogfish glucagon analog treatment, there was a rapid and sustained decrease in non-fasting blood glucose and an assocd. insulinotropic effect (anal. of variance, p < .05 to <.001) compared with saline-treated high-fat-fed controls.  All peptide treatments significantly improved i.p. and oral glucose tolerance with concomitant increased insulin secretion compared with saline-treated high-fat-fed controls (p <.05 to <.001).  After chronic treatment, no receptor desensitization was obsd. but insulin sensitivity was enhanced for all peptide-treated groups (p < .01 to <.001) except [S2a]dogfish glucagon.  Both exendin-4 and [S2a]dogfish glucagon exendin-4(31-39) significantly reduced plasma triglyceride concns. compared with those found in lean controls (p = .0105 and p = .0048, resp.).  Pancreatic insulin content was not affected by peptide treatments but [S2a]dogfish glucagon and [S2a]dogfish glucagon exendin-4(31-39) decreased pancreatic glucagon by 28%-34% (p = .0221 and p = .0075, resp.).  The percentage of β-cell area within islets was increased by exendin-4 and peptide analog treatment groups compared with high-fat-fed controls and the β-cell area decreased (p < .05 to <.01).  Conclusions : Overall, dogfish glucagon co-agonist analogs had several beneficial metabolic effects, showing therapeutic potential for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33HIW_8oZO7Vg90H21EOLACvtfcHk0lja-z8kQmNMHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF&md5=a6c619b6d47964b961f020ad88ea035a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fdom.12713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12713%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DDogfish%2520Glucagon%2520Analogues%2520Counter%2520Hyperglycaemia%2520and%2520Enhance%2520Both%2520Insulin%2520Secretion%2520and%2520Action%2520in%2520Diet-Induced%2520Obese%2520Diabetic%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D10%26spage%3D1013%26epage%3D1024%26doi%3D10.1111%2Fdom.12713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Henderson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornigold, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch Fredin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson-Löfmark, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagroo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimsby, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jermutus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondinone, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M. P.</span><span> </span><span class="NLM_article-title">Robust Anti-Obesity and Metabolic Effects of a Dual GLP-1/Glucagon Receptor Peptide Agonist in Rodents and Non-Human Primates</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1176</span><span class="refDoi"> DOI: 10.1111/dom.12735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fdom.12735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27377054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1176&author=S.+J.+Hendersonauthor=A.+Konkarauthor=D.+C.+Hornigoldauthor=J.+L.+Trevaskisauthor=R.+Jacksonauthor=M.+Fritsch+Fredinauthor=R.+Jansson-L%C3%B6fmarkauthor=J.+Naylorauthor=A.+Rossiauthor=M.+A.+Bednarekauthor=N.+Bhagrooauthor=H.+Salariauthor=S.+Willauthor=S.+Oldhamauthor=G.+Hansenauthor=M.+Feighauthor=T.+Kleinauthor=J.+Grimsbyauthor=S.+Maguireauthor=L.+Jermutusauthor=C.+M.+Rondinoneauthor=M.+P.+Coghlan&title=Robust+Anti-Obesity+and+Metabolic+Effects+of+a+Dual+GLP-1%2FGlucagon+Receptor+Peptide+Agonist+in+Rodents+and+Non-Human+Primates&doi=10.1111%2Fdom.12735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates</span></div><div class="casAuthors">Henderson, S. J.; Konkar, A.; Hornigold, D. C.; Trevaskis, J. L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Loefmark, R.; Naylor, J.; Rossi, A.; Bednarek, M. A.; Bhagroo, N.; Salari, H.; Will, S.; Oldham, S.; Hansen, G.; Feigh, M.; Klein, T.; Grimsby, J.; Maguire, S.; Jermutus, L.; Rondinone, C. M.; Coghlan, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1190</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To characterize the pharmacol. of MEDI0382, a peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors.  Materials and methods : MEDI0382 was evaluated in vitro for its ability to stimulate cAMP accumulation in cell lines expressing transfected recombinant or endogenous GLP-1 or glucagon receptors, to potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic β-cell lines and stimulate hepatic glucose output (HGO) by primary hepatocytes.  The ability of MEDI0382 to reduce body wt. and improve energy balance (i.e. food intake and energy expenditure), as well as control blood glucose, was evaluated in mouse models of obesity and healthy cynomolgus monkeys following single and repeated daily s.c. administration for up to 2 mo.  Results : MEDI0382 potently activated rodent, cynomolgus and human GLP-1 and glucagon receptors and exhibited a fivefold bias for activation of GLP-1 receptor vs. the glucagon receptor.  MEDI0382 produced superior wt. loss and comparable glucose lowering to the GLP-1 peptide analog liraglutide when administered daily at comparable doses in DIO mice.  The addnl. fat mass redn. elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor.  Notably, the significant wt. loss elicited by MEDI0382 in DIO mice was recapitulated in cynomolgus monkeys.  Conclusions : Repeated administration of MEDI0382 elicits profound wt. loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels.  The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving wt. and glucose control in overweight or obese Type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Lj1dV4AsLVg90H21EOLACvtfcHk0lgdFaBgWnDR3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN&md5=e0af76d2553a265b6367aab1cc46df6f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fdom.12735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12735%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BJ.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DHornigold%26aufirst%3DD.%2BC.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DR.%26aulast%3DFritsch%2BFredin%26aufirst%3DM.%26aulast%3DJansson-L%25C3%25B6fmark%26aufirst%3DR.%26aulast%3DNaylor%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26aulast%3DBhagroo%26aufirst%3DN.%26aulast%3DSalari%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DOldham%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DG.%26aulast%3DFeigh%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DGrimsby%26aufirst%3DJ.%26aulast%3DMaguire%26aufirst%3DS.%26aulast%3DJermutus%26aufirst%3DL.%26aulast%3DRondinone%26aufirst%3DC.%2BM.%26aulast%3DCoghlan%26aufirst%3DM.%2BP.%26atitle%3DRobust%2520Anti-Obesity%2520and%2520Metabolic%2520Effects%2520of%2520a%2520Dual%2520GLP-1%252FGlucagon%2520Receptor%2520Peptide%2520Agonist%2520in%2520Rodents%2520and%2520Non-Human%2520Primates%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D1176%26doi%3D10.1111%2Fdom.12735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>Pegapamodutide, C16H27N3O7S, PubChem. <a href="https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties" class="extLink">https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties</a> (accessed Mar 21,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pegapamodutide%2C+C16H27N3O7S%2C+PubChem.+https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fcompound%2F121494121%23section%3DChemical-and-Physical-Properties+%28accessed+Mar+21%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Transition Therapeutics Inc.</span><a href="http://www.transitiontherapeutics.com/technology/tt401.php" class="extLink">http://www.transitiontherapeutics.com/technology/tt401.php</a> (accessed Mar 21,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Transition+Therapeutics+Inc.http%3A%2F%2Fwww.transitiontherapeutics.com%2Ftechnology%2Ftt401.php+%28accessed+Mar+21%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&issue=1&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2eYJMtrM1_3Rl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26issue%3D1%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Eng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raufman, J. P.</span><span> </span><span class="NLM_article-title">Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma Suspectum Venom. Further Evidence for an Exendin Receptor on Dispersed Acini from Guinea Pig Pancreas</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">7402</span><span class="NLM_x">–</span> <span class="NLM_lpage">7405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1313797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK38XktVantbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=7402-7405&issue=11&author=J.+Engauthor=W.+A.+Kleinmanauthor=L.+Singhauthor=G.+Singhauthor=J.+P.+Raufman&title=Isolation+and+Characterization+of+Exendin-4%2C+an+Exendin-3+Analogue%2C+from+Heloderma+Suspectum+Venom.+Further+Evidence+for+an+Exendin+Receptor+on+Dispersed+Acini+from+Guinea+Pig+Pancreas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and characterization of exendin-4, an exendin-3 analog, from Heloderma suspectum venom.  Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas</span></div><div class="casAuthors">Eng, John; Kleinman, Wayne A.; Singh, Latika; Singh, Gurcharn; Raufman, Jean Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7402-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">An amino acid sequencing assay for peptides contg. an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom.  Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical.  The structural differences make exendin-4 distinct from exendin-3 in its bioactivity.  In dispersed acini from guinea pig pancreas, natural and synthetic exendin-4 stimulate a monophasic increase in cAMP beginning at 100 pM that plateaus at 10 nM.  The exendin-4-induced increase in cAMP is inhibited progressively by increasing concns. of the exendin receptor antagonist, exendin-(9-39) amide.  Unlike exendin-3, exendin-4 does not stimulate a second rise in acinar cAMP at concns. >100 nM, does not stimulate amylase release, and does not inhibit the binding of radiolabeled vasoactive intestinal peptide to acini.  This indicates that in dispersed pancreatic acini, exendin-4 interacts only with the recently described exendin receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGIkNL-1j-OLVg90H21EOLACvtfcHk0ljLGwUCMeCzYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVantbw%253D&md5=30a9fa4a1a4f1b307babeb02750af81e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DKleinman%26aufirst%3DW.%2BA.%26aulast%3DSingh%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DRaufman%26aufirst%3DJ.%2BP.%26atitle%3DIsolation%2520and%2520Characterization%2520of%2520Exendin-4%252C%2520an%2520Exendin-3%2520Analogue%252C%2520from%2520Heloderma%2520Suspectum%2520Venom.%2520Further%2520Evidence%2520for%2520an%2520Exendin%2520Receptor%2520on%2520Dispersed%2520Acini%2520from%2520Guinea%2520Pig%2520Pancreas%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D11%26spage%3D7402%26epage%3D7405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gentilella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, C. M.</span><span> </span><span class="NLM_article-title">Exenatide: A Review from Pharmacology to Clinical Practice</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1111/j.1463-1326.2008.01018.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1463-1326.2008.01018.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19383034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslKrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=544-556&issue=6&author=R.+Gentilellaauthor=C.+Bianchiauthor=A.+Rossiauthor=C.+M.+Rotella&title=Exenatide%3A+A+Review+from+Pharmacology+to+Clinical+Practice&doi=10.1111%2Fj.1463-1326.2008.01018.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Exenatide: a review from pharmacology to clinical practice</span></div><div class="casAuthors">Gentilella, R.; Bianchi, C.; Rossi, A.; Rotella, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-556</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Background: Exenatide is an incretin mimetic that activates glucagon-like-peptide-1 receptors.  It blunts the postprandial rise of plasma glucose by increasing glucose-dependent insulin secretion, suppressing inappropriately high glucagon secretion and delaying gastric emptying.  Methods: In seven clin. trials performed in 2845 adult patients with type 2 diabetes mellitus who were inadequately controlled by a sulfonylurea and/or metformin (glycosylated Hb, HbA1c ≤11%), or by thiazolidinediones (with or without metformin) and treated for periods from 16 wk to 3 years, exenatide (5 μg b.i.d. s.c. for the first 4 wk of treatment and 10 μg b.i.d. s.c. thereafter) reduced HbA1c, fasting and postprandial glucose, and body wt. dose dependently, and was similar to insulin glargine and biphasic insulin aspart in reducing HbA1c.  Body wt. diminished with exenatide, whereas it increased with both insulin prepns.  Pos. effects on the lipid profile and a redn. in C-reactive protein were also recorded with exenatide.  Treatment extensions up to 3 years showed that benefits were maintained in the long term.  Adverse events were usually mild to moderate in intensity, and generally the frequency decreased with continued therapy.  The most common was nausea (whose incidence may be reduced by gradual dose escalation from 5 μg b.i.d. to 10 μg b.i.d.), vomiting, diarrhoea, headache and hypoglycemia (almost exclusively in patients treated with a sulfonylurea).  Results and conclusions: Exenatide is a new, promising therapeutic option for type 2 diabetic patients inadequately controlled by oral agents, before insulin therapy, offering the added benefits of body wt. redn. and tight postprandial glucose control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpY_wods_kbVg90H21EOLACvtfcHk0ljLGwUCMeCzYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslKrtLc%253D&md5=654e14d148130da5589b20d28e8b08e0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2008.01018.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2008.01018.x%26sid%3Dliteratum%253Aachs%26aulast%3DGentilella%26aufirst%3DR.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRotella%26aufirst%3DC.%2BM.%26atitle%3DExenatide%253A%2520A%2520Review%2520from%2520Pharmacology%2520to%2520Clinical%2520Practice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2009%26volume%3D11%26issue%3D6%26spage%3D544%26epage%3D556%26doi%3D10.1111%2Fj.1463-1326.2008.01018.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Norris, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakurta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K. S.</span><span> </span><span class="NLM_article-title">Exenatide Efficacy and Safety: A Systematic Review</span> <span class="citation_source-journal">Diabetic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span><span class="refDoi"> DOI: 10.1111/j.1464-5491.2009.02790.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1464-5491.2009.02790.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19719703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=837-846&issue=9&author=S.+L.+Norrisauthor=N.+Leeauthor=S.+Thakurtaauthor=B.+K.+S.+Chan&title=Exenatide+Efficacy+and+Safety%3A+A+Systematic+Review&doi=10.1111%2Fj.1464-5491.2009.02790.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Exenatide efficacy and safety: a systematic review</span></div><div class="casAuthors">Norris, S. L.; Lee, N.; Thakurta, S.; Chan, B. K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetic Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-846</span>CODEN:
                <span class="NLM_cas:coden">DIMEEV</span>;
        ISSN:<span class="NLM_cas:issn">0742-3071</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Objective: To examine the efficacy, effectiveness and side effects of exenatide when compared with oral glucose-lowering agents or insulin therapy.  Research design and methods: Relevant citations were identified from searches of multiple bibliog. databases supplemented with searches of the US Food and Drug Administration website and other sources.  A qual. synthesis was performed, with a random effects meta-anal. when appropriate.  Results: We identified 17 studies.  In placebo-controlled trials of subjects with poorly controlled diabetes (with both groups receiving various oral glucose-lowering agents), exenatide 10 μg twice daily improved glycated Hb (HbA1c) by approx. 1.0% over 30 wk [pooled est. -0.97%, 95% confidence interval (CI), -1.16 to -0.79%, P < 0.0001] and exenatide treatment over 16-30 wk was assocd. with wt. loss of 1.0-2.5 kg.  Exenatide appeared to confer a similar benefit to various insulin regimes for glycemic control at follow-up between 16 and 52 wk (pooled est. HbA1c -0.04%, 95% CI, -0.14 to 0.06%, P = 0.41), but was advantageous over insulin with respect to wt. loss (3-6 kg loss at up to 52 wk of follow-up).  Nausea was the most common adverse event in placebo- and active-controlled trials.  Rates of hypoglycemia were similar in exenatide and insulin groups, but were higher with exenatide 10 μg twice daily compared with placebo and hypoglycemia was most frequent when a sulfonylurea was administered.  Conclusions: In subjects with poorly controlled diabetes, exenatide was assocd. with a redn. in HbA1c that was similar to introducing another oral agent or insulin.  Wt. loss may be an advantage with exenatide.  Long-term studies in diverse and unselected populations are needed to clarify the benefit vs. harm profile of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplZdRe2LxeZrVg90H21EOLACvtfcHk0ljLGwUCMeCzYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gnu7jI&md5=67e66917de24465a7ab4bfad9406df86</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-5491.2009.02790.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-5491.2009.02790.x%26sid%3Dliteratum%253Aachs%26aulast%3DNorris%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DThakurta%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DB.%2BK.%2BS.%26atitle%3DExenatide%2520Efficacy%2520and%2520Safety%253A%2520A%2520Systematic%2520Review%26jtitle%3DDiabetic%2520Med.%26date%3D2009%26volume%3D26%26issue%3D9%26spage%3D837%26epage%3D846%26doi%3D10.1111%2Fj.1464-5491.2009.02790.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Bunck, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliasson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaginian, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskinen, M.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yki-Jarvinen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamant, M.</span><span> </span><span class="NLM_article-title">Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2047</span><span class="refDoi"> DOI: 10.2337/dc11-0291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdc11-0291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=2041-2047&issue=9&author=M.+C.+Bunckauthor=A.+Cornerauthor=B.+Eliassonauthor=R.+J.+Heineauthor=R.+M.+Shaginianauthor=M.-R.+Taskinenauthor=U.+Smithauthor=H.+Yki-Jarvinenauthor=M.+Diamant&title=Effects+of+Exenatide+on+Measures+of+-Cell+Function+After+3+Years+in+Metformin-Treated+Patients+With+Type+2+Diabetes&doi=10.2337%2Fdc11-0291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2337%2Fdc11-0291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-0291%26sid%3Dliteratum%253Aachs%26aulast%3DBunck%26aufirst%3DM.%2BC.%26aulast%3DCorner%26aufirst%3DA.%26aulast%3DEliasson%26aufirst%3DB.%26aulast%3DHeine%26aufirst%3DR.%2BJ.%26aulast%3DShaginian%26aufirst%3DR.%2BM.%26aulast%3DTaskinen%26aufirst%3DM.-R.%26aulast%3DSmith%26aufirst%3DU.%26aulast%3DYki-Jarvinen%26aufirst%3DH.%26aulast%3DDiamant%26aufirst%3DM.%26atitle%3DEffects%2520of%2520Exenatide%2520on%2520Measures%2520of%2520-Cell%2520Function%2520After%25203%2520Years%2520in%2520Metformin-Treated%2520Patients%2520With%2520Type%25202%2520Diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2011%26volume%3D34%26issue%3D9%26spage%3D2041%26epage%3D2047%26doi%3D10.2337%2Fdc11-0291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dritselis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Liraglutide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1038/nrd3148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnrd3148" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=267-268&issue=4&author=D.+J.+Druckerauthor=A.+Dritselisauthor=P.+Kirkpatrick&title=Liraglutide&doi=10.1038%2Fnrd3148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3148%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDritselis%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DLiraglutide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D4%26spage%3D267%26epage%3D268%26doi%3D10.1038%2Fnrd3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Buse, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sesti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zychma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blonde, L.</span><span> </span><span class="NLM_article-title">Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x"> (</span><span class="NLM_issue">9683</span><span class="NLM_x">) </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/S0140-6736(09)60659-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2FS0140-6736%2809%2960659-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19515413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=39-47&issue=9683&author=J.+B.+Buseauthor=J.+Rosenstockauthor=G.+Sestiauthor=W.+E.+Schmidtauthor=E.+Montanyaauthor=J.+H.+Brettauthor=M.+Zychmaauthor=L.+Blonde&title=Liraglutide+Once+a+Day+versus+Exenatide+Twice+a+Day+for+Type+2+Diabetes%3A+A+26-Week+Randomised%2C+Parallel-Group%2C+Multinational%2C+Open-Label+Trial+%28LEAD-6%29&doi=10.1016%2FS0140-6736%2809%2960659-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)</span></div><div class="casAuthors">Buse, John B.; Rosenstock, Julio; Sesti, Giorgio; Schmidt, Wolfgang E.; Montanya, Eduard; Brett, Jason H.; Zychma, Marcin; Blonde, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9683</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Unlike most antihyperglycemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote wt. loss.  We compared the efficacy and safety of liraglutide, a human GLP-1 analog, with exenatide, an exendin-based GLP-1 receptor agonist.  Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulfonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive addnl. liraglutide 1.8 mg once a day (n = 233) or exenatide 10 μg twice a day (n = 231) in a 26-wk open-label, parallel-group, multinational (15 countries) study.  The primary outcome was change in glycosylated Hb (HbA1c).  Efficacy analyses were by intention to treat.  The trial is registered with, no.  Mean baseline HbA1c for the study population was 8.2%.  Liraglutide reduced mean HbA1c significantly more than did exenatide (-1.12% [SE 0.08] vs -0.79% [0.08]; estd. treatment difference -0.33; 95% CI -0.47 to -0.18; p < 0.0001) and more patients achieved a HbA1c value of less than 7% (54%vs 43%, resp.; odds ratio 2.02; 95% CI 1.31 to 3.11; p = 0.0015).  Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mmol/L [SE 0.20] vs -0.60 mmol/L [0.20]; estd. treatment difference -1.01 mmol/L; 95% CI -1.37 to -0.65; p < 0.0001) but postprandial glucose control was less effective after breakfast and dinner.  Both drugs promoted similar wt. losses (liraglutide -3.24 kg vs exenatide -2.87 kg).  Both drugs were well tolerated, but nausea was less persistent (estd. treatment rate ratio 0.448, p < 0.0001) and minor hypoglycemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per yr; rate ratio 0.55; 95% CI 0.34 to 0.88; p = 0.0131; 25.5%vs 33.6% had minor hypoglycemia).  Two patients taking both exenatide and a sulfonylurea had a major hypoglycemic episode.  Liraglutide once a day provided significantly greater improvements in glycemic control than did exenatide twice a day, and was generally better tolerated.  The results suggest that liraglutide might be a treatment option for type 2 diabetes, esp. when wt. loss and risk of hypoglycemia are major considerations.  Funding: Novo Nordisk A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsh9qykvg7dLVg90H21EOLACvtfcHk0lg-DnTnvrGMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgtb4%253D&md5=ac520ef9465d51345328acc40c5b6a1d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2960659-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252960659-0%26sid%3Dliteratum%253Aachs%26aulast%3DBuse%26aufirst%3DJ.%2BB.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DSesti%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DMontanya%26aufirst%3DE.%26aulast%3DBrett%26aufirst%3DJ.%2BH.%26aulast%3DZychma%26aufirst%3DM.%26aulast%3DBlonde%26aufirst%3DL.%26atitle%3DLiraglutide%2520Once%2520a%2520Day%2520versus%2520Exenatide%2520Twice%2520a%2520Day%2520for%2520Type%25202%2520Diabetes%253A%2520A%252026-Week%2520Randomised%252C%2520Parallel-Group%252C%2520Multinational%252C%2520Open-Label%2520Trial%2520%2528LEAD-6%2529%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26issue%3D9683%26spage%3D39%26epage%3D47%26doi%3D10.1016%2FS0140-6736%2809%2960659-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Neidigh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesinmeyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Designing a 20-Residue Protein</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1038/nsb798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnsb798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=11979279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=425-430&issue=6&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=N.+H.+Andersen&title=Designing+a+20-Residue+Protein&doi=10.1038%2Fnsb798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Designing a 20-residue protein</span></div><div class="casAuthors">Neidigh, Jonathan W.; Fesinmeyer, R. Matthew; Andersen, Niels H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">425-430</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Truncation and mutation of a poorly folded 39-residue peptide has produced 20-residue constructs that are >95% folded in water at physiol. pH.  These constructs optimize a novel fold, designated as the 'Trp-cage' motif, and are significantly more stable than any other miniprotein reported to date.  Folding is cooperative and hydrophobically driven by the encapsulation of a Trp side chain in a sheath of Pro rings.  As the smallest protein-like construct, Trp-cage miniproteins should provide a testing ground for both exptl. studies and computational simulations of protein folding and unfolding pathways.  Pro-Trp interactions may be a particularly effective strategy for the a priori design of self-folding peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLL9DJ-UavV7Vg90H21EOLACvtfcHk0lg-DnTnvrGMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFOms7g%253D&md5=4f82538a45b96f90d6e0e7a366a4f412</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsb798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb798%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DDesigning%2520a%252020-Residue%2520Protein%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26issue%3D6%26spage%3D425%26epage%3D430%26doi%3D10.1038%2Fnsb798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Neidigh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesinmeyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickett, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Exendin-4 and Glucagon-like-Peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">13188</span><span class="NLM_x">–</span> <span class="NLM_lpage">13200</span><span class="refDoi"> DOI: 10.1021/bi010902s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010902s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=13188-13200&issue=44&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=K.+S.+Prickettauthor=N.+H.+Andersen&title=Exendin-4+and+Glucagon-like-Peptide-1%3A+NMR+Structural+Comparisons+in+the+Solution+and+Micelle-Associated+States&doi=10.1021%2Fbi010902s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 and Glucagon-like-peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States</span></div><div class="casAuthors">Neidigh, Jonathan W.; Fesinmeyer, R. Matthew; Prickett, Kathryn S.; Andersen, Niels H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13188-13200</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exendin-4, a 39 amino acid peptide originally isolated from the oral secretions of the lizard Heloderma suspectum, has been shown to share certain activities with glucagon-like-peptide-1 (GLP-1), a 30 amino acid peptide.  We have detd. the structuring preferences of exendin-4 and GLP-1 by NMR in both the soln. and dodecylphosphocholine (DPC) micelle-assocd. states.  Based on both chem. shift deviations and the pattern of intermediate range NOEs, both peptides display significant helicity from residue 7 to residue 28 with greater fraying at the N-terminus.  Thornton and Gorenstein [(1994) Biochem. 33, 3532-3539] reported that the presence of a flexible, helix-destabilizing, glycine at residue 16 in GLP-1 was an important feature for membrane and receptor binding. Exendin-4 has a helix-favoring glutamate as residue 16.  In the micelle-assocd. state, NMR data indicate that GLP-1 is less helical than exendin-4 due to the presence of Gly16; chem. shift deviations along the peptide sequence suggest that Gly16 serves as an N-cap for a second, more persistent, helix.  In 30 vol-% trifluoroethanol (TFE), a single continuous helix is evident in a significant fraction of the GLP-1 conformers present. Exendin-4 has a more regular and less fluxional helix in both media and displays stable tertiary structure in the soln. state.  In the micelle-bound state of exendin-4, a single helix (residues 11-27) is obsd. with residues 31-39 completely disordered and undergoing rapid segmental motion.  In aq. fluoroalc. or aq. glycol, the Leu21-Pro38 span of exendin-4 forms a compact tertiary fold (the Trp-cage) which shields the side chain of Trp25 from solvent exposure and produces ring current shifts as large as 3 ppm.  This tertiary structure is partially populated in water and fully populated in aq. TFE.  The Leu21-Pro38 segment of exendin-4 may be the smallest protein-like folding unit obsd. to date.  When the Trp-cage forms, fraying of the exendin-4 helix occurs exclusively from the N-terminus; backbone NHs for the C-terminal residues of the helix display H/D exchange protection factors as large as 105 at 9 °C.  In contrast, no tertiary structure is evident when exendin-4 binds to DPC micelles.  An energetically favorable insertion of the tryptophan ring into the DPC micelle is suggested as the basis for this change.  With the exception of exendin-4 in media contg. fluoro alc. cosolvents, NMR structure ensembles generated from the NOE data do not fully reflect the conformational averaging present in these systems.  Secondary structure definition from chem. shift deviations may be the most appropriate treatment for peptides that lack tertiary structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wHXw0VmZgrVg90H21EOLACvtfcHk0lg-DnTnvrGMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFagt7s%253D&md5=ab4a09dd8ee0e83395452cccc42af447</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi010902s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010902s%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DPrickett%26aufirst%3DK.%2BS.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExendin-4%2520and%2520Glucagon-like-Peptide-1%253A%2520NMR%2520Structural%2520Comparisons%2520in%2520the%2520Solution%2520and%2520Micelle-Associated%2520States%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D44%26spage%3D13188%26epage%3D13200%26doi%3D10.1021%2Fbi010902s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Chabenne, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Optimization of the Native Glucagon Sequence for Medicinal Purposes</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1322</span><span class="NLM_x">–</span> <span class="NLM_lpage">1331</span><span class="refDoi"> DOI: 10.1177/193229681000400605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1177%2F193229681000400605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21129326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1322-1331&issue=6&author=J.+R.+Chabenneauthor=M.+A.+DiMarchiauthor=V.+M.+Gelfanovauthor=R.+D.+DiMarchi&title=Optimization+of+the+Native+Glucagon+Sequence+for+Medicinal+Purposes&doi=10.1177%2F193229681000400605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the native glucagon sequence for medicinal purposes</span></div><div class="casAuthors">Chabenne Joseph R; DiMarchi Maria A; Gelfanov Vasily M; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1322-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glucagon is a life-saving medication used in the treatment of hypoglycemia.  It possesses poor solubility in aqueous buffers at or near physiological pH values.  At low and high pH, at which the peptide can be formulated to concentrations of a milligram or more per milliliter, the chemical integrity of the hormone is limited, as evidenced by the formation of multiple degradation-related peptides.  Consequently, the commercial preparation is provided as a lyophilized solid with an acidic diluent and directions for rendering it soluble at the time of use.  Any unused material is recommended for disposal immediately after initial use.  METHODS:  A set of glucagon analogs was prepared by solid-phase peptide synthesis to explore the identification of a glucagon analog with enhanced solubility and chemical stability at physiological pH.  The physical properties of the peptide analogs were studied by solubility determination, high-performance chromatography, and mass spectral analysis.  The biochemical properties were determined in engineered human embryonic kidney cell line 293 (HEK293) cells that overexpressed either the human glucagon or glucagon-like peptide-1 (GLP-1) receptors linked to a luciferase reporter gene.  RESULTS:  We observed the previously characterized formation of glucagon degradation products upon incubation of the peptide in dilute acid for extended periods or elevated temperature.  Lowering the isoelectric point of the hormone through the substitution of asparagine-28 with aspartic acid significantly increased the solubility at physiological pH.  Similarly, the C-terminal extension (Cex) of the hormone with an exendin-based, 10-residue, C-terminal sequence yielded a peptide of dramatically enhanced solubility.  These two glucagon analogs, D28 and Cex, maintained high potency and selectivity for the glucagon receptor relative to GLP-1 receptor.  CONCLUSIONS:  Glucagon presents unique structural challenges to the identification of an analog of high biological activity and selectivity that also possesses sufficient aqueous solubility and stability such that it might be developed as a ready-to-use medicine.  The glucagon analogs D28 and Cex demonstrated all of the chemical, physical, and biochemical properties supportive of further study as potential clinical candidates for treatment of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIRWfpMXQLRstfW6udTcc2eY7pucof7vr9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D&md5=9a27028640295b5f4a6c2bd040bcd120</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F193229681000400605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400605%26sid%3Dliteratum%253Aachs%26aulast%3DChabenne%26aufirst%3DJ.%2BR.%26aulast%3DDiMarchi%26aufirst%3DM.%2BA.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520the%2520Native%2520Glucagon%2520Sequence%2520for%2520Medicinal%2520Purposes%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1322%26epage%3D1331%26doi%3D10.1177%2F193229681000400605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Runge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Ligand-Bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">11340</span><span class="NLM_x">–</span> <span class="NLM_lpage">11347</span><span class="refDoi"> DOI: 10.1074/jbc.M708740200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M708740200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=18287102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11340-11347&issue=17&author=S.+Rungeauthor=H.+Th%C3%B8gersenauthor=K.+Madsenauthor=J.+Lauauthor=R.+Rudolph&title=Crystal+Structure+of+the+Ligand-Bound+Glucagon-like+Peptide-1+Receptor+Extracellular+Domain&doi=10.1074%2Fjbc.M708740200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span></div><div class="casAuthors">Runge, Steffen; Thogersen, Henning; Madsen, Kjeld; Lau, Jesper; Rudolph, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11340-11347</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide hormone glucagon-like peptide-1 (GLP-1).  GLP-1 is involved in glucose homeostasis, and activation of GLP-1R in the plasma membrane of pancreatic β-cells potentiates glucose-dependent insulin secretion.  The N-terminal extracellular domain (nGLP-1R) is an important ligand binding domain that binds GLP-1 and the homologous peptide Exendin-4 with differential affinity.  Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp cage", which is absent in GLP-1.  The Trp cage was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4.  However, the mol. details that govern ligand binding and specificity of nGLP-1R remain undefined.  Here the authors report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9-39) solved by the multiwavelength anomalous dispersion method to 2.2Å resoln.  The structure reveals that Exendin-4(9-39) is an amphipathic α-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R.  The Trp cage of Exendin-4 is not involved in binding to nGLP-1R.  The hydrophobic binding site of nGLP-1R is defined by discontinuous segments including primarily a well defined α-helix in the N terminus of nGLP-1R and a loop between two antiparallel β-strands.  The structure provides for the first time detailed mol. insight into ligand binding of the human GLP-1 receptor, an established target for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCFNrYkVbPLVg90H21EOLACvtfcHk0lgrPpYyWrSx9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D&md5=43529117c437b477afb23e0ba196b1b1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708740200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708740200%26sid%3Dliteratum%253Aachs%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Ligand-Bound%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Extracellular%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D17%26spage%3D11340%26epage%3D11347%26doi%3D10.1074%2Fjbc.M708740200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Underwood, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garibay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastrup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedtz-Runge, S.</span><span> </span><span class="NLM_article-title">Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span><span class="refDoi"> DOI: 10.1074/jbc.M109.033829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M109.033829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19861722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SqtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=723-730&issue=1&author=C.+R.+Underwoodauthor=P.+Garibayauthor=L.+B.+Knudsenauthor=S.+Hastrupauthor=G.+H.+Petersauthor=R.+Rudolphauthor=S.+Reedtz-Runge&title=Crystal+Structure+of+Glucagon-like+Peptide-1+in+Complex+with+the+Extracellular+Domain+of+the+Glucagon-like+Peptide-1+Receptor&doi=10.1074%2Fjbc.M109.033829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor</span></div><div class="casAuthors">Underwood, Christina Rye; Garibay, Patrick; Knudsen, Lotte Bjerre; Hastrup, Sven; Peters, Guenther H.; Rudolph, Rainer; Reedtz-Runge, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">723-730</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to food intake.  Activation of the GLP-1 receptor potentiates the synthesis and release of insulin from pancreatic β-cells in a glucose-dependent manner.  The GLP-1 receptor belongs to class B of the G-protein-coupled receptors, a subfamily characterized by a large N-terminal extracellular ligand binding domain.  Exendin-4 and GLP-1 are 50% identical, and exendin-4 is a full agonist with similar affinity and potency for the GLP-1 receptor.  We recently solved the crystal structure of the GLP-1 receptor extracellular domain in complex with the competitive antagonist exendin-4(9-39).  Interestingly, the isolated extracellular domain binds exendin-4 with much higher affinity than the endogenous agonist GLP-1.  Here, we have solved the crystal structure of the extracellular domain in complex with GLP-1 to 2.1 Åresoln.  The structure shows that important hydrophobic ligand-receptor interactions are conserved in agonist- and antagonist-bound forms of the extracellular domain, but certain residues in the ligand-binding site adopt a GLP-1-specific conformation.  GLP-1 is a kinked but continuous α-helix from Thr13 to Val33 when bound to the extracellular domain.  We supplemented the crystal structure with site-directed mutagenesis to link the structural information of the isolated extracellular domain with the binding properties of the full-length receptor.  The data support the existence of differences in the binding modes of GLP-1 and exendin-4 on the full-length GLP-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpex-ZPbuqSCrVg90H21EOLACvtfcHk0lgrPpYyWrSx9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SqtrrM&md5=59f7b2cee843c4299acab5900036172c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.033829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.033829%26sid%3Dliteratum%253Aachs%26aulast%3DUnderwood%26aufirst%3DC.%2BR.%26aulast%3DGaribay%26aufirst%3DP.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DHastrup%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DG.%2BH.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26atitle%3DCrystal%2520Structure%2520of%2520Glucagon-like%2520Peptide-1%2520in%2520Complex%2520with%2520the%2520Extracellular%2520Domain%2520of%2520the%2520Glucagon-like%2520Peptide-1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26issue%3D1%26spage%3D723%26epage%3D730%26doi%3D10.1074%2Fjbc.M109.033829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Simonsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, C. F.</span><span> </span><span class="NLM_article-title">The C-Terminal Extension of Exendin-4 Provides Additional Metabolic Stability When Added to GLP-1, While There Is Minimal Effect of Truncating Exendin-4 in Anaesthetized Pigs</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.regpep.2012.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.regpep.2012.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=23318502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2jsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2013&pages=17-21&author=L.+Simonsenauthor=J.+J.+Holstauthor=K.+Madsenauthor=C.+F.+Deacon&title=The+C-Terminal+Extension+of+Exendin-4+Provides+Additional+Metabolic+Stability+When+Added+to+GLP-1%2C+While+There+Is+Minimal+Effect+of+Truncating+Exendin-4+in+Anaesthetized+Pigs&doi=10.1016%2Fj.regpep.2012.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anesthetized pigs</span></div><div class="casAuthors">Simonsen, L.; Holst, J. J.; Madsen, K.; Deacon, C. F.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-21</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The most striking sequence difference between glucagon-like peptide-1 (GLP-1) and the longer-acting GLP-1 receptor agonist, exendin-4 (Ex-4), is the nine-amino acid C-terminal extension of Ex-4.  The authors investigated the contribution of this extension to the survival time of Ex-4.  The authors assessed the overall metab. of GLP-1, Ex-4, a C-terminally extended GLP-1 peptide (GLP-1 + Ex(31-39); GLP-Ex), and a C-terminally truncated exendin peptide (Ex(1-30)) in anesthetized, catheterized pigs, with focus on the extn. across the kidneys and a peripheral tissue (a hindleg, representing muscle, adipose- and connective tissue).  Peptide anal. was carried out with assays against the mid-region of the peptides, whereby the role of dipeptidyl peptidase-4 (DPP-4) mediated N-terminal degrdn. could be disregarded.  The half-life of GLP-1 was significantly increased when the C-terminal extension of Ex-4 was added (GLP-1 4.8±3.3 min; GLP-Ex 19.5±3.3 min).  In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1 min; Ex(1-30) 28.4±1.7 min).  Ex-4 and Ex(1-30) were cleared solely by the kidneys at rates corresponding to the glomerular filtration rate (GFR), while GLP-1 and GLP-Ex were cleared by both the kidneys and peripheral tissues.  Both extn. rates were, however, significantly reduced with GLP-Ex compared to GLP-1.  The renal clearance rate of GLP-1 greatly exceeded GFR, while GLP-Ex was cleared at a rate resembling GFR.  In conclusion, the C-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addn. of this sequence to GLP-1 significantly reduces its clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmxwbNCyPNG7Vg90H21EOLACvtfcHk0lhewDGLQSgEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2jsbw%253D&md5=a67fdc8032ef2a9ba23ac87e1f4c4484</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2012.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2012.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DSimonsen%26aufirst%3DL.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26atitle%3DThe%2520C-Terminal%2520Extension%2520of%2520Exendin-4%2520Provides%2520Additional%2520Metabolic%2520Stability%2520When%2520Added%2520to%2520GLP-1%252C%2520While%2520There%2520Is%2520Minimal%2520Effect%2520of%2520Truncating%2520Exendin-4%2520in%2520Anaesthetized%2520Pigs%26jtitle%3DRegul.%2520Pept.%26date%3D2013%26volume%3D181%26spage%3D17%26epage%3D21%26doi%3D10.1016%2Fj.regpep.2012.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Hudson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Exenatide: NMR/CD Evaluation of the Medium Dependence of Conformation and Aggregation State</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1002/bip.20126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fbip.20126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=298-308&issue=4&author=F.+M.+Hudsonauthor=N.+H.+Andersen&title=Exenatide%3A+NMR%2FCD+Evaluation+of+the+Medium+Dependence+of+Conformation+and+Aggregation+State&doi=10.1002%2Fbip.20126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fbip.20126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20126%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DF.%2BM.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExenatide%253A%2520NMR%252FCD%2520Evaluation%2520of%2520the%2520Medium%2520Dependence%2520of%2520Conformation%2520and%2520Aggregation%2520State%26jtitle%3DBiopolymers%26date%3D2004%26volume%3D76%26issue%3D4%26spage%3D298%26epage%3D308%26doi%3D10.1002%2Fbip.20126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madjidi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estevez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotzel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, B. B.</span><span> </span><span class="NLM_article-title">Molecular Basis for Negative Regulation of the Glucagon Receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">36</span><span class="NLM_x">) </span> <span class="NLM_fpage">14393</span><span class="NLM_x">–</span> <span class="NLM_lpage">14398</span><span class="refDoi"> DOI: 10.1073/pnas.1206734109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1073%2Fpnas.1206734109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=14393-14398&issue=36&author=C.+M.+Kothauthor=J.+M.+Murrayauthor=S.+Mukundauthor=A.+Madjidiauthor=A.+Minnauthor=H.+J.+Clarkeauthor=T.+Wongauthor=V.+Chiangauthor=E.+Luisauthor=A.+Estevezauthor=J.+Rondonauthor=Y.+Zhangauthor=I.+Hotzelauthor=B.+B.+Allan&title=Molecular+Basis+for+Negative+Regulation+of+the+Glucagon+Receptor&doi=10.1073%2Fpnas.1206734109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1206734109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1206734109%26sid%3Dliteratum%253Aachs%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DMadjidi%26aufirst%3DA.%26aulast%3DMinn%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DV.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DRondon%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHotzel%26aufirst%3DI.%26aulast%3DAllan%26aufirst%3DB.%2BB.%26atitle%3DMolecular%2520Basis%2520for%2520Negative%2520Regulation%2520of%2520the%2520Glucagon%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D36%26spage%3D14393%26epage%3D14398%26doi%3D10.1073%2Fpnas.1206734109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Sasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamiak, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T.</span><span> </span><span class="NLM_article-title">X-Ray Analysis of Glucagon and Its Relationship to Receptor Binding</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x"> (</span><span class="NLM_issue">5529</span><span class="NLM_x">) </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span><span class="refDoi"> DOI: 10.1038/257751a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2F257751a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=171582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaE28XislWjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1975&pages=751-757&issue=5529&author=K.+Sasakiauthor=S.+Dockerillauthor=D.+A.+Adamiakauthor=I.+J.+Tickleauthor=T.+Blundell&title=X-Ray+Analysis+of+Glucagon+and+Its+Relationship+to+Receptor+Binding&doi=10.1038%2F257751a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray analysis of glucagon and its relation to receptor binding</span></div><div class="casAuthors">Sasaki, Kyoyu; Dockerill, Susan; Adamiak, Dorota A.; Tickle, Ian J.; Blundell, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5529</span>),
    <span class="NLM_cas:pages">751-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-ray anal. of glucagon showed that in crystals the polypeptide adopted a mainly helical conformation, which was stabilized by hydrophobic interactions between mols. related by 3-fold symmetry.  A model is presented in which the glucagon mol. exists in dil. solns. as an equil. population of conformers with little retention of structure, and in which the helical conformation is stabilized by hydrophobic interactions either as an oligomer or as a complex with the receptor.  The relevance of the structure, which is compared with that of insulin, to storage in α cells is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfDTG1R-OBDLVg90H21EOLACvtfcHk0lhewDGLQSgEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XislWjtw%253D%253D&md5=37d49f9d5ff7703acd7d3f3f41d88548</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2F257751a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F257751a0%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DDockerill%26aufirst%3DS.%26aulast%3DAdamiak%26aufirst%3DD.%2BA.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DBlundell%26aufirst%3DT.%26atitle%3DX-Ray%2520Analysis%2520of%2520Glucagon%2520and%2520Its%2520Relationship%2520to%2520Receptor%2520Binding%26jtitle%3DNature%26date%3D1975%26volume%3D257%26issue%3D5529%26spage%3D751%26epage%3D757%26doi%3D10.1038%2F257751a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Siu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the Human Glucagon Class B G-Protein-Coupled Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">499</span><span class="NLM_x"> (</span><span class="NLM_issue">7459</span><span class="NLM_x">) </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span><span class="refDoi"> DOI: 10.1038/nature12393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnature12393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=23863937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2013&pages=444-449&issue=7459&author=F.+Y.+Siuauthor=M.+Heauthor=C.+de+Graafauthor=G.+W.+Hanauthor=D.+Yangauthor=Z.+Zhangauthor=C.+Zhouauthor=Q.+Xuauthor=D.+Wackerauthor=J.+S.+Josephauthor=W.+Liuauthor=J.+Lauauthor=V.+Cherezovauthor=V.+Katritchauthor=M.-W.+Wangauthor=R.+C.+Stevens&title=Structure+of+the+Human+Glucagon+Class+B+G-Protein-Coupled+Receptor&doi=10.1038%2Fnature12393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human glucagon class B G-protein-coupled receptor</span></div><div class="casAuthors">Siu, Fai Yiu; He, Min; de Graaf, Chris; Han, Gye Won; Yang, Dehua; Zhang, Zhiyun; Zhou, Caihong; Xu, Qingping; Wacker, Daniel; Joseph, Jeremiah S.; Liu, Wei; Lau, Jesper; Cherezov, Vadim; Katritch, Vsevolod; Wang, Ming-Wei; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">7459</span>),
    <span class="NLM_cas:pages">444-449</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Binding of the glucagon peptide to the glucagon receptor (GCGR) triggers the release of glucose from the liver during fasting; thus GCGR plays an important role in glucose homeostasis.  Here we report the crystal structure of the seven transmembrane helical domain of human GCGR at 3.4 Å resoln., complemented by extensive site-specific mutagenesis, and a hybrid model of glucagon bound to GCGR to understand the mol. recognition of the receptor for its native ligand.  Beyond the shared seven transmembrane fold, the GCGR transmembrane domain deviates from class A G-protein-coupled receptors with a large ligand-binding pocket and the first transmembrane helix having a 'stalk' region that extends three alpha-helical turns above the plane of the membrane.  The stalk positions the extracellular domain (∼12 kilodaltons) relative to the membrane to form the glucagon-binding site that captures the peptide and facilitates the insertion of glucagon's amino terminus into the seven transmembrane domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXzQjGi9t48rVg90H21EOLACvtfcHk0lgDd4WXFgaNkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWktbzN&md5=ba4801075b7fc13454710def7f083710</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature12393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12393%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DF.%2BY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Glucagon%2520Class%2520B%2520G-Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2013%26volume%3D499%26issue%3D7459%26spage%3D444%26epage%3D449%26doi%3D10.1038%2Fnature12393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huusfeldt, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, F. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agersø, H.</span><span> </span><span class="NLM_article-title">Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1664</span><span class="NLM_x">–</span> <span class="NLM_lpage">1669</span><span class="refDoi"> DOI: 10.1021/jm9909645</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9909645" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1664-1669&issue=9&author=L.+B.+Knudsenauthor=P.+F.+Nielsenauthor=P.+O.+Huusfeldtauthor=N.+L.+Johansenauthor=K.+Madsenauthor=F.+Z.+Pedersenauthor=H.+Th%C3%B8gersenauthor=M.+Wilkenauthor=H.+Agers%C3%B8&title=Potent+Derivatives+of+Glucagon-like+Peptide-1+with+Pharmacokinetic+Properties+Suitable+for+Once+Daily+Administration&doi=10.1021%2Fjm9909645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration</span></div><div class="casAuthors">Knudsen, Lotte B.; Nielsen, Per F.; Huusfeldt, Per O.; Johansen, Nils L.; Madsen, Kjeld; Pedersen, Freddy Z.; Thogersen, Henning; Wilken, Michael; Agerso, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1664-1669</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of very potent derivs. of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described.  The compds. were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC50) of 55 pM for the cloned human GLP-1 receptor.  Many of the compds. had similar or even higher potencies, despite quite large substituents.  All compds. derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients.  A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency.  Derivatization with two fatty acid substituents led to a considerable loss of potency.  A structure-activity relationship on derivatization of specific amino acids generally was obtained.  It was found that the longer the fatty acid, the more potency was lost.  Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_iyZt3E6tG7Vg90H21EOLACvtfcHk0lgDd4WXFgaNkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKksLg%253D&md5=d050c27dd6aea795191798254e2bf080</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm9909645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909645%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DHuusfeldt%26aufirst%3DP.%2BO.%26aulast%3DJohansen%26aufirst%3DN.%2BL.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DPedersen%26aufirst%3DF.%2BZ.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DM.%26aulast%3DAgers%25C3%25B8%26aufirst%3DH.%26atitle%3DPotent%2520Derivatives%2520of%2520Glucagon-like%2520Peptide-1%2520with%2520Pharmacokinetic%2520Properties%2520Suitable%2520for%2520Once%2520Daily%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D9%26spage%3D1664%26epage%3D1669%26doi%3D10.1021%2Fjm9909645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agersoe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, N. L.</span><span> </span><span class="NLM_article-title">Structure–Activity and Protraction Relationship of Long-Acting Glucagon-like Peptide-1 Derivatives: Importance of Fatty Acid Length, Polarity, and Bulkiness</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6126</span><span class="NLM_x">–</span> <span class="NLM_lpage">6132</span><span class="refDoi"> DOI: 10.1021/jm070861j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070861j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6126-6132&issue=24&author=K.+Madsenauthor=L.+B.+Knudsenauthor=H.+Agersoeauthor=P.+F.+Nielsenauthor=H.+Th%C3%B8gersenauthor=M.+Wilkenauthor=N.+L.+Johansen&title=Structure%E2%80%93Activity+and+Protraction+Relationship+of+Long-Acting+Glucagon-like+Peptide-1+Derivatives%3A+Importance+of+Fatty+Acid+Length%2C+Polarity%2C+and+Bulkiness&doi=10.1021%2Fjm070861j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm070861j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070861j%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DAgersoe%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DN.%2BL.%26atitle%3DStructure%25E2%2580%2593Activity%2520and%2520Protraction%2520Relationship%2520of%2520Long-Acting%2520Glucagon-like%2520Peptide-1%2520Derivatives%253A%2520Importance%2520of%2520Fatty%2520Acid%2520Length%252C%2520Polarity%252C%2520and%2520Bulkiness%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D24%26spage%3D6126%26epage%3D6132%26doi%3D10.1021%2Fjm070861j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Ward, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Peptide Lipidation Stabilizes Structure to Enhance Biological Function</span> <span class="citation_source-journal">Mol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1016/j.molmet.2013.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.molmet.2013.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=24327962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=468-479&issue=4&author=B.+P.+Wardauthor=N.+L.+Ottawayauthor=D.+Perez-Tilveauthor=D.+Maauthor=V.+M.+Gelfanovauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Peptide+Lipidation+Stabilizes+Structure+to+Enhance+Biological+Function&doi=10.1016%2Fj.molmet.2013.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide lipidation stabilizes structure to enhance biological function</span></div><div class="casAuthors">Ward, Brian P.; Ottaway, Nickki L.; Perez-Tilve, Diego; Ma, Dejian; Gelfanov, Vasily M.; Tschop, Matthias H.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-479</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Medicines that decrease body wt. and restore nutrient tolerance could improve human diabetes and obesity treatment outcomes.  We developed lipid-acylated glucagon analogs that are co-agonists for the glucagon and glucagon-like peptide 1 receptors, and stimulate wt. loss and plasma glucose lowering in pre-diabetic obese mice.  Our studies identified lipid acylation (lipidation) can increase and balance in vitro potencies of select glucagon analogs for the two aforementioned receptors in a lipidation site-dependent manner.  A general capacity for lipidation to enhance the secondary structure of glucagon analogs was recognized, and the energetics of this effect quantified.  The mol. structure of a lipid-acylated glucagon analog in water was also characterized.  These results support that lipidation can modify biol. activity through thermodynamically-favorable intramol. interactions which stabilize structure.  This establishes use of lipidation to achieve specific pharmacol. and implicates similar endogenous post-translational modifications as physiol. tools capable of refining biol. action in means previously underappreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nclxtgAVyLVg90H21EOLACvtfcHk0lhMKMkoeNHYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K&md5=021ed975227b94ca2d47394d22e19d1a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BP.%26aulast%3DOttaway%26aufirst%3DN.%2BL.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520Lipidation%2520Stabilizes%2520Structure%2520to%2520Enhance%2520Biological%2520Function%26jtitle%3DMol.%2520Metab.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D468%26epage%3D479%26doi%3D10.1016%2Fj.molmet.2013.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Amon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolios, N.</span><span> </span><span class="NLM_article-title">Lipidation and Glycosylation of a T Cell Antigen Receptor (TCR) Transmembrane Hydrophobic Peptide Dramatically Enhances in Vitro and in Vivo Function</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1763</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2006.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bbamcr.2006.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=16782215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWhsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1763&publication_year=2006&pages=879-888&issue=8&author=M.+A.+Amonauthor=M.+Aliauthor=V.+Benderauthor=Y.-N.+Chanauthor=I.+Tothauthor=N.+Manolios&title=Lipidation+and+Glycosylation+of+a+T+Cell+Antigen+Receptor+%28TCR%29+Transmembrane+Hydrophobic+Peptide+Dramatically+Enhances+in+Vitro+and+in+Vivo+Function&doi=10.1016%2Fj.bbamcr.2006.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function</span></div><div class="casAuthors">Amon, Michael A.; Ali, Marina; Bender, Vera; Chan, Yiu-Ngok; Toth, Istvan; Manolios, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1763</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">879-888</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A T cell antigen receptor (TCR) transmembrane sequence derived peptide (CP) has been shown to inhibit T cell activation both in vitro and in vivo at the membrane level of the receptor signal transduction.  To examine the effect of sugar or lipid conjugations on CP function, we linked CP to 1-aminoglucosesuccinate (GS), N-myristate (MYR), mono-di-tripalmitate (LP1, LP2, or LP3), and a lipoamino acid (LA) and examd. the effects of these compds. on T cell activation in vitro and by using a rat model of adjuvant-induced arthritis, in vivo.  In vitro, antigen presentation results demonstrated that lipid conjugation enhanced CP's ability to lower IL-2 prodn. from 56.99% ± 15.69 S.D. obsd. with CP, to 12.08% ± 3.34 S.D. obsd. with LA.  The sugar conjugate GS resulted in only a mild loss of in vitro activity compared to CP (82.95% ± 14.96 S.D.).  In vivo, lipid conjugation retarded the progression of adjuvant-induced arthritis by approx. 50%, whereas the sugar conjugated CP, GS, almost completely inhibited the progression of arthritis.  This study demonstrates that hydrophobic peptide activity is markedly enhanced in vitro and in vivo by conjugation to lipids or sugars.  This may have practical applications in drug delivery and bioavailability of hydrophobic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp65WRA7ptptbVg90H21EOLACvtfcHk0lhMKMkoeNHYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWhsb4%253D&md5=919a3ab54dc57740d55fcf203abdede2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2006.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2006.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DAmon%26aufirst%3DM.%2BA.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DY.-N.%26aulast%3DToth%26aufirst%3DI.%26aulast%3DManolios%26aufirst%3DN.%26atitle%3DLipidation%2520and%2520Glycosylation%2520of%2520a%2520T%2520Cell%2520Antigen%2520Receptor%2520%2528TCR%2529%2520Transmembrane%2520Hydrophobic%2520Peptide%2520Dramatically%2520Enhances%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Function%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2006%26volume%3D1763%26issue%3D8%26spage%3D879%26epage%3D888%26doi%3D10.1016%2Fj.bbamcr.2006.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Sal-Man, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shai, Y.</span><span> </span><span class="NLM_article-title">The Identification of a Minimal Dimerization Motif QXXS That Enables Homo- and Hetero-Association of Transmembrane Helices in Vivo</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x"> (</span><span class="NLM_issue">29</span><span class="NLM_x">) </span> <span class="NLM_fpage">27449</span><span class="NLM_x">–</span> <span class="NLM_lpage">27457</span><span class="refDoi"> DOI: 10.1074/jbc.M503095200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M503095200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=27449-27457&issue=29&author=N.+Sal-Manauthor=D.+Gerberauthor=Y.+Shai&title=The+Identification+of+a+Minimal+Dimerization+Motif+QXXS+That+Enables+Homo-+and+Hetero-Association+of+Transmembrane+Helices+in+Vivo&doi=10.1074%2Fjbc.M503095200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503095200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503095200%26sid%3Dliteratum%253Aachs%26aulast%3DSal-Man%26aufirst%3DN.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DShai%26aufirst%3DY.%26atitle%3DThe%2520Identification%2520of%2520a%2520Minimal%2520Dimerization%2520Motif%2520QXXS%2520That%2520Enables%2520Homo-%2520and%2520Hetero-Association%2520of%2520Transmembrane%2520Helices%2520in%2520Vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D29%26spage%3D27449%26epage%3D27457%26doi%3D10.1074%2Fjbc.M503095200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Majerle, A.</span><span> </span><span class="NLM_article-title">Enhancement of Antibacterial and Lipopolysaccharide Binding Activities of a Human Lactoferrin Peptide Fragment by the Addition of Acyl Chain</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span><span class="refDoi"> DOI: 10.1093/jac/dkg219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1093%2Fjac%2Fdkg219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=12697647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=1159-1165&issue=5&author=A.+Majerle&title=Enhancement+of+Antibacterial+and+Lipopolysaccharide+Binding+Activities+of+a+Human+Lactoferrin+Peptide+Fragment+by+the+Addition+of+Acyl+Chain&doi=10.1093%2Fjac%2Fdkg219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain</span></div><div class="casAuthors">Majerle, Andreja; Kidric, Jurka; Jerala, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1159-1165</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cationic antibacterial peptides are potentially therapeutic in the treatment of sepsis, because of their amalgamated antibacterial and lipopolysaccharide-binding activities.  We prepd. acyl analogs of the peptide fragment of human lactoferrin, which originally had weak antibacterial activity.  It was found that 12 carbon units constitute the optimal acyl chain length, enhancing the antibacterial activity and binding of lipopolysaccharide by up to two orders of magnitude.  Lactoferrin-based lipopeptides approached the activity of polymyxin B, a lipopeptide of natural origin, but were also active against Gram-pos. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnoQ3lM7zAjbVg90H21EOLACvtfcHk0lhMKMkoeNHYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVKlsbg%253D&md5=68abef2b99fb137c2d455f053aab5222</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg219%26sid%3Dliteratum%253Aachs%26aulast%3DMajerle%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520Antibacterial%2520and%2520Lipopolysaccharide%2520Binding%2520Activities%2520of%2520a%2520Human%2520Lactoferrin%2520Peptide%2520Fragment%2520by%2520the%2520Addition%2520of%2520Acyl%2520Chain%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3D5%26spage%3D1159%26epage%3D1165%26doi%3D10.1093%2Fjac%2Fdkg219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Stoffel, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macrae, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Premont, R. T.</span><span> </span><span class="NLM_article-title">Palmitoylation Increases the Kinase Activity of the G Protein-Coupled Receptor Kinase, GRK6</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">46</span><span class="NLM_x">) </span> <span class="NLM_fpage">16053</span><span class="NLM_x">–</span> <span class="NLM_lpage">16059</span><span class="refDoi"> DOI: 10.1021/bi981432d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981432d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=16053-16059&issue=46&author=R.+H.+Stoffelauthor=J.+Ingleseauthor=A.+D.+Macraeauthor=R.+J.+Lefkowitzauthor=R.+T.+Premont&title=Palmitoylation+Increases+the+Kinase+Activity+of+the+G+Protein-Coupled+Receptor+Kinase%2C+GRK6&doi=10.1021%2Fbi981432d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fbi981432d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981432d%26sid%3Dliteratum%253Aachs%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DMacrae%26aufirst%3DA.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26atitle%3DPalmitoylation%2520Increases%2520the%2520Kinase%2520Activity%2520of%2520the%2520G%2520Protein-Coupled%2520Receptor%2520Kinase%252C%2520GRK6%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26issue%3D46%26spage%3D16053%26epage%3D16059%26doi%3D10.1021%2Fbi981432d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Staes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Absil, P.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lins, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasseur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecouturier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fievez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">des Rieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mingeot-Leclercq, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raussens, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Préat, V.</span><span> </span><span class="NLM_article-title">Acylated and Unacylated Ghrelin Binding to Membranes and to Ghrelin Receptor: Towards a Better Understanding of the Underlying Mechanisms</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1798</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2102</span><span class="NLM_x">–</span> <span class="NLM_lpage">2113</span><span class="refDoi"> DOI: 10.1016/j.bbamem.2010.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bbamem.2010.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=20637180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=2102-2113&issue=11&author=E.+Staesauthor=P.-A.+Absilauthor=L.+Linsauthor=R.+Brasseurauthor=M.+Deleuauthor=N.+Lecouturierauthor=V.+Fievezauthor=A.+des+Rieuxauthor=M.-P.+Mingeot-Leclercqauthor=V.+Raussensauthor=V.+Pr%C3%A9at&title=Acylated+and+Unacylated+Ghrelin+Binding+to+Membranes+and+to+Ghrelin+Receptor%3A+Towards+a+Better+Understanding+of+the+Underlying+Mechanisms&doi=10.1016%2Fj.bbamem.2010.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acylated and unacylated ghrelin binding to membranes and to ghrelin receptor: Towards a better understanding of the underlying mechanisms</span></div><div class="casAuthors">Staes, Edith; Absil, Pierre-Antoine; Lins, Laurence; Brasseur, Robert; Deleu, Magali; Lecouturier, Nathalie; Fievez, Virginie; des Rieux, Anne; Mingeot-Leclercq, Marie-Paule; Raussens, Vincent; Preat, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2102-2113</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The O-octanoylation of human ghrelin is a natural post-translational modification that enhances its binding to model membranes and could potentially play a central role in ghrelin biol. activities.  Here, we aimed to clarify the mechanisms that drive ghrelin to the membrane and hence to its receptor that mediates most of its endocrinol. effects.  As the acylation enhances ghrelin lipophilicity and that ghrelin contains many basic residues, we examd. the electrostatic attraction and/or hydrophobic interactions with membranes.  Using various liposomes and buffer conditions in binding, zeta potential and isothermal titrn. calorimetry studies, we found that whereas acylated and unacylated ghrelin were both electrostatically attracted towards the membrane, only acylated ghrelin penetrated into the headgroup and the lipid backbone regions of neg. charged membranes.  The O-acylation induced a 120-fold increase in ghrelin local concn. in the membrane.  However, acylated ghrelin did not deeply penetrate the membrane nor did it perturb its organization.  Conformational studies by CD and attenuated total reflection Fourier transformed IR as well as in silico modeling revealed that both forms of ghrelin mainly adopted the same structure in aq., micellar and bilayer environments even though acylated ghrelin structure is slightly more α-helical in a lipid bilayer environment.  Altogether our results suggest that membrane acts as a "catalyst" in acylated ghrelin binding to the ghrelin receptor and hence could explain why acylated and unacylated ghrelin are both full agonists of this receptor but in the nanomolar and micromolar range, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIf2UPZ5hvLLVg90H21EOLACvtfcHk0lhbEb80LHZkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvE&md5=e7709c8683413d25a2adf016ef47d6df</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DStaes%26aufirst%3DE.%26aulast%3DAbsil%26aufirst%3DP.-A.%26aulast%3DLins%26aufirst%3DL.%26aulast%3DBrasseur%26aufirst%3DR.%26aulast%3DDeleu%26aufirst%3DM.%26aulast%3DLecouturier%26aufirst%3DN.%26aulast%3DFievez%26aufirst%3DV.%26aulast%3Ddes%2BRieux%26aufirst%3DA.%26aulast%3DMingeot-Leclercq%26aufirst%3DM.-P.%26aulast%3DRaussens%26aufirst%3DV.%26aulast%3DPr%25C3%25A9at%26aufirst%3DV.%26atitle%3DAcylated%2520and%2520Unacylated%2520Ghrelin%2520Binding%2520to%2520Membranes%2520and%2520to%2520Ghrelin%2520Receptor%253A%2520Towards%2520a%2520Better%2520Understanding%2520of%2520the%2520Underlying%2520Mechanisms%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26issue%3D11%26spage%3D2102%26epage%3D2113%26doi%3D10.1016%2Fj.bbamem.2010.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Elvert, R.; Herling, A.; Weiss, T.; Bossart, M.; Zhang, B.; Wenski, P.; Wandschneider, J.; Kleutsch, S.; Butty, U.; Kannt, A.; Wagner, M.; Haack, T.; Evers, A.; Dudda, A.; Larsen; Philip, J.</span><span> </span><span class="NLM_article-title">Running on Mixed Fuel: Dual Agonistic Approach of GLP-1 and GCG Receptors Leads to Beneficial Impact on Body Weight and Blood Glucose Control. A Comparative Study between Mice and Non-Human Primates</span>. Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Elvert%2C+R.%3B+Herling%2C+A.%3B+Weiss%2C+T.%3B+Bossart%2C+M.%3B+Zhang%2C+B.%3B+Wenski%2C+P.%3B+Wandschneider%2C+J.%3B+Kleutsch%2C+S.%3B+Butty%2C+U.%3B+Kannt%2C+A.%3B+Wagner%2C+M.%3B+Haack%2C+T.%3B+Evers%2C+A.%3B+Dudda%2C+A.%3B+Larsen%3B+Philip%2C+J.+Running+on+Mixed+Fuel%3A+Dual+Agonistic+Approach+of+GLP-1+and+GCG+Receptors+Leads+to+Beneficial+Impact+on+Body+Weight+and+Blood+Glucose+Control.+A+Comparative+Study+between+Mice+and+Non-Human+Primates.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DElvert%26aufirst%3DR.%26atitle%3DRunning%2520on%2520Mixed%2520Fuel%253A%2520Dual%2520Agonistic%2520Approach%2520of%2520GLP-1%2520and%2520GCG%2520Receptors%2520Leads%2520to%2520Beneficial%2520Impact%2520on%2520Body%2520Weight%2520and%2520Blood%2520Glucose%2520Control.%2520A%2520Comparative%2520Study%2520between%2520Mice%2520and%2520Non-Human%2520Primates" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocai, A.</span><span> </span><span class="NLM_article-title">Optimization of Co-Agonism at GLP-1 and Glucagon Receptors to Safely Maximize Weight Reduction in DIO-Rodents</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1002/bip.22072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fbip.22072" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=443-450&issue=5&author=J.+W.+Dayauthor=V.+Gelfanovauthor=D.+Smileyauthor=P.+E.+Carringtonauthor=G.+Eiermannauthor=G.+Chicchiauthor=M.+D.+Erionauthor=J.+Giddaauthor=N.+A.+Thornberryauthor=M.+H.+Tsch%C3%B6pauthor=D.+J.+Marshauthor=R.+SinhaRoyauthor=R.+DiMarchiauthor=A.+Pocai&title=Optimization+of+Co-Agonism+at+GLP-1+and+Glucagon+Receptors+to+Safely+Maximize+Weight+Reduction+in+DIO-Rodents&doi=10.1002%2Fbip.22072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbip.22072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22072%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DChicchi%26aufirst%3DG.%26aulast%3DErion%26aufirst%3DM.%2BD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DPocai%26aufirst%3DA.%26atitle%3DOptimization%2520of%2520Co-Agonism%2520at%2520GLP-1%2520and%2520Glucagon%2520Receptors%2520to%2520Safely%2520Maximize%2520Weight%2520Reduction%2520in%2520DIO-Rodents%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26issue%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1002%2Fbip.22072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pincus, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">A Hierarchical Approach to All-Atom Protein Loop Prediction</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1002/prot.10613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fprot.10613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=15048827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=351-367&issue=2&author=M.+P.+Jacobsonauthor=D.+L.+Pincusauthor=C.+S.+Rappauthor=T.+J.+F.+Dayauthor=B.+Honigauthor=D.+E.+Shawauthor=R.+A.+Friesner&title=A+Hierarchical+Approach+to+All-Atom+Protein+Loop+Prediction&doi=10.1002%2Fprot.10613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A hierarchical approach to all-atom protein loop prediction</span></div><div class="casAuthors">Jacobson, Matthew P.; Pincus, David L.; Rapp, Chaya S.; Day, Tyler J. F.; Honig, Barry; Shaw, David E.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-367</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The application of all-atom force fields (and explicit or implicit solvent models) to protein homol.-modeling tasks such as side-chain and loop prediction remains challenging both because of the expense of the individual energy calcns. and because of the difficulty of sampling the rugged all-atom energy surface.  Here the authors address this challenge for the problem of loop prediction through the development of numerous new algorithms, with an emphasis on multiscale and hierarchical techniques.  As a first step in evaluating the performance of the authors' loop prediction algorithm, the authors have applied it to the problem of reconstructing loops in native structures; the authors also explicitly include crystal packing to provide a fair comparison with crystal structures.  In brief, large nos. of loops are generated by using a dihedral angle-based buildup procedure followed by iterative cycles of clustering, side-chain optimization, and complete energy minimization of selected loop structures.  The authors evaluate this method by the largest test set yet used for validation of a loop prediction method, with a total of 833 loops ranging from 4 to 12 residues in length.  Av./median backbone root-mean-square deviations (RMSDs) to the native structures (superimposing the body of the protein, not the loop itself) are 0.42/0.24 Å for 5 residue loops, 1.00/0.44 Å for 8 residue loops, and 2.47/1.83 Å for 11 residue loops.  Median RMSDs are substantially lower than the avs. because of a small no. of outliers; the causes of these failures are examd. in some detail, and many can be attributed to errors in assignment of protonation states of titratable residues, omission of ligands from the simulation, and, in a few cases, probable errors in the exptl. detd. structures.  When these obvious problems in the data sets are filtered out, av. RMSDs to the native structures improve to 0.43 Å for 5 residue loops, 0.84 Å for 8 residue loops, and 1.63 Å for 11 residue loops.  In the vast majority of cases, the method locates energy min. that are lower than or equal to that of the minimized native loop, thus indicating that sampling rarely limits prediction accuracy.  The overall results are, to the authors' knowledge, the best reported to date, and the authors attribute this success to the combination of an accurate all-atom energy function, efficient methods for loop buildup and side-chain optimization, and, esp. for the longer loops, the hierarchical refinement protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHqYMnqaWXvLVg90H21EOLACvtfcHk0lhbEb80LHZkxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKhsrc%253D&md5=e0eff655eeefb30ea00ae041ea9099c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fprot.10613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10613%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DPincus%26aufirst%3DD.%2BL.%26aulast%3DRapp%26aufirst%3DC.%2BS.%26aulast%3DDay%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DHonig%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DA%2520Hierarchical%2520Approach%2520to%2520All-Atom%2520Protein%2520Loop%2520Prediction%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D55%26issue%3D2%26spage%3D351%26epage%3D367%26doi%3D10.1002%2Fprot.10613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">King, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, G. B.</span><span> </span><span class="NLM_article-title">A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1990.tb00976.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1399-3011.1990.tb00976.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=2279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=255-266&issue=3&author=D.+S.+Kingauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=A+Cleavage+Method+Which+Minimizes+Side+Reactions+Following+Fmoc+Solid+Phase+Peptide+Synthesis&doi=10.1111%2Fj.1399-3011.1990.tb00976.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">King, David S.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-66</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The success of solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl (Fmoc) amino acids is often limited by deleterious side reactions which occur during CF3CO2H (TFA) peptide-resin cleavage and side-chain deprotection.  The majority of these side reactions modify susceptible residues, such as Trp, Tyr, Met, and Cys, with TFA-liberated side-chain protecting groups and linkers.  The relative effectiveness of various scavengers in suppressing these side reactions was studied.  The cleavage mixt. 82.5% TFA : 5% H2O : 5% thioanisole : 2.5% 1,2-ethanedithiol (reagent K) was maximally efficient in inhibiting a great variety of side reactions.  Synthesis and cleavage of 10 peptides, each contg. 20-50 residues, demonstrated the complementarity of Fmoc chem. with reagent K for efficient synthesis of complex peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwcooNm7oD7Vg90H21EOLACvtfcHk0lh2uOP5Zc0wpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D&md5=ecf761fc6877559af82062c6345306ab</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00976.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00976.x%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DD.%2BS.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DA%2520Cleavage%2520Method%2520Which%2520Minimizes%2520Side%2520Reactions%2520Following%2520Fmoc%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26issue%3D3%26spage%3D255%26epage%3D266%26doi%3D10.1111%2Fj.1399-3011.1990.tb00976.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Chhabra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hothi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bycroft, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span> </span><span class="NLM_article-title">An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1606</span><span class="refDoi"> DOI: 10.1016/S0040-4039(97)10828-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2FS0040-4039%2897%2910828-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1603-1606&issue=12&author=S.+R.+Chhabraauthor=B.+Hothiauthor=D.+J.+Evansauthor=P.+D.+Whiteauthor=B.+W.+Bycroftauthor=W.+C.+Chan&title=An+Appraisal+of+New+Variants+of+Dde+Amine+Protecting+Group+for+Solid+Phase+Peptide+Synthesis&doi=10.1016%2FS0040-4039%2897%2910828-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2910828-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252910828-0%26sid%3Dliteratum%253Aachs%26aulast%3DChhabra%26aufirst%3DS.%2BR.%26aulast%3DHothi%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26aulast%3DBycroft%26aufirst%3DB.%2BW.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Appraisal%2520of%2520New%2520Variants%2520of%2520Dde%2520Amine%2520Protecting%2520Group%2520for%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26issue%3D12%26spage%3D1603%26epage%3D1606%26doi%3D10.1016%2FS0040-4039%2897%2910828-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 60 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chun Han, Yuqing Sun, Qimeng Yang, Feng Zhou, Xinyu Chen, Lintao Wu, Lidan Sun, <span class="NLM_string-name hlFld-ContribAuthor">Jing Han</span>. </span><span class="cited-content_cbyCitation_article-title">Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (8)
                                     , 2906-2923. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00995" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00995%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DStapled%25252C%252BLong-Acting%252BXenopus%252BGLP-1-Based%252BDual%252BGLP-1%25252FGlucagon%252BReceptor%252BAgonists%252Bwith%252BPotent%252BTherapeutic%252BEfficacy%252Bfor%252BMetabolic%252BDisease%26aulast%3DHan%26aufirst%3DChun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D05102020%26date%3D29062021%26date%3D24062021%26date%3D09072021%26volume%3D18%26issue%3D8%26spage%3D2906%26epage%3D2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ian C. Tinsley, Tito Borner, MacKenzie L. Swanson, Oleg G. Chepurny, Sarah A. Doebley, Varun Kamat, Ian R. Sweet, George G. Holz, Matthew R. Hayes, Bart C. De Jonghe, <span class="NLM_string-name hlFld-ContribAuthor">Robert P. Doyle</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3479-3492. <a href="https://doi.org/10.1021/acs.jmedchem.1c00185" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00185%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252BOptimization%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BCorrinated%252BConjugates%252Bof%252Bthe%252BGLP-1R%252BAgonist%252BExendin-4%26aulast%3DTinsley%26aufirst%3DIan%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D06032021%26volume%3D64%26issue%3D6%26spage%3D3479%26epage%3D3492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xinyu Chen, Junjie Fu, Feng Zhou, Qimeng Yang, Jialing Wang, Hui Feng, Wen Jiang, Luofan Jin, Xuelin Tang, Neng Jiang, Jian Yin, <span class="NLM_string-name hlFld-ContribAuthor">Jing Han</span>. </span><span class="cited-content_cbyCitation_article-title">Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12595-12613. <a href="https://doi.org/10.1021/acs.jmedchem.0c00736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00736%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStapled%252Band%252BXenopus%252BGlucagon-Like%252BPeptide%252B1%252B%252528GLP-1%252529-Based%252BDual%252BGLP-1%25252FGastrin%252BReceptor%252BAgonists%252Bwith%252BImproved%252BMetabolic%252BBenefits%252Bin%252BRodent%252BModels%252Bof%252BObesity%252Band%252BDiabetes%26aulast%3DChen%26aufirst%3DXinyu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D02052020%26date%3D30102020%26volume%3D63%26issue%3D21%26spage%3D12595%26epage%3D12613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dan Sindhikara, Michael Wagner, Paraskevi Gkeka, Stefan Güssregen, Garima Tiwari, Gerhard Hessler, Engin Yapici, Ziyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Evers</span>. </span><span class="cited-content_cbyCitation_article-title">Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12100-12115. <a href="https://doi.org/10.1021/acs.jmedchem.0c01500" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01500%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAutomated%252BDesign%252Bof%252BMacrocycles%252Bfor%252BTherapeutic%252BApplications%25253A%252BFrom%252BSmall%252BMolecules%252Bto%252BPeptides%252Band%252BProteins%26aulast%3DSindhikara%26aufirst%3DDan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27082020%26date%3D05102020%26volume%3D63%26issue%3D20%26spage%3D12100%26epage%3D12115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">María Méndez, Hans Matter, Elisabeth Defossa, Michael Kurz, Sylvain Lebreton, Ziyu Li, Matthias Lohmann, Matthias Löhn, Hartmut Mors, Michael Podeschwa, Nils Rackelmann, Jens Riedel, Pavel Safar, David S. Thorpe, Matthias Schäfer, Dietmar Weitz, <span class="NLM_string-name hlFld-ContribAuthor">Kristin Breitschopf</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2292-2307. <a href="https://doi.org/10.1021/acs.jmedchem.9b01071" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01071%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252BPotent%252BPositive%252BAllosteric%252BModulators%252Bof%252Bthe%252BGlucagon-like%252BPeptide-1%252BReceptor%252B%252528GLP-1R%252529%26aulast%3DM%25C3%25A9ndez%26aufirst%3DMar%25C3%25ADa%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03072019%26date%3D23102019%26date%3D09102019%26volume%3D63%26issue%3D5%26spage%3D2292%26epage%3D2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Martin Wolff, Anja Schüler, Klaus Gast, Robert Seckler, Andreas Evers, Stefania Pfeiffer-Marek, Michael Kurz, Norbert Nagel, Torsten Haack, Michael Wagner, <span class="NLM_string-name hlFld-ContribAuthor">Anja Thalhammer</span>. </span><span class="cited-content_cbyCitation_article-title">Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (3)
                                     , 965-978. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b01195" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b01195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b01195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b01195%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSelf-Assembly%252Bof%252BExendin-4-Derived%252BDual%252BPeptide%252BAgonists%252Bis%252BMediated%252Bby%252BAcylation%252Band%252BCorrelated%252Bto%252Bthe%252BLength%252Bof%252BConjugated%252BFatty%252BAcyl%252BChains%26aulast%3DWolff%26aufirst%3DMartin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2020%26date%3D20112019%26date%3D21012020%26date%3D10012020%26date%3D05022020%26date%3D23012020%26volume%3D17%26issue%3D3%26spage%3D965%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Seyed Ebrahim Alavi, Peter J. Cabot, <span class="NLM_string-name hlFld-ContribAuthor">Peter M. Moyle</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (6)
                                     , 2278-2295. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00308" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00308%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DGlucagon-Like%252BPeptide-1%252BReceptor%252BAgonists%252Band%252BStrategies%252BTo%252BImprove%252BTheir%252BEfficiency%26aulast%3DAlavi%26aufirst%3DSeyed%2BEbrahim%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15032019%26date%3D03052019%26date%3D24042019%26date%3D13052019%26date%3D03052019%26volume%3D16%26issue%3D6%26spage%3D2278%26epage%3D2295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shaoyong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 24-45. <a href="https://doi.org/10.1021/acs.jmedchem.7b01844" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01844%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BAllosteric%252BModulators%252Bof%252BG-Protein-Coupled%252BReceptors%25253A%252BDrug%2525E2%252580%252593Target%252BInteractions%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2019%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D26022018%26date%3D19022018%26volume%3D62%26issue%3D1%26spage%3D24%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andreas Evers, Martin Bossart, Stefania Pfeiffer-Marek, Ralf Elvert, Herman Schreuder, Michael Kurz, Siegfried Stengelin, Martin Lorenz, Andreas Herling, Anish Konkar, Ulrike Lukasczyk, Anja Pfenninger, Katrin Lorenz, Torsten Haack, Dieter Kadereit, <span class="NLM_string-name hlFld-ContribAuthor">Michael Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5580-5593. <a href="https://doi.org/10.1021/acs.jmedchem.8b00292" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00292%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BGlucagon-like%252BPeptide%252B1%252B%252528GLP-1%252529%25252FGlucagon%252BReceptor%252BAgonists%252BSpecifically%252BOptimized%252Bfor%252BMultidose%252BFormulations%26aulast%3DEvers%26aufirst%3DAndreas%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20022018%26date%3D25062018%26date%3D07062018%26volume%3D61%26issue%3D13%26spage%3D5580%26epage%3D5593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jing Han, Xinyu Chen, Liming Zhao, Junjie Fu, Lidan Sun, Ying Zhang, Feng Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Yingying Fei</span>. </span><span class="cited-content_cbyCitation_article-title">Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (7)
                                     , 2840-2856. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00336" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00336%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DLithocholic%252BAcid-Based%252BPeptide%252BDelivery%252BSystem%252Bfor%252Ban%252BEnhanced%252BPharmacological%252Band%252BPharmacokinetic%252BProfile%252Bof%252BXenopus%252BGLP-1%252BAnalogs%26aulast%3DHan%26aufirst%3DJing%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29032018%26date%3D25052018%26date%3D04052018%26date%3D04062018%26date%3D25052018%26volume%3D15%26issue%3D7%26spage%3D2840%26epage%3D2856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olof  Eriksson</span>, <span class="hlFld-ContribAuthor ">Irina  Velikyan</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Philip J.  Larsen</span>, <span class="hlFld-ContribAuthor ">Jan Erik  Berglund</span>, <span class="hlFld-ContribAuthor ">Gunnar  Antoni</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Joachim  Tillner</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nuclear Medicine</span><span> <strong>2021,</strong> <em>62 </em>
                                    (6)
                                     , 833-838. <a href="https://doi.org/10.2967/jnumed.118.213306" title="DOI URL">https://doi.org/10.2967/jnumed.118.213306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2967/jnumed.118.213306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2967%2Fjnumed.118.213306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nuclear%2520Medicine%26atitle%3DImaging%252Bof%252Bthe%252BGlucagon%252BReceptor%252Bin%252BSubjects%252Bwith%252BType%252B2%252BDiabetes%26aulast%3DEriksson%26aufirst%3DOlof%26date%3D2021%26date%3D2020%26volume%3D62%26issue%3D6%26spage%3D833%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Anish  Konkar</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon‐Like Peptide‐1 Receptor Activators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-69. <a href="https://doi.org/10.1002/0471266949.bmc268" title="DOI URL">https://doi.org/10.1002/0471266949.bmc268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc268%26sid%3Dliteratum%253Aachs%26atitle%3DGlucagon%2525E2%252580%252590Like%252BPeptide%2525E2%252580%2525901%252BReceptor%252BActivators%26aulast%3DWagner%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D69%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olof  Eriksson</span>, <span class="hlFld-ContribAuthor ">Irina  Velikyan</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Katrin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Philip J.  Larsen</span>, <span class="hlFld-ContribAuthor ">Oliver  Plettenburg</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography. </span><span class="cited-content_cbyCitation_journal-name">Diabetes</span><span> <strong>2021,</strong> <em>70 </em>
                                    (4)
                                     , 842-853. <a href="https://doi.org/10.2337/db20-1096" title="DOI URL">https://doi.org/10.2337/db20-1096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2337/db20-1096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2337%2Fdb20-1096%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%26atitle%3DDrug%252BOccupancy%252BAssessment%252Bat%252Bthe%252BGlucose-Dependent%252BInsulinotropic%252BPolypeptide%252BReceptor%252Bby%252BPositron%252BEmission%252BTomography%26aulast%3DEriksson%26aufirst%3DOlof%26date%3D2021%26date%3D2021%26volume%3D70%26issue%3D4%26spage%3D842%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neng  Jiang</span>, <span class="hlFld-ContribAuthor ">Lin  Jing</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Sibiao  Su</span>, <span class="hlFld-ContribAuthor ">Qimeng  Yang</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xinyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Chunli  Tang</span>, <span class="hlFld-ContribAuthor ">Weizhong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113118. <a href="https://doi.org/10.1016/j.ejmech.2020.113118" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113118%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bnovel%252BXenopus%252BGLP-1-based%252Bdual%252Bglucagon-like%252Bpeptide%252B1%252B%252528GLP-1%252529%25252Fglucagon%252Breceptor%252Bagonists%26aulast%3DJiang%26aufirst%3DNeng%26date%3D2021%26volume%3D212%26spage%3D113118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John J.  Nestor</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Zhang</span>, <span class="hlFld-ContribAuthor ">Sarah  Jaw‐Tsai</span>, <span class="hlFld-ContribAuthor ">David G.  Parkes</span>, <span class="hlFld-ContribAuthor ">Cyrus K.  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">Design and characterization of a surfactant‐conjugated, long‐acting, balanced
              GLP
              ‐1/glucagon receptor dual agonist. </span><span class="cited-content_cbyCitation_journal-name">Peptide Science</span><span> <strong>2021,</strong> <em>377 </em><a href="https://doi.org/10.1002/pep2.24221" title="DOI URL">https://doi.org/10.1002/pep2.24221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pep2.24221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpep2.24221%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Science%26atitle%3DDesign%252Band%252Bcharacterization%252Bof%252Ba%252Bsurfactant%2525E2%252580%252590conjugated%25252C%252Blong%2525E2%252580%252590acting%25252C%252Bbalanced%252BGLP%252B%2525E2%252580%2525901%25252Fglucagon%252Breceptor%252Bdual%252Bagonist%26aulast%3DNestor%26aufirst%3DJohn%2BJ.%26date%3D2021%26date%3D2021%26volume%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olof  Eriksson</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Youssef  Hijazi</span>, <span class="hlFld-ContribAuthor ">Lenore  Teichert</span>, <span class="hlFld-ContribAuthor ">Veronique  Tavernier</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Jan Erik  Berglund</span>, <span class="hlFld-ContribAuthor ">Gunnar  Antoni</span>, <span class="hlFld-ContribAuthor ">Irina  Velikyan</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Joachim  Tillner</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-73815-5" title="DOI URL">https://doi.org/10.1038/s41598-020-73815-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-73815-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-73815-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DReceptor%252Boccupancy%252Bof%252Bdual%252Bglucagon-like%252Bpeptide%252B1%25252Fglucagon%252Breceptor%252Bagonist%252BSAR425899%252Bin%252Bindividuals%252Bwith%252Btype%252B2%252Bdiabetes%26aulast%3DEriksson%26aufirst%3DOlof%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Cui</span>, <span class="hlFld-ContribAuthor ">Anquan  Shang</span>, <span class="hlFld-ContribAuthor ">Weiwei  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>260 </em>, 118339. <a href="https://doi.org/10.1016/j.lfs.2020.118339" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.118339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.118339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.118339%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DRational%252Bdesign%252Bof%252Ba%252BGLP-1%25252FGIP%25252FGcg%252Breceptor%252Btriagonist%252Bto%252Bcorrect%252Bhyperglycemia%25252C%252Bobesity%252Band%252Bdiabetic%252Bnephropathy%252Bin%252Brodent%252Banimals%26aulast%3DCui%26aufirst%3DJie%26date%3D2020%26volume%3D260%26spage%3D118339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalia R.V.  Dragano</span>, <span class="hlFld-ContribAuthor ">Johan  Fernø</span>, <span class="hlFld-ContribAuthor ">Carlos  Diéguez</span>, <span class="hlFld-ContribAuthor ">Miguel  López</span>, <span class="hlFld-ContribAuthor ">Edward  Milbank</span>. </span><span class="cited-content_cbyCitation_article-title">Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience</span><span> <strong>2020,</strong> <em>447 </em>, 191-215. <a href="https://doi.org/10.1016/j.neuroscience.2020.08.009" title="DOI URL">https://doi.org/10.1016/j.neuroscience.2020.08.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuroscience.2020.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuroscience.2020.08.009%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%26atitle%3DReprint%252Bof%25253A%252BRecent%252BUpdates%252Bon%252BObesity%252BTreatments%25253A%252BAvailable%252BDrugs%252Band%252BFuture%252BDirections%26aulast%3DDragano%26aufirst%3DNathalia%2BR.V.%26date%3D2020%26volume%3D447%26spage%3D191%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanaz  Darbalaei</span>, <span class="hlFld-ContribAuthor ">Elita  Yuliantie</span>, <span class="hlFld-ContribAuthor ">Antao  Dai</span>, <span class="hlFld-ContribAuthor ">Rulue  Chang</span>, <span class="hlFld-ContribAuthor ">Peishen  Zhao</span>, <span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Patrick M.  Sexton</span>, <span class="hlFld-ContribAuthor ">Denise  Wootten</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>180 </em>, 114150. <a href="https://doi.org/10.1016/j.bcp.2020.114150" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114150%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DEvaluation%252Bof%252Bbiased%252Bagonism%252Bmediated%252Bby%252Bdual%252Bagonists%252Bof%252Bthe%252BGLP-1%252Band%252Bglucagon%252Breceptors%26aulast%3DDarbalaei%26aufirst%3DSanaz%26date%3D2020%26volume%3D180%26spage%3D114150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Stefania  Pfeiffer‐Marek</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Ralf  Elvert</span>, <span class="hlFld-ContribAuthor ">Katrin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Christoph  Heubel</span>, <span class="hlFld-ContribAuthor ">Ana Villar  Garea</span>, <span class="hlFld-ContribAuthor ">Katrin  Schroeter</span>, <span class="hlFld-ContribAuthor ">Jens  Riedel</span>, <span class="hlFld-ContribAuthor ">Ursula  Stock</span>, <span class="hlFld-ContribAuthor ">Anish  Konkar</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Multiparameter Peptide Optimization toward Stable Triple Agonists for the Treatment of Diabetes and Obesity. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (9)
                                     , 2000052. <a href="https://doi.org/10.1002/adtp.202000052" title="DOI URL">https://doi.org/10.1002/adtp.202000052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000052%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DMultiparameter%252BPeptide%252BOptimization%252Btoward%252BStable%252BTriple%252BAgonists%252Bfor%252Bthe%252BTreatment%252Bof%252BDiabetes%252Band%252BObesity%26aulast%3DEvers%26aufirst%3DAndreas%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D9%26spage%3D2000052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Cong  Ma</span>, <span class="hlFld-ContribAuthor ">Li  Zeng</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>256 </em>, 117853. <a href="https://doi.org/10.1016/j.lfs.2020.117853" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.117853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.117853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.117853%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DA%252Bnovel%252Bthrombin-based%252Btriagonist%252Bwith%252Bdiabetes-protective%252Band%252Bweight-lowering%252Bpotential%26aulast%3DZhang%26aufirst%3DJingyu%26date%3D2020%26volume%3D256%26spage%3D117853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yumin  Wu</span>, <span class="hlFld-ContribAuthor ">Tiemei  Ji</span>, <span class="hlFld-ContribAuthor ">Jie  Lv</span>, <span class="hlFld-ContribAuthor ">Zhicun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>257 </em>, 118025. <a href="https://doi.org/10.1016/j.lfs.2020.118025" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.118025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.118025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.118025%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DRapid%252Bselection%252Bof%252Ba%252Bnovel%252BGLP-1%25252FGIP%252Bdual%252Breceptor%252Bagonist%252Bwith%252Bprolonged%252Bglycemic%252Bcontrol%252Band%252Bweight%252Bloss%252Bin%252Brodent%252Banimals%26aulast%3DWu%26aufirst%3DYumin%26date%3D2020%26volume%3D257%26spage%3D118025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Johan G.  Doverfjord</span>, <span class="hlFld-ContribAuthor ">Joachim  Tillner</span>, <span class="hlFld-ContribAuthor ">Gunnar  Antoni</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Olof  Eriksson</span>, <span class="hlFld-ContribAuthor ">Irina  Velikyan</span>. </span><span class="cited-content_cbyCitation_article-title">Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (8)
                                     , 176. <a href="https://doi.org/10.3390/ph13080176" title="DOI URL">https://doi.org/10.3390/ph13080176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13080176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13080176%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DAutomated%252BGMP-Compliant%252BProduction%252Bof%252B%25255B68Ga%25255DGa-DO3A-Tuna-2%252Bfor%252BPET%252BMicrodosing%252BStudies%252Bof%252Bthe%252BGlucagon%252BReceptor%252Bin%252BHumans%26aulast%3DWagner%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D8%26spage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>, <span class="hlFld-ContribAuthor ">Qimeng  Yang</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xinyu  Chen</span>, <span class="hlFld-ContribAuthor ">Chenglin  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>198 </em>, 112389. <a href="https://doi.org/10.1016/j.ejmech.2020.112389" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112389%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdesign%252Band%252Bbiological%252Bevaluation%252Bof%252Bgemfibrozil%252Bmodified%252BXenopus%252BGLP-1%252Bderivatives%252Bas%252Blong-acting%252Bhypoglycemic%252Bagents%26aulast%3DHan%26aufirst%3DJing%26date%3D2020%26volume%3D198%26spage%3D112389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna V.  Graham</span>, <span class="hlFld-ContribAuthor ">J. Michael  Conlon</span>, <span class="hlFld-ContribAuthor ">Yasser H.  Abdel-Wahab</span>, <span class="hlFld-ContribAuthor ">Peter R.  Flatt</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>878 </em>, 173101. <a href="https://doi.org/10.1016/j.ejphar.2020.173101" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173101%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DGlucagon%252Bfrom%252Bthe%252Bphylogenetically%252Bancient%252Bpaddlefish%252Bprovides%252Ba%252Btemplate%252Bfor%252Bthe%252Bdesign%252Bof%252Ba%252Blong-acting%252Bpeptide%252Bwith%252Beffective%252Banti-diabetic%252Band%252Banti-obesity%252Bactivities%26aulast%3DGraham%26aufirst%3DGalyna%2BV.%26date%3D2020%26volume%3D878%26spage%3D173101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinxian  Deng</span>, <span class="hlFld-ContribAuthor ">Mojdeh S.  Tavallaie</span>, <span class="hlFld-ContribAuthor ">Ran  Sun</span>, <span class="hlFld-ContribAuthor ">Juntao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingqing  Cai</span>, <span class="hlFld-ContribAuthor ">Jian  Shen</span>, <span class="hlFld-ContribAuthor ">Shuwen  Lei</span>, <span class="hlFld-ContribAuthor ">Lei  Fu</span>, <span class="hlFld-ContribAuthor ">Faqin  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug discovery approaches targeting the incretin pathway. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103810. <a href="https://doi.org/10.1016/j.bioorg.2020.103810" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103810%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDrug%252Bdiscovery%252Bapproaches%252Btargeting%252Bthe%252Bincretin%252Bpathway%26aulast%3DDeng%26aufirst%3DXinxian%26date%3D2020%26volume%3D99%26spage%3D103810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalia R.V.  Dragano</span>, <span class="hlFld-ContribAuthor ">Johan  Fernø</span>, <span class="hlFld-ContribAuthor ">Carlos  Diéguez</span>, <span class="hlFld-ContribAuthor ">Miguel  López</span>, <span class="hlFld-ContribAuthor ">Edward  Milbank</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Updates on Obesity Treatments: Available Drugs and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience</span><span> <strong>2020,</strong> <em>437 </em>, 215-239. <a href="https://doi.org/10.1016/j.neuroscience.2020.04.034" title="DOI URL">https://doi.org/10.1016/j.neuroscience.2020.04.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuroscience.2020.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuroscience.2020.04.034%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%26atitle%3DRecent%252BUpdates%252Bon%252BObesity%252BTreatments%25253A%252BAvailable%252BDrugs%252Band%252BFuture%252BDirections%26aulast%3DDragano%26aufirst%3DNathalia%2BR.V.%26date%3D2020%26volume%3D437%26spage%3D215%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohan  Patil</span>, <span class="hlFld-ContribAuthor ">Nitin J.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Mahesh  Patel</span>, <span class="hlFld-ContribAuthor ">Ganesh V.  Sangle</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon-based therapy: Past, present and future. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2020,</strong> <em>127 </em>, 170296. <a href="https://doi.org/10.1016/j.peptides.2020.170296" title="DOI URL">https://doi.org/10.1016/j.peptides.2020.170296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2020.170296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2020.170296%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DGlucagon-based%252Btherapy%25253A%252BPast%25252C%252Bpresent%252Band%252Bfuture%26aulast%3DPatil%26aufirst%3DMohan%26date%3D2020%26volume%3D127%26spage%3D170296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick J.  Knerr</span>, <span class="hlFld-ContribAuthor ">Stephanie A.  Mowery</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Diego  Perez-Tilve</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2020,</strong> <em>125 </em>, 170225. <a href="https://doi.org/10.1016/j.peptides.2019.170225" title="DOI URL">https://doi.org/10.1016/j.peptides.2019.170225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2019.170225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2019.170225%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DSelection%252Band%252Bprogression%252Bof%252Bunimolecular%252Bagonists%252Bat%252Bthe%252BGIP%25252C%252BGLP-1%25252C%252Band%252Bglucagon%252Breceptors%252Bas%252Bdrug%252Bcandidates%26aulast%3DKnerr%26aufirst%3DPatrick%2BJ.%26date%3D2020%26volume%3D125%26spage%3D170225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kerstin  Stemmer</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into incretin-based therapies for treatment of diabetic dyslipidemia. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2020,</strong> <em>159 </em>, 34-53. <a href="https://doi.org/10.1016/j.addr.2020.05.008" title="DOI URL">https://doi.org/10.1016/j.addr.2020.05.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2020.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2020.05.008%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DInsights%252Binto%252Bincretin-based%252Btherapies%252Bfor%252Btreatment%252Bof%252Bdiabetic%252Bdyslipidemia%26aulast%3DStemmer%26aufirst%3DKerstin%26date%3D2020%26volume%3D159%26spage%3D34%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xingguang  Cai</span>, <span class="hlFld-ContribAuthor ">Chengye  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuxuan  Dai</span>, <span class="hlFld-ContribAuthor ">Yosefa  Avraham</span>, <span class="hlFld-ContribAuthor ">Lidan  Sun</span>, <span class="hlFld-ContribAuthor ">Chunxia  Liu</span>, <span class="hlFld-ContribAuthor ">Jiayi  Tong</span>, <span class="hlFld-ContribAuthor ">Yao  Wang</span>, <span class="hlFld-ContribAuthor ">Xinzhou  Bi</span>, <span class="hlFld-ContribAuthor ">Liang  He</span>, <span class="hlFld-ContribAuthor ">Wenlong  Huang</span>, <span class="hlFld-ContribAuthor ">Hai  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>95 </em>, 103538. <a href="https://doi.org/10.1016/j.bioorg.2019.103538" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103538</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103538%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252Bglucagon-%252Band%252BOXM-based%252Bpeptides%252Bacting%252Bthrough%252Bglucagon%252Band%252BGLP-1%252Breceptors%252Bwith%252Bbody%252Bweight%252Breduction%252Band%252Banti-diabetic%252Bproperties%26aulast%3DCai%26aufirst%3DXingguang%26date%3D2020%26volume%3D95%26spage%3D103538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raul C.  Camacho</span>, <span class="hlFld-ContribAuthor ">Seohee  You</span>, <span class="hlFld-ContribAuthor ">Katharine E.  D’Aquino</span>, <span class="hlFld-ContribAuthor ">Wenyu  Li</span>, <span class="hlFld-ContribAuthor ">Yuanping  Wang</span>, <span class="hlFld-ContribAuthor ">Joseph  Gunnet</span>, <span class="hlFld-ContribAuthor ">James  Littrell</span>, <span class="hlFld-ContribAuthor ">Jian Shen  Qi</span>, <span class="hlFld-ContribAuthor ">Lijuan  Kang</span>, <span class="hlFld-ContribAuthor ">Wenying  Jian</span>, <span class="hlFld-ContribAuthor ">Mary  MacDonald</span>, <span class="hlFld-ContribAuthor ">Timothy  Tat</span>, <span class="hlFld-ContribAuthor ">Derek  Steiner</span>, <span class="hlFld-ContribAuthor ">Yue-Mei  Zhang</span>, <span class="hlFld-ContribAuthor ">James  Lanter</span>, <span class="hlFld-ContribAuthor ">Raymond  Patch</span>, <span class="hlFld-ContribAuthor ">Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiali  Li</span>, <span class="hlFld-ContribAuthor ">Suzanne  Edavettal</span>, <span class="hlFld-ContribAuthor ">Wilson  Edwards</span>, <span class="hlFld-ContribAuthor ">Thai  Dinh</span>, <span class="hlFld-ContribAuthor ">Li Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Judy  Connor</span>, <span class="hlFld-ContribAuthor ">Michael  Hunter</span>, <span class="hlFld-ContribAuthor ">Ellen  Chi</span>, <span class="hlFld-ContribAuthor ">Ronald V.  Swanson</span>, <span class="hlFld-ContribAuthor ">James N.  Leonard</span>, <span class="hlFld-ContribAuthor ">Martin A.  Case</span>. </span><span class="cited-content_cbyCitation_article-title">Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     , 1794687. <a href="https://doi.org/10.1080/19420862.2020.1794687" title="DOI URL">https://doi.org/10.1080/19420862.2020.1794687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2020.1794687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2020.1794687%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DConjugation%252Bof%252Ba%252Bpeptide%252Bto%252Ban%252Bantibody%252Bengineered%252Bwith%252Bfree%252Bcysteines%252Bdramatically%252Bimproves%252Bhalf-life%252Band%252Bactivity%26aulast%3DCamacho%26aufirst%3DRaul%2BC.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D1%26spage%3D1794687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerald  Grandl</span>, <span class="hlFld-ContribAuthor ">Aaron  Novikoff</span>, <span class="hlFld-ContribAuthor ">Richard  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Gut Peptide Agonism in the Treatment of Obesity and Diabetes. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 99-124. <a href="https://doi.org/10.1002/cphy.c180044" title="DOI URL">https://doi.org/10.1002/cphy.c180044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cphy.c180044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcphy.c180044%26sid%3Dliteratum%253Aachs%26atitle%3DGut%252BPeptide%252BAgonism%252Bin%252Bthe%252BTreatment%252Bof%252BObesity%252Band%252BDiabetes%26aulast%3DGrandl%26aufirst%3DGerald%26date%3D2019%26date%3D2019%26spage%3D99%26epage%3D124%26pub%3DWiley%26atitle%3DComprehensive%252BPhysiology%26aulast%3DTerjung%26aufirst%3DRonald%26date%3D2011%26date%3D2011%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.D.  Müller</span>, <span class="hlFld-ContribAuthor ">B.  Finan</span>, <span class="hlFld-ContribAuthor ">S.R.  Bloom</span>, <span class="hlFld-ContribAuthor ">D.  D'Alessio</span>, <span class="hlFld-ContribAuthor ">D.J.  Drucker</span>, <span class="hlFld-ContribAuthor ">P.R.  Flatt</span>, <span class="hlFld-ContribAuthor ">A.  Fritsche</span>, <span class="hlFld-ContribAuthor ">F.  Gribble</span>, <span class="hlFld-ContribAuthor ">H.J.  Grill</span>, <span class="hlFld-ContribAuthor ">J.F.  Habener</span>, <span class="hlFld-ContribAuthor ">J.J.  Holst</span>, <span class="hlFld-ContribAuthor ">W.  Langhans</span>, <span class="hlFld-ContribAuthor ">J.J.  Meier</span>, <span class="hlFld-ContribAuthor ">M.A.  Nauck</span>, <span class="hlFld-ContribAuthor ">D.  Perez-Tilve</span>, <span class="hlFld-ContribAuthor ">A.  Pocai</span>, <span class="hlFld-ContribAuthor ">F.  Reimann</span>, <span class="hlFld-ContribAuthor ">D.A.  Sandoval</span>, <span class="hlFld-ContribAuthor ">T.W.  Schwartz</span>, <span class="hlFld-ContribAuthor ">R.J.  Seeley</span>, <span class="hlFld-ContribAuthor ">K.  Stemmer</span>, <span class="hlFld-ContribAuthor ">M.  Tang-Christensen</span>, <span class="hlFld-ContribAuthor ">S.C.  Woods</span>, <span class="hlFld-ContribAuthor ">R.D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">M.H.  Tschöp</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon-like peptide 1 (GLP-1). </span><span class="cited-content_cbyCitation_journal-name">Molecular Metabolism</span><span> <strong>2019,</strong> <em>30 </em>, 72-130. <a href="https://doi.org/10.1016/j.molmet.2019.09.010" title="DOI URL">https://doi.org/10.1016/j.molmet.2019.09.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmet.2019.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmet.2019.09.010%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Metabolism%26atitle%3DGlucagon-like%252Bpeptide%252B1%252B%252528GLP-1%252529%26aulast%3DM%25C3%25BCller%26aufirst%3DT.D.%26date%3D2019%26volume%3D30%26spage%3D72%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olof  Eriksson</span>, <span class="hlFld-ContribAuthor ">Irina  Velikyan</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Philip J.  Larsen</span>, <span class="hlFld-ContribAuthor ">Oliver  Plettenburg</span>, <span class="hlFld-ContribAuthor ">Akihiro  Takano</span>, <span class="hlFld-ContribAuthor ">Christer  Halldin</span>, <span class="hlFld-ContribAuthor ">Gunnar  Antoni</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-51530-0" title="DOI URL">https://doi.org/10.1038/s41598-019-51530-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-51530-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-51530-0%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DAssessment%252Bof%252Bglucagon%252Breceptor%252Boccupancy%252Bby%252BPositron%252BEmission%252BTomography%252Bin%252Bnon-human%252Bprimates%26aulast%3DEriksson%26aufirst%3DOlof%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irina  Velikyan</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Philip  Larsen</span>, <span class="hlFld-ContribAuthor ">Oliver  Plettenburg</span>, <span class="hlFld-ContribAuthor ">Lars  Johansson</span>, <span class="hlFld-ContribAuthor ">Stefan  Pierrou</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Olof  Eriksson</span>. </span><span class="cited-content_cbyCitation_article-title">First-in-class positron emission tomography tracer for the glucagon receptor. </span><span class="cited-content_cbyCitation_journal-name">EJNMMI Research</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13550-019-0482-0" title="DOI URL">https://doi.org/10.1186/s13550-019-0482-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13550-019-0482-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13550-019-0482-0%26sid%3Dliteratum%253Aachs%26jtitle%3DEJNMMI%2520Research%26atitle%3DFirst-in-class%252Bpositron%252Bemission%252Btomography%252Btracer%252Bfor%252Bthe%252Bglucagon%252Breceptor%26aulast%3DVelikyan%26aufirst%3DIrina%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximilian  Kleinert</span>, <span class="hlFld-ContribAuthor ">Stephan  Sachs</span>, <span class="hlFld-ContribAuthor ">Kirk M.  Habegger</span>, <span class="hlFld-ContribAuthor ">Susanna M.  Hofmann</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon Regulation of Energy Expenditure. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (21)
                                     , 5407. <a href="https://doi.org/10.3390/ijms20215407" title="DOI URL">https://doi.org/10.3390/ijms20215407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20215407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20215407%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DGlucagon%252BRegulation%252Bof%252BEnergy%252BExpenditure%26aulast%3DKleinert%26aufirst%3DMaximilian%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D21%26spage%3D5407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas K.  Smith</span>, <span class="hlFld-ContribAuthor ">Troy A.  Hackett</span>, <span class="hlFld-ContribAuthor ">Aurelio  Galli</span>, <span class="hlFld-ContribAuthor ">Charles R.  Flynn</span>. </span><span class="cited-content_cbyCitation_article-title">GLP-1: Molecular mechanisms and outcomes of a complex signaling system. </span><span class="cited-content_cbyCitation_journal-name">Neurochemistry International</span><span> <strong>2019,</strong> <em>128 </em>, 94-105. <a href="https://doi.org/10.1016/j.neuint.2019.04.010" title="DOI URL">https://doi.org/10.1016/j.neuint.2019.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuint.2019.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuint.2019.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurochemistry%2520International%26atitle%3DGLP-1%25253A%252BMolecular%252Bmechanisms%252Band%252Boutcomes%252Bof%252Ba%252Bcomplex%252Bsignaling%252Bsystem%26aulast%3DSmith%26aufirst%3DNicholas%2BK.%26date%3D2019%26volume%3D128%26spage%3D94%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omar  Al-Massadi</span>, <span class="hlFld-ContribAuthor ">Johan  Fernø</span>, <span class="hlFld-ContribAuthor ">Carlos  Diéguez</span>, <span class="hlFld-ContribAuthor ">Ruben  Nogueiras</span>, <span class="hlFld-ContribAuthor ">Mar  Quiñones</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon Control on Food Intake and Energy Balance. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (16)
                                     , 3905. <a href="https://doi.org/10.3390/ijms20163905" title="DOI URL">https://doi.org/10.3390/ijms20163905</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20163905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20163905%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DGlucagon%252BControl%252Bon%252BFood%252BIntake%252Band%252BEnergy%252BBalance%26aulast%3DAl-Massadi%26aufirst%3DOmar%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D16%26spage%3D3905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryota  Usui</span>, <span class="hlFld-ContribAuthor ">Daisuke  Yabe</span>, <span class="hlFld-ContribAuthor ">Yutaka  Seino</span>. </span><span class="cited-content_cbyCitation_article-title">Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Diabetes Investigation</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 902-905. <a href="https://doi.org/10.1111/jdi.13005" title="DOI URL">https://doi.org/10.1111/jdi.13005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jdi.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjdi.13005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Diabetes%2520Investigation%26atitle%3DTwincretin%252Bas%252Ba%252Bpotential%252Btherapeutic%252Bfor%252Bthe%252Bmanagement%252Bof%252Btype%2525C2%2525A02%252Bdiabetes%252Bwith%252Bobesity%26aulast%3DUsui%26aufirst%3DRyota%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D4%26spage%3D902%26epage%3D905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Tingting  Meng</span>, <span class="hlFld-ContribAuthor ">Xinyu  Chen</span>, <span class="hlFld-ContribAuthor ">Yue  Han</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Yingying  Fei</span>, <span class="hlFld-ContribAuthor ">Chenglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The chronic administration of two novel long‐acting
              Xenopus
              glucagon‐like peptide‐1 analogs xGLP159 and XGLP296 potently improved systemic metabolism and glycemic control in rodent models. </span><span class="cited-content_cbyCitation_journal-name">The FASEB Journal</span><span> <strong>2019,</strong> <em>33 </em>
                                    (6)
                                     , 7113-7125. <a href="https://doi.org/10.1096/fj.201801479R" title="DOI URL">https://doi.org/10.1096/fj.201801479R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fj.201801479R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffj.201801479R%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FASEB%2520Journal%26atitle%3DThe%252Bchronic%252Badministration%252Bof%252Btwo%252Bnovel%252Blong%2525E2%252580%252590acting%252BXenopus%252Bglucagon%2525E2%252580%252590like%252Bpeptide%2525E2%252580%2525901%252Banalogs%252BxGLP159%252Band%252BXGLP296%252Bpotently%252Bimproved%252Bsystemic%252Bmetabolism%252Band%252Bglycemic%252Bcontrol%252Bin%252Brodent%252Bmodels%26aulast%3DHan%26aufirst%3DJing%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D6%26spage%3D7113%26epage%3D7125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mar  Quiñones</span>, <span class="hlFld-ContribAuthor ">Johan  Fernø</span>, <span class="hlFld-ContribAuthor ">Carlos  Diéguez</span>, <span class="hlFld-ContribAuthor ">Ruben  Nogueiras</span>, <span class="hlFld-ContribAuthor ">Omar  Al-Massadi</span>. </span><span class="cited-content_cbyCitation_article-title">Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2019,</strong> <em>14 </em>
                                    (5)
                                     , 421-431. <a href="https://doi.org/10.1080/17460441.2019.1583642" title="DOI URL">https://doi.org/10.1080/17460441.2019.1583642</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2019.1583642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2019.1583642%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DExciting%252Badvances%252Bin%252BGPCR-based%252Bdrugs%252Bdiscovery%252Bfor%252Btreating%252Bmetabolic%252Bdisease%252Band%252Bfuture%252Bperspectives%26aulast%3DQui%25C3%25B1ones%26aufirst%3DMar%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D5%26spage%3D421%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle Khai Khun  Yap</span>, <span class="hlFld-ContribAuthor ">Nurhamimah  Misuan</span>. </span><span class="cited-content_cbyCitation_article-title">Exendin‐4 from
              Heloderma suspectum
              venom: From discovery to its latest application as type
              II
              diabetes combatant. </span><span class="cited-content_cbyCitation_journal-name">Basic & Clinical Pharmacology & Toxicology</span><span> <strong>2019,</strong> <em>124 </em>
                                    (5)
                                     , 513-527. <a href="https://doi.org/10.1111/bcpt.13169" title="DOI URL">https://doi.org/10.1111/bcpt.13169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcpt.13169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcpt.13169%26sid%3Dliteratum%253Aachs%26jtitle%3DBasic%2520%2526%2520Clinical%2520Pharmacology%2520%2526%2520Toxicology%26atitle%3DExendin%2525E2%252580%2525904%252Bfrom%252BHeloderma%252Bsuspectum%252Bvenom%25253A%252BFrom%252Bdiscovery%252Bto%252Bits%252Blatest%252Bapplication%252Bas%252Btype%252BII%252Bdiabetes%252Bcombatant%26aulast%3DYap%26aufirst%3DMichelle%2BKhai%2BKhun%26date%3D2019%26date%3D2018%26volume%3D124%26issue%3D5%26spage%3D513%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katrine D.  Galsgaard</span>, <span class="hlFld-ContribAuthor ">Jens  Pedersen</span>, <span class="hlFld-ContribAuthor ">Filip K.  Knop</span>, <span class="hlFld-ContribAuthor ">Jens J.  Holst</span>, <span class="hlFld-ContribAuthor ">Nicolai J.  Wewer Albrechtsen</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon Receptor Signaling and Lipid Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Physiology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphys.2019.00413" title="DOI URL">https://doi.org/10.3389/fphys.2019.00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphys.2019.00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphys.2019.00413%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Physiology%26atitle%3DGlucagon%252BReceptor%252BSignaling%252Band%252BLipid%252BMetabolism%26aulast%3DGalsgaard%26aufirst%3DKatrine%2BD.%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleg G.  Chepurny</span>, <span class="hlFld-ContribAuthor ">Minos-Timotheos  Matsoukas</span>, <span class="hlFld-ContribAuthor ">George  Liapakis</span>, <span class="hlFld-ContribAuthor ">Colin A.  Leech</span>, <span class="hlFld-ContribAuthor ">Brandon T.  Milliken</span>, <span class="hlFld-ContribAuthor ">Robert P.  Doyle</span>, <span class="hlFld-ContribAuthor ">George G.  Holz</span>. </span><span class="cited-content_cbyCitation_article-title">Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2019,</strong> <em>294 </em>
                                    (10)
                                     , 3514-3531. <a href="https://doi.org/10.1074/jbc.RA118.005682" title="DOI URL">https://doi.org/10.1074/jbc.RA118.005682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA118.005682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA118.005682%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DNonconventional%252Bglucagon%252Band%252BGLP-1%252Breceptor%252Bagonist%252Band%252Bantagonist%252Binterplay%252Bat%252Bthe%252BGLP-1%252Breceptor%252Brevealed%252Bin%252Bhigh-throughput%252BFRET%252Bassays%252Bfor%252BcAMP%26aulast%3DChepurny%26aufirst%3DOleg%2BG.%26date%3D2019%26volume%3D294%26issue%3D10%26spage%3D3514%26epage%3D3531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javier  Gargallo-Vaamonde</span>, <span class="hlFld-ContribAuthor ">Gema  Frühbeck</span>, <span class="hlFld-ContribAuthor ">Javier  Salvador</span>. </span><span class="cited-content_cbyCitation_article-title">New advances and novel approaches in obesity pharmacotherapy. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Endocrine and Metabolic Research</span><span> <strong>2019,</strong> <em>4 </em>, 75-82. <a href="https://doi.org/10.1016/j.coemr.2018.08.003" title="DOI URL">https://doi.org/10.1016/j.coemr.2018.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coemr.2018.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coemr.2018.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Endocrine%2520and%2520Metabolic%2520Research%26atitle%3DNew%252Badvances%252Band%252Bnovel%252Bapproaches%252Bin%252Bobesity%252Bpharmacotherapy%26aulast%3DGargallo-Vaamonde%26aufirst%3DJavier%26date%3D2019%26volume%3D4%26spage%3D75%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoffer  Clemmensen</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Susanna M.  Hofmann</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Endocrinology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (2)
                                     , 90-104. <a href="https://doi.org/10.1038/s41574-018-0118-x" title="DOI URL">https://doi.org/10.1038/s41574-018-0118-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41574-018-0118-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41574-018-0118-x%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Endocrinology%26atitle%3DEmerging%252Bhormonal-based%252Bcombination%252Bpharmacotherapies%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetabolic%252Bdiseases%26aulast%3DClemmensen%26aufirst%3DChristoffer%26date%3D2019%26date%3D2018%26volume%3D15%26issue%3D2%26spage%3D90%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joachim  Tillner</span>, <span class="hlFld-ContribAuthor ">Maximilian G.  Posch</span>, <span class="hlFld-ContribAuthor ">Frank  Wagner</span>, <span class="hlFld-ContribAuthor ">Lenore  Teichert</span>, <span class="hlFld-ContribAuthor ">Youssef  Hijazi</span>, <span class="hlFld-ContribAuthor ">Christine  Einig</span>, <span class="hlFld-ContribAuthor ">Stefanie  Keil</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Philip J.  Larsen</span>. </span><span class="cited-content_cbyCitation_article-title">A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. </span><span class="cited-content_cbyCitation_journal-name">Diabetes, Obesity and Metabolism</span><span> <strong>2019,</strong> <em>21 </em>
                                    (1)
                                     , 120-128. <a href="https://doi.org/10.1111/dom.13494" title="DOI URL">https://doi.org/10.1111/dom.13494</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/dom.13494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fdom.13494%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%252C%2520Obesity%2520and%2520Metabolism%26atitle%3DA%252Bnovel%252Bdual%252Bglucagon-like%252Bpeptide%252Band%252Bglucagon%252Breceptor%252Bagonist%252BSAR425899%25253A%252BResults%252Bof%252Brandomized%25252C%252Bplacebo-controlled%252Bfirst-in-human%252Band%252Bfirst-in-patient%252Btrials%26aulast%3DTillner%26aufirst%3DJoachim%26date%3D2019%26date%3D2018%26volume%3D21%26issue%3D1%26spage%3D120%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Demartis</span>, <span class="hlFld-ContribAuthor ">Armin  Lahm</span>, <span class="hlFld-ContribAuthor ">Licia  Tomei</span>, <span class="hlFld-ContribAuthor ">Elisa  Beghetto</span>, <span class="hlFld-ContribAuthor ">Valentina  Di Biasio</span>, <span class="hlFld-ContribAuthor ">Federica  Orvieto</span>, <span class="hlFld-ContribAuthor ">Francesco  Frattolillo</span>, <span class="hlFld-ContribAuthor ">Paul E.  Carrington</span>, <span class="hlFld-ContribAuthor ">Sheena  Mumick</span>, <span class="hlFld-ContribAuthor ">Brian  Hawes</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Bianchi</span>, <span class="hlFld-ContribAuthor ">Anandan  Palani</span>, <span class="hlFld-ContribAuthor ">Antonello  Pessi</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-18494-5" title="DOI URL">https://doi.org/10.1038/s41598-017-18494-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-18494-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-18494-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPolypharmacy%252Bthrough%252BPhage%252BDisplay%25253A%252BSelection%252Bof%252BGlucagon%252Band%252BGLP-1%252BReceptor%252BCo-agonists%252Bfrom%252Ba%252BPhage-Displayed%252BPeptide%252BLibrary%26aulast%3DDemartis%26aufirst%3DAnna%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. D.  Müller</span>, <span class="hlFld-ContribAuthor ">C.  Clemmensen</span>, <span class="hlFld-ContribAuthor ">B.  Finan</span>, <span class="hlFld-ContribAuthor ">R. D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">M. H.  Tschöp</span>, . </span><span class="cited-content_cbyCitation_article-title">Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2018,</strong> <em>70 </em>
                                    (4)
                                     , 712-746. <a href="https://doi.org/10.1124/pr.117.014803" title="DOI URL">https://doi.org/10.1124/pr.117.014803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.117.014803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.117.014803%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DAnti-Obesity%252BTherapy%25253A%252Bfrom%252BRainbow%252BPills%252Bto%252BPolyagonists%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26date%3D2018%26date%3D2018%26volume%3D70%26issue%3D4%26spage%3D712%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Megan E  Capozzi</span>, <span class="hlFld-ContribAuthor ">Richard D  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H  Tschöp</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Jonathan E  Campbell</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. </span><span class="cited-content_cbyCitation_journal-name">Endocrine Reviews</span><span> <strong>2018,</strong> <em>39 </em>
                                    (5)
                                     , 719-738. <a href="https://doi.org/10.1210/er.2018-00117" title="DOI URL">https://doi.org/10.1210/er.2018-00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/er.2018-00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fer.2018-00117%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine%2520Reviews%26atitle%3DTargeting%252Bthe%252BIncretin%25252FGlucagon%252BSystem%252BWith%252BTriagonists%252Bto%252BTreat%252BDiabetes%26aulast%3DCapozzi%26aufirst%3DMegan%2BE%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D5%26spage%3D719%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ralf  Elvert</span>, <span class="hlFld-ContribAuthor ">Andreas W.  Herling</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Tilo  Weiss</span>, <span class="hlFld-ContribAuthor ">Baohong  Zhang</span>, <span class="hlFld-ContribAuthor ">Pierre  Wenski</span>, <span class="hlFld-ContribAuthor ">Jörn  Wandschneider</span>, <span class="hlFld-ContribAuthor ">Sabrina  Kleutsch</span>, <span class="hlFld-ContribAuthor ">Uwe  Butty</span>, <span class="hlFld-ContribAuthor ">Aimo  Kannt</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Angela  Dudda</span>, <span class="hlFld-ContribAuthor ">Martin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Stefanie  Keil</span>, <span class="hlFld-ContribAuthor ">Philip J.  Larsen</span>. </span><span class="cited-content_cbyCitation_article-title">Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. </span><span class="cited-content_cbyCitation_journal-name">Diabetes, Obesity and Metabolism</span><span> <strong>2018,</strong> <em>20 </em>
                                    (8)
                                     , 1836-1851. <a href="https://doi.org/10.1111/dom.13212" title="DOI URL">https://doi.org/10.1111/dom.13212</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/dom.13212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fdom.13212%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%252C%2520Obesity%2520and%2520Metabolism%26atitle%3DRunning%252Bon%252Bmixed%252Bfuel-dual%252Bagonistic%252Bapproach%252Bof%252BGLP-1%252Band%252BGCG%252Breceptors%252Bleads%252Bto%252Bbeneficial%252Bimpact%252Bon%252Bbody%252Bweight%252Band%252Bblood%252Bglucose%252Bcontrol%25253A%252BA%252Bcomparative%252Bstudy%252Bbetween%252Bmice%252Band%252Bnon-human%252Bprimates%26aulast%3DElvert%26aufirst%3DRalf%26date%3D2018%26date%3D2018%26volume%3D20%26issue%3D8%26spage%3D1836%26epage%3D1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ralf  Elvert</span>, <span class="hlFld-ContribAuthor ">Martin  Bossart</span>, <span class="hlFld-ContribAuthor ">Andreas W  Herling</span>, <span class="hlFld-ContribAuthor ">Tilo  Weiss</span>, <span class="hlFld-ContribAuthor ">Baohong  Zhang</span>, <span class="hlFld-ContribAuthor ">Aimo  Kannt</span>, <span class="hlFld-ContribAuthor ">Michael  Wagner</span>, <span class="hlFld-ContribAuthor ">Torsten  Haack</span>, <span class="hlFld-ContribAuthor ">Andreas  Evers</span>, <span class="hlFld-ContribAuthor ">Angela  Dudda</span>, <span class="hlFld-ContribAuthor ">Stefanie  Keil</span>, <span class="hlFld-ContribAuthor ">Martin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Katrin  Lorenz</span>, <span class="hlFld-ContribAuthor ">Michela  Riz</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Hennerici</span>, <span class="hlFld-ContribAuthor ">Philip J  Larsen</span>. </span><span class="cited-content_cbyCitation_article-title">Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. </span><span class="cited-content_cbyCitation_journal-name">Endocrinology</span><span> <strong>2018,</strong> <em>159 </em>
                                    (8)
                                     , 3105-3119. <a href="https://doi.org/10.1210/en.2018-00399" title="DOI URL">https://doi.org/10.1210/en.2018-00399</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/en.2018-00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fen.2018-00399%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrinology%26atitle%3DTeam%252BPlayers%252Bor%252BOpponents%25253A%252BCoadministration%252Bof%252BSelective%252BGlucagon%252Band%252BGLP-1%252BReceptor%252BAgonists%252Bin%252BObese%252BDiabetic%252BMonkeys%26aulast%3DElvert%26aufirst%3DRalf%26date%3D2018%26date%3D2018%26volume%3D159%26issue%3D8%26spage%3D3105%26epage%3D3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S J  Brandt</span>, <span class="hlFld-ContribAuthor ">M  Kleinert</span>, <span class="hlFld-ContribAuthor ">M H  Tschöp</span>, <span class="hlFld-ContribAuthor ">T D  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Are peptide conjugates the golden therapy against obesity?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Endocrinology</span><span> <strong>2018,</strong> <em>238 </em>
                                    (2)
                                     , R109-R119. <a href="https://doi.org/10.1530/JOE-18-0264" title="DOI URL">https://doi.org/10.1530/JOE-18-0264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/JOE-18-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FJOE-18-0264%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Endocrinology%26atitle%3DAre%252Bpeptide%252Bconjugates%252Bthe%252Bgolden%252Btherapy%252Bagainst%252Bobesity%25253F%26aulast%3DBrandt%26aufirst%3DS%2BJ%26date%3D2018%26volume%3D238%26issue%3D2%26spage%3DR109%26epage%3DR119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patrick J.  Knerr</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Vasily  Gelfanov</span>, <span class="hlFld-ContribAuthor ">Diego  Perez-Tilve</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Richard D.  DiMarchi</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of peptide-based polyagonists for treatment of diabetes and obesity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (10)
                                     , 2873-2881. <a href="https://doi.org/10.1016/j.bmc.2017.10.047" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.10.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.10.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.10.047%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bpeptide-based%252Bpolyagonists%252Bfor%252Btreatment%252Bof%252Bdiabetes%252Band%252Bobesity%26aulast%3DKnerr%26aufirst%3DPatrick%2BJ.%26date%3D2018%26volume%3D26%26issue%3D10%26spage%3D2873%26epage%3D2881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia Ying  Cheang</span>, <span class="hlFld-ContribAuthor ">Peter M.  Moyle</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (7)
                                     , 662-671. <a href="https://doi.org/10.1002/cmdc.201700781" title="DOI URL">https://doi.org/10.1002/cmdc.201700781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700781%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DGlucagon-Like%252BPeptide-1%252B%252528GLP-1%252529-Based%252BTherapeutics%25253A%252BCurrent%252BStatus%252Band%252BFuture%252BOpportunities%252Bbeyond%252BType%2525E2%252580%2525852%252BDiabetes%26aulast%3DCheang%26aufirst%3DJia%2BYing%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D7%26spage%3D662%26epage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara J.  Brandt</span>, <span class="hlFld-ContribAuthor ">Anna  Götz</span>, <span class="hlFld-ContribAuthor ">Matthias H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Gut hormone polyagonists for the treatment of type 2 diabetes. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2018,</strong> <em>100 </em>, 190-201. <a href="https://doi.org/10.1016/j.peptides.2017.12.021" title="DOI URL">https://doi.org/10.1016/j.peptides.2017.12.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2017.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2017.12.021%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DGut%252Bhormone%252Bpolyagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Btype%252B2%252Bdiabetes%26aulast%3DBrandt%26aufirst%3DSara%2BJ.%26date%3D2018%26volume%3D100%26spage%3D190%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Yingying  Fei</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xinyu  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  Liu</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Xenopus
              -derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2018,</strong> <em>175 </em>
                                    (3)
                                     , 544-557. <a href="https://doi.org/10.1111/bph.14107" title="DOI URL">https://doi.org/10.1111/bph.14107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14107%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DXenopus%252B-derived%252Bglucagon-like%252Bpeptide-1%252Band%252Bpolyethylene-glycosylated%252Bglucagon-like%252Bpeptide-1%252Breceptor%252Bagonists%25253A%252Blong-acting%252Bhypoglycaemic%252Band%252Binsulinotropic%252Bactivities%252Bwith%252Bpotential%252Btherapeutic%252Butilities%26aulast%3DHan%26aufirst%3DJing%26date%3D2018%26date%3D2018%26volume%3D175%26issue%3D3%26spage%3D544%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>, <span class="hlFld-ContribAuthor ">Lidan  Sun</span>, <span class="hlFld-ContribAuthor ">Yue  Han</span>, <span class="hlFld-ContribAuthor ">Qiuyi  Mao</span>, <span class="hlFld-ContribAuthor ">Fang  Liao</span>, <span class="hlFld-ContribAuthor ">Xinshi  Zheng</span>, <span class="hlFld-ContribAuthor ">Ke  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified
              Xenopus
              glucagon-like peptide-1 analogs. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 67-80. <a href="https://doi.org/10.1039/C7MD00471K" title="DOI URL">https://doi.org/10.1039/C7MD00471K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00471K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00471K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DSynthesis%252Band%252Bpharmaceutical%252Bcharacterization%252Bof%252Bsite%252Bspecific%252Bmycophenolic%252Bacid-modified%252BXenopus%252Bglucagon-like%252Bpeptide-1%252Banalogs%26aulast%3DHan%26aufirst%3DJing%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D67%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Chilukuri</span>, <span class="hlFld-ContribAuthor ">M. J.  Kulkarni</span>, <span class="hlFld-ContribAuthor ">M.  Fernandes</span>. </span><span class="cited-content_cbyCitation_article-title">Revisiting amino acids and peptides as anti-glycation agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (4)
                                     , 614-624. <a href="https://doi.org/10.1039/C7MD00514H" title="DOI URL">https://doi.org/10.1039/C7MD00514H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00514H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00514H%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DRevisiting%252Bamino%252Bacids%252Band%252Bpeptides%252Bas%252Banti-glycation%252Bagents%26aulast%3DChilukuri%26aufirst%3DH.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D614%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 3D structures of exendin-4 (derived from a NMR structure in solution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>), glucagon (derived from an X-ray structure, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1gcn">1gcn</a>), and binding hypotheses for these peptides to the extracellular domain (ECD) of the GLP-1 receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59">3c59</a>) and glucagon receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers">4ers</a>). The color coding of peptide residues is equivalent to the sequence color coding outlined in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Residue Trp25, which is exposed to the solvent in glucagon and shielded from the solvent by the Trp cage motif in exendin-4, is shown in spacefill representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeling hypotheses of <span class="smallcaps smallerCapital">d</span>-Ser2 variants containing an additional lysine residue, which is modified by addition of a palmitic acid at the ε-amino group using a γ-glutamic acid spacer in positions expected not to disturb receptor binding/activation. Full amino acid sequences and EC<sub>50</sub> values (in pM) of the corresponding peptides are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NMR structure of peptide <b>14</b> in solution. For structural clarity, only heavy atoms are depicted. (a) Superposition of 10 structures derived from a 2 ns restrained MD simulation “in water”. All backbone atoms of residues 9–37 were used for fitting. (b) Individual structure with the lowest constraint violation compared to the NMR structure of exendin-4 (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj">1jrj</a>). The secondary structure is shown in ribbon presentation, the palmitic acids side chain of peptide <b>14</b> is shown as spacefill.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Predicted binding mode of peptide <b>14</b> (color) to the full-length homology model of the glucagon receptor (orange), shown in ribbon representation.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The palmitic acid side chain of peptide <b>14</b> is shown in spacefill representation. (b) Key interactions of the N-terminal domain of the peptide with specific regions in the transmembrane domain of the receptor are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Relative body weight change (%) versus baseline values on day 0 prior to start of treatment. Female diet-induced obese (DIO) C57BL/6N mice are fed with standard diet (SD control), with high fat diet (HFD control) and HFD plus treatment with peptide <b>14</b> and liraglutide. Both control groups were treated with vehicle. All mice were treated twice daily with 50 μg/kg (b.i.d.). An oral glucose tolerance test (oGTT) was performed on day 21 of chronic treatment (data not shown), with an overnight starvation prior to glucose load. Relative weight loss is shown as mean values ± SEM, <i>n</i> = 8 per group. Black bar indicates statistically different body weight change from day 1 to day 33 of treatment for both peptides: (∗) <i>p</i> < 0.001 vs baseline and (#) vs HFD controls, one-way ANOVA with Dunnett’s post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/medium/jm-2017-00174x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. HbA1c (%), start vs end of study after 32 days. Female diabetic (db/db) mice were treated with vehicle or peptide <b>14</b> or liraglutide with 50 μg/kg twice daily. Data are shown as mean values ± SEM, <i>n</i> = 8 per group: (∗) <i>p</i> < 0.001 vs baseline and (#) vs db/db controls, one-way ANOVA with Dunnett’s post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00174/20170519/images/large/jm-2017-00174x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00174&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Farag, Y. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaballa, M. R.</span><span> </span><span class="NLM_article-title">Diabesity: An Overview of a Rising Epidemic</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1093/ndt/gfq576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1093%2Fndt%2Fgfq576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21045078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FlvFSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=28-35&issue=1&author=Y.+M.+K.+Faragauthor=M.+R.+Gaballa&title=Diabesity%3A+An+Overview+of+a+Rising+Epidemic&doi=10.1093%2Fndt%2Fgfq576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Diabesity: an overview of a rising epidemic</span></div><div class="casAuthors">Farag Youssef M K; Gaballa Mahmoud R</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">'Diabesity' is the term for diabetes occurring in the context of obesity.  In this review, we will overview the latest epidemiological data available describing the rising prevalence, health impact and economic impact of diabesity.  We will also outline the measures required to slowdown this newly evolving epidemic.  The global prevalence of diabetes in 2010 was 284 million people worldwide constituting around 6.4% of the world population, which is higher than was projected in earlier studies.  Furthermore, the projections for 2030 show the prevalence to reach 439 million individuals comprising ~7.7% of the world population.  The burden of diabetes on the world economy has been rising steadily in the last decade to reach $376 billion in 2010 and is expected to reach $490 billion in 2030.  Diabesity represents a substantial economic burden as reflected by diabetes and obesity consuming 14 and 5.7% of the USA's total health expenditure, respectively, representing the highest known expenditure on diabesity worldwide.  When costs associated with being overweight were also included, the upper limit of obesity expenditure rises to 9.1% of the USA's total healthcare expenditure.  The highest recorded expenditure on diabetes alone was in Saudi Arabia consuming 21% of the country's total health expenditure, with no data available about the health expenditure on obesity.  The health impact of diabesity is substantial to include long-term diabetic complications, reduction in health-related functioning, reduction of quality of life and reduced overall life expectancy.  Long-term complications include myocardial infarction, cerebrovascular stroke and end-stage renal disease.  Also recent advances have found that there is an association between chronic stress, depression and sleeping troubles to both diabetes and obesity.  This century is the unprecedented diabetogenic era in human history.  It is thus urgent to take steps including screening, prevention and early management in an attempt to control this evolving epidemic of diabesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSum7uGROUeDX6HPRus0rAafW6udTcc2eY8AwQH5fYM-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FlvFSgsw%253D%253D&md5=9188f8aa4eef047545c181eff170b42f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfq576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfq576%26sid%3Dliteratum%253Aachs%26aulast%3DFarag%26aufirst%3DY.%2BM.%2BK.%26aulast%3DGaballa%26aufirst%3DM.%2BR.%26atitle%3DDiabesity%253A%2520An%2520Overview%2520of%2520a%2520Rising%2520Epidemic%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2011%26volume%3D26%26issue%3D1%26spage%3D28%26epage%3D35%26doi%3D10.1093%2Fndt%2Fgfq576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ross, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzida, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khunti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligthelm, R. J.</span><span> </span><span class="NLM_article-title">Impact of Weight Gain on Outcomes in Type 2 Diabetes</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1431</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1185/03007995.2011.585396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1185%2F03007995.2011.585396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21599553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3MngvVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=1431-1438&issue=7&author=S.+A.+Rossauthor=G.+Dzidaauthor=J.+Voraauthor=K.+Khuntiauthor=M.+Kaiserauthor=R.+J.+Ligthelm&title=Impact+of+Weight+Gain+on+Outcomes+in+Type+2+Diabetes&doi=10.1185%2F03007995.2011.585396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of weight gain on outcomes in type 2 diabetes</span></div><div class="casAuthors">Ross Stuart A; Dzida Grzegorz; Vora Jiten; Khunti Kamlesh; Kaiser Marcel; Ligthelm Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Current medical research and opinion</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1431-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The majority of patients with type 2 diabetes mellitus (T2DM) are overweight or obese.  Obesity is a significant risk factor for increased morbidity and mortality in people with T2DM, and increased weight has been shown to worsen glycemic control and increase the risk of diabetes progression.  METHODS:  A search was conducted of the National Library of Medicine (PubMed) for articles published from 1990 to 2009 about the treatments of T2DM, relationship between T2DM and weight gain, obesity-related comorbidities of T2DM, and T2DM therapies associated with increased weight.  Reference lists of retrieved articles were reviewed for additional publications.  FINDINGS:  Results from large, prospective clinical trials have shown that weight reduction significantly improves glycemic control and blood pressure in T2DM patients and lowers the risk of progression of T2DM as well as CV disease and cancer.  Treatment-related weight gain is a side effect of many oral antidiabetes agents and insulin.  The thiazolidinediones (TZD), sulfonylureas, and glinides are associated with weight gain.  Despite the weight gain, TZDs also redistribute fat from the central to peripheral compartments, which may lead to a beneficial effect on insulin resistance.  Among insulin products, the basal insulin analog detemir is typically associated with a smaller weight increase than human insulin and insulin analog preparations, including glargine, biphasic, and prandial insulin regimens.  Alpha-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors are weight neutral, whereas glucagon-like peptide1-R agonists and metformin are associated with weight loss.  DISCUSSION:  An effective approach to management of the obese patient with diabetes is to communicate the significant benefits of a 1 kg reduction in body weight or prevention of weight gain on glycemic control and reduced morbidity and mortality.  LIMITATION:  This article is based on an extensive literature review rather than the prospective studies needed to define further the effect of weight gain on the management of T2DM.  CONCLUSION:  Weight management should be an integral part of a T2DM treatment strategy that includes selecting oral antidiabetes medications and insulin products that are weight beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGUU-12gBb3252AMpI4GK2fW6udTcc2eY8AwQH5fYM-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MngvVSquw%253D%253D&md5=0d8d603e4c20a738023b77b59a66f33d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1185%2F03007995.2011.585396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2011.585396%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DS.%2BA.%26aulast%3DDzida%26aufirst%3DG.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DKhunti%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DLigthelm%26aufirst%3DR.%2BJ.%26atitle%3DImpact%2520of%2520Weight%2520Gain%2520on%2520Outcomes%2520in%2520Type%25202%2520Diabetes%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2011%26volume%3D27%26issue%3D7%26spage%3D1431%26epage%3D1438%26doi%3D10.1185%2F03007995.2011.585396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Wadden, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronne, L.</span><span> </span><span class="NLM_article-title">NN8022–1923 Investigators. Weight Maintenance and Additional Weight Loss with Liraglutide after Low-Calorie-Diet-Induced Weight Loss: The SCALE Maintenance Randomized Study</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/ijo.2013.120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fijo.2013.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslynsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=1443-1451&issue=11&author=T.+A.+Waddenauthor=P.+Hollanderauthor=S.+Kleinauthor=K.+Niswenderauthor=V.+Wooauthor=P.+M.+Haleauthor=L.+Aronne&title=NN8022%E2%80%931923+Investigators.+Weight+Maintenance+and+Additional+Weight+Loss+with+Liraglutide+after+Low-Calorie-Diet-Induced+Weight+Loss%3A+The+SCALE+Maintenance+Randomized+Study&doi=10.1038%2Fijo.2013.120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study</span></div><div class="casAuthors">Wadden, T. A.; Hollander, P.; Klein, S.; Niswender, K.; Woo, V.; Hale, P. M.; Aronne, L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1443-1451</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced clin. meaningful wt. loss in a phase 2 study in obese individuals without diabetes.  The present randomized phase 3 trial assessed the efficacy of liraglutide in maintaining wt. loss achieved with a low-calorie diet (LCD).  Methods: Obese/overweight participants (≥18 years, body mass index ≥30 kg m-2 or ≥27 kg m-2 with comorbidities) who lost ≥5% of initial wt. during a LCD run-in were randomly assigned to liraglutide 3.0 mg per day or placebo (s.c. administration) for 56 wk.  Diet and exercise counseling were provided throughout the trial.  Co-primary end points were percentage wt. change from randomization, the proportion of participants that maintained the initial ≥5% wt. loss, and the proportion that lost ≥5% of randomization wt. (intention-to-treat anal.).  ClinicalTrials.gov identifier: NCT00781937.  Results: Participants (n=422) lost a mean 6.0% (s.d. 0.9) of screening wt. during run-in.  From randomization to week 56, wt. decreased an addnl. mean 6.2% (s.d. 7.3) with liraglutide and 0.2% (s.d. 7.0) with placebo (estd. difference -6.1% (95% class intervals -7.5 to -4.6), P<0.0001).  More participants receiving liraglutide (81.4%) maintained the ≥5% run-in wt. loss, compared with those receiving placebo (48.9%) (estd. odds ratio 4.8 (3.0; 7.7), P<0.0001), and 50.5% vs. 21.8% of participants lost ≥5% of randomization wt. (estd. odds ratio 3.9 (2.4; 6.1), P<0.0001).  Liraglutide produced small but statistically significant improvements in several cardiometabolic risk factors compared with placebo.  Gastrointestinal (GI) disorders were reported more frequently with liraglutide than placebo, but most events were transient, and mild or moderate in severity.  Conclusion: Liraglutide, with diet and exercise, maintained wt. loss achieved by caloric restriction and induced further wt. loss over 56 wk.  Improvements in some cardiovascular disease-risk factors were also obsd.  Liraglutide, prescribed as 3.0 mg per day, holds promise for improving the maintenance of lost wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqTz_P82QSLVg90H21EOLACvtfcHk0lg3P3XGg8PI8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslynsr3I&md5=bf1f08f83e6edc6c5003697d3eb405ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fijo.2013.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2013.120%26sid%3Dliteratum%253Aachs%26aulast%3DWadden%26aufirst%3DT.%2BA.%26aulast%3DHollander%26aufirst%3DP.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DNiswender%26aufirst%3DK.%26aulast%3DWoo%26aufirst%3DV.%26aulast%3DHale%26aufirst%3DP.%2BM.%26aulast%3DAronne%26aufirst%3DL.%26atitle%3DNN8022%25E2%2580%25931923%2520Investigators.%2520Weight%2520Maintenance%2520and%2520Additional%2520Weight%2520Loss%2520with%2520Liraglutide%2520after%2520Low-Calorie-Diet-Induced%2520Weight%2520Loss%253A%2520The%2520SCALE%2520Maintenance%2520Randomized%2520Study%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2013%26volume%3D37%26issue%3D11%26spage%3D1443%26epage%3D1451%26doi%3D10.1038%2Fijo.2013.120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pi-Sunyer, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujioka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenway, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpern, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krempf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, D. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">le Roux, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violante Ortiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, J. P. H.</span><span> </span><span class="NLM_article-title">SCALE Obesity and Prediabetes NN8022–1839 Study Group. A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1056%2FNEJMoa1411892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=26132939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbps1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=11-22&issue=1&author=X.+Pi-Sunyerauthor=A.+Astrupauthor=K.+Fujiokaauthor=F.+Greenwayauthor=A.+Halpernauthor=M.+Krempfauthor=D.+C.+W.+Lauauthor=C.+W.+le+Rouxauthor=R.+Violante+Ortizauthor=C.+B.+Jensenauthor=J.+P.+H.+Wilding&title=SCALE+Obesity+and+Prediabetes+NN8022%E2%80%931839+Study+Group.+A+Randomized%2C+Controlled+Trial+of+3.0+Mg+of+Liraglutide+in+Weight+Management&doi=10.1056%2FNEJMoa1411892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management</span></div><div class="casAuthors">Pi-Sunyer Xavier; Astrup Arne; Fujioka Ken; Greenway Frank; Halpern Alfredo; Krempf Michel; Lau David C W; le Roux Carel W; Violante Ortiz Rafael; Jensen Christine Bjorn; Wilding John P H</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone.  Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.  METHODS:  We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension.  We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification.  The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight.  RESULTS:  At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes.  At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).  A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001).  The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea.  Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group.  CONCLUSIONS:  In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOB_K8FQ7n-bqxQ2mb9Pu8fW6udTcc2eaCJN1KSiCgY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbps1GrsQ%253D%253D&md5=6ab59797f31ac5a44c9335007c96c211</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411892%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DFujioka%26aufirst%3DK.%26aulast%3DGreenway%26aufirst%3DF.%26aulast%3DHalpern%26aufirst%3DA.%26aulast%3DKrempf%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DD.%2BC.%2BW.%26aulast%3Dle%2BRoux%26aufirst%3DC.%2BW.%26aulast%3DViolante%2BOrtiz%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DC.%2BB.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DSCALE%2520Obesity%2520and%2520Prediabetes%2520NN8022%25E2%2580%25931839%2520Study%2520Group.%2520A%2520Randomized%252C%2520Controlled%2520Trial%2520of%25203.0%2520Mg%2520of%2520Liraglutide%2520in%2520Weight%2520Management%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D1%26spage%3D11%26epage%3D22%26doi%3D10.1056%2FNEJMoa1411892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Schulman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carleton, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehorn, J. C.</span><span> </span><span class="NLM_article-title">Effect of Glucagon on Food Intake and Body Weight in Man</span> <span class="citation_source-journal">J. Appl. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1957</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1957&pages=419-421&issue=3&author=J.+L.+Schulmanauthor=J.+L.+Carletonauthor=G.+Whitneyauthor=J.+C.+Whitehorn&title=Effect+of+Glucagon+on+Food+Intake+and+Body+Weight+in+Man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchulman%26aufirst%3DJ.%2BL.%26aulast%3DCarleton%26aufirst%3DJ.%2BL.%26aulast%3DWhitney%26aufirst%3DG.%26aulast%3DWhitehorn%26aufirst%3DJ.%2BC.%26atitle%3DEffect%2520of%2520Glucagon%2520on%2520Food%2520Intake%2520and%2520Body%2520Weight%2520in%2520Man%26jtitle%3DJ.%2520Appl.%2520Physiol.%26date%3D1957%26volume%3D11%26issue%3D3%26spage%3D419%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartness, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">The Metabolic Actions of Glucagon Revisited</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">697</span><span class="refDoi"> DOI: 10.1038/nrendo.2010.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnrendo.2010.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=20957001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=689-697&issue=12&author=K.+M.+Habeggerauthor=K.+M.+Heppnerauthor=N.+Gearyauthor=T.+J.+Bartnessauthor=R.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=The+Metabolic+Actions+of+Glucagon+Revisited&doi=10.1038%2Fnrendo.2010.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic actions of glucagon revisited</span></div><div class="casAuthors">Habegger, Kirk M.; Heppner, Kristy M.; Geary, Nori; Bartness, Timothy J.; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The diabetogenic effect of glucagon has long overshadowed the potential of this pancreatic hormone as an endogenous satiety and anti-obesity factor.  This Review discusses the role of glucagon as a beneficial endocrine factor in lipid and energy metab. and its potential as a therapeutic agent on the basis of studies that combine the agonism of glucagon receptor and glucagon-like peptide 1 receptor.  The initial identification of glucagon as a counter-regulatory hormone to insulin revealed this hormone to be of largely singular physiol. and pharmacol. purpose.  Glucagon agonism, however, has also been shown to exert effects on lipid metab., energy balance, body adipose tissue mass and food intake.  The ability of glucagon to stimulate energy expenditure, along with its hypolipidemic and satiating effects, in particular, make this hormone an attractive pharmaceutical agent for the treatment of dyslipidemia and obesity.  Studies that describe novel preclin. applications of glucagon, alone and in concert with glucagon-like peptide 1 agonism, have revealed potential benefits of glucagon agonism in the treatment of the metabolic syndrome.  Collectively, these observations challenge us to thoroughly investigate the physiol. and therapeutic potential of insulin's long-known opponent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOL0wBOH5c17Vg90H21EOLACvtfcHk0lh2QFNAEc9Rgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsL%252FE&md5=e9654fcb821e11f5388ef74e95513bc0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.187%26sid%3Dliteratum%253Aachs%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DHeppner%26aufirst%3DK.%2BM.%26aulast%3DGeary%26aufirst%3DN.%26aulast%3DBartness%26aufirst%3DT.%2BJ.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Metabolic%2520Actions%2520of%2520Glucagon%2520Revisited%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2010%26volume%3D6%26issue%3D12%26spage%3D689%26epage%3D697%26doi%3D10.1038%2Fnrendo.2010.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arafat, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapps, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alessio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharitonenkov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spranger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span> </span><span class="NLM_article-title">Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1453</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span><span class="refDoi"> DOI: 10.2337/db12-1116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdb12-1116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=1453-1463&issue=5&author=K.+M.+Habeggerauthor=K.+Stemmerauthor=C.+Chengauthor=T.+D.+M%C3%BCllerauthor=K.+M.+Heppnerauthor=N.+Ottawayauthor=J.+Hollandauthor=J.+L.+Hembreeauthor=D.+Smileyauthor=V.+Gelfanovauthor=R.+Krishnaauthor=A.+M.+Arafatauthor=A.+Konkarauthor=S.+Belliauthor=M.+Kappsauthor=S.+C.+Woodsauthor=S.+M.+Hofmannauthor=D.+D%E2%80%99Alessioauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+J.+Seeleyauthor=M.+Konishiauthor=N.+Itohauthor=A.+Kharitonenkovauthor=J.+Sprangerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=Fibroblast+Growth+Factor+21+Mediates+Specific+Glucagon+Actions&doi=10.2337%2Fdb12-1116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2337%2Fdb12-1116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb12-1116%26sid%3Dliteratum%253Aachs%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DHeppner%26aufirst%3DK.%2BM.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%2BL.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DArafat%26aufirst%3DA.%2BM.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DKapps%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DHofmann%26aufirst%3DS.%2BM.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DN.%26aulast%3DKharitonenkov%26aufirst%3DA.%26aulast%3DSpranger%26aufirst%3DJ.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DFibroblast%2520Growth%2520Factor%252021%2520Mediates%2520Specific%2520Glucagon%2520Actions%26jtitle%3DDiabetes%26date%3D2013%26volume%3D62%26issue%3D5%26spage%3D1453%26epage%3D1463%26doi%3D10.2337%2Fdb12-1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wynne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wren, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2390</span><span class="NLM_x">–</span> <span class="NLM_lpage">2395</span><span class="refDoi"> DOI: 10.2337/diabetes.54.8.2390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdiabetes.54.8.2390" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2390-2395&issue=8&author=K.+Wynneauthor=A.+J.+Parkauthor=C.+J.+Smallauthor=M.+Pattersonauthor=S.+M.+Ellisauthor=K.+G.+Murphyauthor=A.+M.+Wrenauthor=G.+S.+Frostauthor=K.+Meeranauthor=M.+A.+Ghateiauthor=S.+R.+Bloom&title=Subcutaneous+Oxyntomodulin+Reduces+Body+Weight+in+Overweight+and+Obese+Subjects%3A+A+Double-Blind%2C+Randomized%2C+Controlled+Trial&doi=10.2337%2Fdiabetes.54.8.2390"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.8.2390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.8.2390%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DPatterson%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DS.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BG.%26aulast%3DWren%26aufirst%3DA.%2BM.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DMeeran%26aufirst%3DK.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DSubcutaneous%2520Oxyntomodulin%2520Reduces%2520Body%2520Weight%2520in%2520Overweight%2520and%2520Obese%2520Subjects%253A%2520A%2520Double-Blind%252C%2520Randomized%252C%2520Controlled%2520Trial%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26issue%3D8%26spage%3D2390%26epage%3D2395%26doi%3D10.2337%2Fdiabetes.54.8.2390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Wynne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meeran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Oxyntomodulin Increases Energy Expenditure in Addition to Decreasing Energy Intake in Overweight and Obese Humans: A Randomised Controlled Trial</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1729</span><span class="NLM_x">–</span> <span class="NLM_lpage">1736</span><span class="refDoi"> DOI: 10.1038/sj.ijo.0803344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fsj.ijo.0803344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ClsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=1729-1736&issue=12&author=K.+Wynneauthor=A.+J.+Parkauthor=C.+J.+Smallauthor=K.+Meeranauthor=M.+A.+Ghateiauthor=G.+S.+Frostauthor=S.+R.+Bloom&title=Oxyntomodulin+Increases+Energy+Expenditure+in+Addition+to+Decreasing+Energy+Intake+in+Overweight+and+Obese+Humans%3A+A+Randomised+Controlled+Trial&doi=10.1038%2Fsj.ijo.0803344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial</span></div><div class="casAuthors">Wynne, K.; Park, A. J.; Small, C. J.; Meeran, K.; Ghatei, M. A.; Frost, G. S.; Bloom, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1729-1736</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Oxyntomodulin has recently been found to decrease body-wt. in obese humans and may be a potential anti-obesity therapy.  Objective:To det. whether oxyntomodulin alters energy expenditure, in addn. to reducing energy intake, in free-living' overweight and obese volunteers.  Design:Randomized double-blind controlled cross-over trial.  Setting:Community and hospital-based.  Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m2).  All volunteers completed the study protocol.Interventions:Four-day s.c. self-administration of pre-prandial oxyntomodulin, three times daily.  Participants were advised to maintain their normal dietary and exercise regimen.  Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.  Results: Oxyntomodulin administration reduced energy intake at the study meal by 128±29 kcal (P=0.0006) or 17.3±5.5% (P=0.0071), with no change in meal palatability.  Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143±109 kcal/day or 26.2±9.9% (P=0.0221); total energy expenditure by 9.4±4.8% (P=0.0454) and phys. activity level by 9.5±4.6% (P=0.0495).  A redn. in body wt. of 0.5±0.2% was obsd. during the oxyntomodulin administration period (P=0.0232).  Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in neg. energy balance.  This data supports the role of oxyntomodulin as a potential anti-obesity therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUKdXvSPC2VLVg90H21EOLACvtfcHk0lgFHO3mzpTpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ClsL%252FO&md5=ca668aed35743288fdff04e49b6d11a6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803344%26sid%3Dliteratum%253Aachs%26aulast%3DWynne%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DMeeran%26aufirst%3DK.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DOxyntomodulin%2520Increases%2520Energy%2520Expenditure%2520in%2520Addition%2520to%2520Decreasing%2520Energy%2520Intake%2520in%2520Overweight%2520and%2520Obese%2520Humans%253A%2520A%2520Randomised%2520Controlled%2520Trial%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2006%26volume%3D30%26issue%3D12%26spage%3D1729%26epage%3D1736%26doi%3D10.1038%2Fsj.ijo.0803344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nauck, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft-Nielsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willms, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span> </span><span class="NLM_article-title">Both Subcutaneously and Intravenously Administered Glucagon-like Peptide I Are Rapidly Degraded from the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1126</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.2337/diab.44.9.1126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdiab.44.9.1126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=7657039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK2MXotVGhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1995&pages=1126-1131&issue=9&author=C.+F.+Deaconauthor=M.+A.+Nauckauthor=M.+Toft-Nielsenauthor=L.+Pridalauthor=B.+Willmsauthor=J.+J.+Holst&title=Both+Subcutaneously+and+Intravenously+Administered+Glucagon-like+Peptide+I+Are+Rapidly+Degraded+from+the+NH2-Terminus+in+Type+II+Diabetic+Patients+and+in+Healthy+Subjects&doi=10.2337%2Fdiab.44.9.1126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects</span></div><div class="casAuthors">Deacon, Carolyn F.; Nauck, Michael A.; Toft-Nielsen, Maibritt; Pridal, Lone; Willms, Berend; Holst, Jens J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1126-31</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">The fate of exogenous glucagon-like peptide I (GLP-I)(7-36) amide was studied in nondiabetic and type II diabetic subjects using a combination of HPLC, specific RIAs, and a sensitive ELISA, whereby intact biol. active GLP-I and its metabolites could be detd.  After GLP-I administration, the intact peptide could be measured using an N-terminally direct RIA or ELISA, while the difference in concn. between these assays and a C-terminal-specific RIA allowed detn. of N-terminally truncated metabolites.  S.c. GLP-I was rapidly degraded in a time-dependent manner, forming a metabolite, which coeluted on HPLC with GLP-I(9-36) amide and had the same immunoreactive profile.  Thirty minutes after s.c. GLP-I administration to diabetic patients, the metabolite accounted for 88.5% of the increase in plasma immunoreactivity detd. by the C-terminal RIA, which was higher than the levels measured in healthy subjects (78.4%).  I.v. infused GLP-I was also extensively degraded, but no significant differences were seen between the 2 groups.  Intact GLP-I accounted for only 19.9% of the increase in immunoreactivity measured with the C-terminal RIA in normal subjects and 25.0% of the increase in diabetic subjects, the remainder being the N-terminally truncated metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4B-dpZvjbLVg90H21EOLACvtfcHk0lgFHO3mzpTpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotVGhu7c%253D&md5=f8a989897d4e40a0662d51cb89aba34f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2337%2Fdiab.44.9.1126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.44.9.1126%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DToft-Nielsen%26aufirst%3DM.%26aulast%3DPridal%26aufirst%3DL.%26aulast%3DWillms%26aufirst%3DB.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DBoth%2520Subcutaneously%2520and%2520Intravenously%2520Administered%2520Glucagon-like%2520Peptide%2520I%2520Are%2520Rapidly%2520Degraded%2520from%2520the%2520NH2-Terminus%2520in%2520Type%2520II%2520Diabetic%2520Patients%2520and%2520in%2520Healthy%2520Subjects%26jtitle%3DDiabetes%26date%3D1995%26volume%3D44%26issue%3D9%26spage%3D1126%26epage%3D1131%26doi%3D10.2337%2Fdiab.44.9.1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sountis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capito’, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2258</span><span class="NLM_x">–</span> <span class="NLM_lpage">2266</span><span class="refDoi"> DOI: 10.2337/db09-0278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdb09-0278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19602537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&issue=10&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiangauthor=F.+Liuauthor=C.+Millerauthor=L.+M.+Totaauthor=G.+Zhouauthor=X.+Zhangauthor=M.+M.+Sountisauthor=A.+Santopreteauthor=E.+Capito%E2%80%99author=G.+G.+Chicchiauthor=N.+Thornberryauthor=E.+Bianchiauthor=A.+Pessiauthor=D.+J.+Marshauthor=R.+SinhaRoy&title=Glucagon-Like+Peptide+1%2FGlucagon+Receptor+Dual+Agonism+Reverses+Obesity+in+Mice&doi=10.2337%2Fdb09-0278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span></div><div class="casAuthors">Pocai, Alessandro; Carrington, Paul E.; Adams, Jennifer R.; Wright, Michael; Eiermann, George; Zhu, Lan; Du, Xiaobing; Petrov, Aleksandr; Lassman, Michael E.; Jiang, Guoqiang; Liu, Franklin; Miller, Corey; Tota, Laurie M.; Zhou, Gaochao; Zhang, Xiaoping; Sountis, Michael M.; Santoprete, Alessia; Capito, Elena; Chicchi, Gary G.; Thornberry, Nancy; Bianchi, Elisabetta; Pessi, Antonello; Marsh, Donald J.; Sinha Roy, Ranabir</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2258-2266</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body wt. in obese subjects through increased energy expenditure and decreased energy intake.  The metabolic effects of OXM have been attributed primarily to GLP1R agonism.  We examd. whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist.  Research Design and Methods-We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics.  The metabolic effects of these two peptides with respect to wt. loss, caloric redn., glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice.  Acute studies in DIO mice revealed metabolic pathways that were modulated independent of wt. loss.  Studies in Glp1r-/- and Gcgr-/- mice enabled delineation of the contribution of GLP1R vs. GCGR activation to the pharmacol. of DualAG.  Results-Peptide DualAG exhibits superior wt. loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG.  Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG.  Dual receptor agonism also increased fatty acid oxidn. and reduced hepatic steatosis in DIO mice.  The antiobesity effects of DualAG require activation of both GLP1R and GCGR.  Conclusions-Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX2C2QNX0zG7Vg90H21EOLACvtfcHk0li6UpBbiP2QCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yku7jK&md5=412b04ba021de2fdfb2c6b011c289eeb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2337%2Fdb09-0278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb09-0278%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DTota%26aufirst%3DL.%2BM.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSountis%26aufirst%3DM.%2BM.%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapito%25E2%2580%2599%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26atitle%3DGlucagon-Like%2520Peptide%25201%252FGlucagon%2520Receptor%2520Dual%2520Agonism%2520Reverses%2520Obesity%2520in%2520Mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26issue%3D10%26spage%3D2258%26epage%3D2266%26doi%3D10.2337%2Fdb09-0278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capitò, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finotto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingallinella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zytko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bufali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veneziano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">DPP-IV-Resistant, Long-Acting Oxyntomodulin Derivatives</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/psc.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fpsc.1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21294225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVGis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=270-280&issue=4&author=A.+Santopreteauthor=E.+Capit%C3%B2author=P.+E.+Carringtonauthor=A.+Pocaiauthor=M.+Finottoauthor=A.+Langellaauthor=P.+Ingallinellaauthor=K.+Zytkoauthor=S.+Bufaliauthor=S.+Cianettiauthor=M.+Venezianoauthor=F.+Bonelliauthor=L.+Zhuauthor=E.+Monteagudoauthor=D.+J.+Marshauthor=R.+SinhaRoyauthor=E.+Bianchiauthor=A.+Pessi&title=DPP-IV-Resistant%2C+Long-Acting+Oxyntomodulin+Derivatives&doi=10.1002%2Fpsc.1328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">DPP-IV-resistant, long-acting oxyntomodulin derivatives</span></div><div class="casAuthors">Santoprete, Alessia; Capito, Elena; Carrington, Paul E.; Pocai, Alessandro; Finotto, Marco; Langella, Annunziata; Ingallinella, Paolo; Zytko, Karolina; Bufali, Simone; Cianetti, Simona; Veneziano, Maria; Bonelli, Fabio; Zhu, Lan; Monteagudo, Edith; Marsh, Donald J.; Sinha Roy, Ranabir; Bianchi, Elisabetta; Pessi, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-280</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Obesity is one of the major risk factors for type 2 diabetes, and the development of agents, that can simultaneously achieve glucose control and wt. loss, is being actively pursued.  Therapies based on peptide mimetics of the gut hormone glucagon-like peptide 1 (GLP-1) are rapidly gaining favor, due to their ability to increase insulin secretion in a strictly glucose-dependent manner, with little or no risk of hypoglycemia, and to their addnl. benefit of causing a modest, but durable wt. loss.  Oxyntomodulin (OXM), a 37-amino acid peptide hormone of the glucagon (GCG) family with dual agonistic activity on both the GLP-1 (GLP1R) and the GCG (GCGR) receptors, has been shown to reduce food intake and body wt. in humans, with a lower incidence of treatment-assocd. nausea than GLP-1 mimetics.  As for other peptide hormones, its clin. application is limited by the short circulatory half-life, a major component of which is cleavage by the enzyme dipeptidyl peptidase IV (DPP-IV).  SAR studies on OXM, described herein, led to the identification of mols. resistant to DPP-IV degrdn., with increased potency as compared to the natural hormone.  Analogs derivatized with a cholesterol moiety display increased duration of action in vivo.  Moreover, the authors identified a single substitution which can change the OXM pharmacol. profile from a dual GLP1R/GCGR agonist to a selective GLP1R agonist.  The latter finding enabled studies, described in detail in a sep. study, which highlight the potential of GLP1R/GCGR dual agonists as a potentially superior class of therapeutics over the pure GLP1R agonists currently in clin. use.  Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0kcyP1jgOzbVg90H21EOLACvtfcHk0li6UpBbiP2QCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVGis7o%253D&md5=e0197f794ec64e967c06081058f0b423</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1328%26sid%3Dliteratum%253Aachs%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapit%25C3%25B2%26aufirst%3DE.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DFinotto%26aufirst%3DM.%26aulast%3DLangella%26aufirst%3DA.%26aulast%3DIngallinella%26aufirst%3DP.%26aulast%3DZytko%26aufirst%3DK.%26aulast%3DBufali%26aufirst%3DS.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DVeneziano%26aufirst%3DM.%26aulast%3DBonelli%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DDPP-IV-Resistant%252C%2520Long-Acting%2520Oxyntomodulin%2520Derivatives%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2011%26volume%3D17%26issue%3D4%26spage%3D270%26epage%3D280%26doi%3D10.1002%2Fpsc.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">D-Ser2)Oxm[mPEG-PAL]: A Novel Chemically Modified Analogue of Oxyntomodulin with Antihyperglycaemic, Insulinotropic and Anorexigenic Actions</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1735</span><span class="refDoi"> DOI: 10.1016/j.bcp.2010.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bcp.2010.08.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=1727-1735&issue=11&author=B.+D.+Kerrauthor=P.+R.+Flattauthor=V.+A.+Gault&title=D-Ser2%29Oxm%5BmPEG-PAL%5D%3A+A+Novel+Chemically+Modified+Analogue+of+Oxyntomodulin+with+Antihyperglycaemic%2C+Insulinotropic+and+Anorexigenic+Actions&doi=10.1016%2Fj.bcp.2010.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DD-Ser2%2529Oxm%255BmPEG-PAL%255D%253A%2520A%2520Novel%2520Chemically%2520Modified%2520Analogue%2520of%2520Oxyntomodulin%2520with%2520Antihyperglycaemic%252C%2520Insulinotropic%2520and%2520Anorexigenic%2520Actions%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26issue%3D11%26spage%3D1727%26epage%3D1735%26doi%3D10.1016%2Fj.bcp.2010.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A Novel DPP IV-Resistant C-Terminally Extended Glucagon Analogue Exhibits Weight-Lowering and Diabetes-Protective Effects in High-Fat-Fed Mice Mediated through Glucagon and GLP-1 Receptor Activation</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1927</span><span class="NLM_x">–</span> <span class="NLM_lpage">1936</span><span class="refDoi"> DOI: 10.1007/s00125-014-3296-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1007%2Fs00125-014-3296-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1927-1936&issue=9&author=A.+M.+Lynchauthor=N.+Pathakauthor=V.+Pathakauthor=F.+P.+M.+O%E2%80%99Harteauthor=P.+R.+Flattauthor=N.+Irwinauthor=V.+A.+Gault&title=A+Novel+DPP+IV-Resistant+C-Terminally+Extended+Glucagon+Analogue+Exhibits+Weight-Lowering+and+Diabetes-Protective+Effects+in+High-Fat-Fed+Mice+Mediated+through+Glucagon+and+GLP-1+Receptor+Activation&doi=10.1007%2Fs00125-014-3296-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3296-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3296-7%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DPathak%26aufirst%3DN.%26aulast%3DPathak%26aufirst%3DV.%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520Novel%2520DPP%2520IV-Resistant%2520C-Terminally%2520Extended%2520Glucagon%2520Analogue%2520Exhibits%2520Weight-Lowering%2520and%2520Diabetes-Protective%2520Effects%2520in%2520High-Fat-Fed%2520Mice%2520Mediated%2520through%2520Glucagon%2520and%2520GLP-1%2520Receptor%2520Activation%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D9%26spage%3D1927%26epage%3D1936%26doi%3D10.1007%2Fs00125-014-3296-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Novel Dual Agonist Peptide Analogues Derived from Dogfish Glucagon Show Promising in Vitro Insulin Releasing Actions and Antihyperglycaemic Activity in Mice</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">431</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1016/j.mce.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.mce.2016.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27179756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2016&pages=133-144&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Novel+Dual+Agonist+Peptide+Analogues+Derived+from+Dogfish+Glucagon+Show+Promising+in+Vitro+Insulin+Releasing+Actions+and+Antihyperglycaemic+Activity+in+Mice&doi=10.1016%2Fj.mce.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The antidiabetic potential of thirteen novel dogfish glucagon derived analogs were assessed in vitro and in acute in vivo studies.  Stable peptide analogs enhanced insulin secretion from BRIN-BD11 β-cells (p < 0.001) and reduced acute glycemic responses following i.p. glucose (25 nmol/kg) in healthy NIH Swiss mice (p < 0.05-p<0.001).  The in vitro insulinotropic actions of [S2a]dogfish glucagon, [S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL, were blocked (p < 0.05-p<0.001) by the specific GLP-1 and glucagon receptor antagonists, exendin-4(9-39) and (desHis1Pro4Glu9)glucagon amide but not by (Pro3)GIP, indicating lack of GIP receptor involvement.  These analogs dose-dependently stimulated cAMP prodn. in GLP-1 and glucagon (p < 0.05-p<0.001) but not GIP-receptor transfected cells.  They improved acute glycemic and insulinotropic responses in high-fat fed diabetic mice and in wild-type C57BL/6J and GIPR-KO mice (p < 0.05-p<0.001), but not GLP-1R-KO mice, confirming action on GLP-1 but not GIP receptors.  Overall, dogfish glucagon analogs have potential for diabetes therapy, exerting beneficial metabolic effects via GLP-1 and glucagon receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYMG0tNkdC2LVg90H21EOLACvtfcHk0lhb5VAKbYBMnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1anur0%253D&md5=50d438aaa6ea3d9910faa9063c66f441</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Dual%2520Agonist%2520Peptide%2520Analogues%2520Derived%2520from%2520Dogfish%2520Glucagon%2520Show%2520Promising%2520in%2520Vitro%2520Insulin%2520Releasing%2520Actions%2520and%2520Antihyperglycaemic%2520Activity%2520in%2520Mice%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2016%26volume%3D431%26spage%3D133%26epage%3D144%26doi%3D10.1016%2Fj.mce.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">O’Harte, F. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Dogfish Glucagon Analogues Counter Hyperglycaemia and Enhance Both Insulin Secretion and Action in Diet-Induced Obese Diabetic Mice</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span><span class="refDoi"> DOI: 10.1111/dom.12713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fdom.12713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27357054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1013-1024&issue=10&author=F.+P.+M.+O%E2%80%99Harteauthor=M.+T.+Ngauthor=A.+M.+Lynchauthor=J.+M.+Conlonauthor=P.+R.+Flatt&title=Dogfish+Glucagon+Analogues+Counter+Hyperglycaemia+and+Enhance+Both+Insulin+Secretion+and+Action+in+Diet-Induced+Obese+Diabetic+Mice&doi=10.1111%2Fdom.12713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice</span></div><div class="casAuthors">O'Harte, F. P. M.; Ng, M. T.; Lynch, A. M.; Conlon, J. M.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1024</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To investigate the antidiabetic actions of three dogfish glucagon peptide analogs [known glucagon-like peptide-1 and glucagon receptor co-agonists] after chronic administration in diet-induced high-fat-diet-fed diabetic mice.  Materials and methods : National Institutes of Health Swiss mice were pre-conditioned to a high-fat diet (45% fat) for 100 days, and control mice were fed a normal diet (10% fat).  Normal diet control and high-fat-fed control mice received twice-daily i.p. (i.p.) saline injections, while the high-fat-fed treatment groups (n = 8) received twice-daily injections of exendin-4(1-39), [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (25 nmol/kg body wt.) for 51 days.  Results : After dogfish glucagon analog treatment, there was a rapid and sustained decrease in non-fasting blood glucose and an assocd. insulinotropic effect (anal. of variance, p < .05 to <.001) compared with saline-treated high-fat-fed controls.  All peptide treatments significantly improved i.p. and oral glucose tolerance with concomitant increased insulin secretion compared with saline-treated high-fat-fed controls (p <.05 to <.001).  After chronic treatment, no receptor desensitization was obsd. but insulin sensitivity was enhanced for all peptide-treated groups (p < .01 to <.001) except [S2a]dogfish glucagon.  Both exendin-4 and [S2a]dogfish glucagon exendin-4(31-39) significantly reduced plasma triglyceride concns. compared with those found in lean controls (p = .0105 and p = .0048, resp.).  Pancreatic insulin content was not affected by peptide treatments but [S2a]dogfish glucagon and [S2a]dogfish glucagon exendin-4(31-39) decreased pancreatic glucagon by 28%-34% (p = .0221 and p = .0075, resp.).  The percentage of β-cell area within islets was increased by exendin-4 and peptide analog treatment groups compared with high-fat-fed controls and the β-cell area decreased (p < .05 to <.01).  Conclusions : Overall, dogfish glucagon co-agonist analogs had several beneficial metabolic effects, showing therapeutic potential for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33HIW_8oZO7Vg90H21EOLACvtfcHk0lhb5VAKbYBMnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2qtbzF&md5=a6c619b6d47964b961f020ad88ea035a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fdom.12713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12713%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Harte%26aufirst%3DF.%2BP.%2BM.%26aulast%3DNg%26aufirst%3DM.%2BT.%26aulast%3DLynch%26aufirst%3DA.%2BM.%26aulast%3DConlon%26aufirst%3DJ.%2BM.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DDogfish%2520Glucagon%2520Analogues%2520Counter%2520Hyperglycaemia%2520and%2520Enhance%2520Both%2520Insulin%2520Secretion%2520and%2520Action%2520in%2520Diet-Induced%2520Obese%2520Diabetic%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3D10%26spage%3D1013%26epage%3D1024%26doi%3D10.1111%2Fdom.12713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Henderson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornigold, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch Fredin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson-Löfmark, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagroo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimsby, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jermutus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondinone, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M. P.</span><span> </span><span class="NLM_article-title">Robust Anti-Obesity and Metabolic Effects of a Dual GLP-1/Glucagon Receptor Peptide Agonist in Rodents and Non-Human Primates</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1176</span><span class="refDoi"> DOI: 10.1111/dom.12735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fdom.12735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27377054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1176&author=S.+J.+Hendersonauthor=A.+Konkarauthor=D.+C.+Hornigoldauthor=J.+L.+Trevaskisauthor=R.+Jacksonauthor=M.+Fritsch+Fredinauthor=R.+Jansson-L%C3%B6fmarkauthor=J.+Naylorauthor=A.+Rossiauthor=M.+A.+Bednarekauthor=N.+Bhagrooauthor=H.+Salariauthor=S.+Willauthor=S.+Oldhamauthor=G.+Hansenauthor=M.+Feighauthor=T.+Kleinauthor=J.+Grimsbyauthor=S.+Maguireauthor=L.+Jermutusauthor=C.+M.+Rondinoneauthor=M.+P.+Coghlan&title=Robust+Anti-Obesity+and+Metabolic+Effects+of+a+Dual+GLP-1%2FGlucagon+Receptor+Peptide+Agonist+in+Rodents+and+Non-Human+Primates&doi=10.1111%2Fdom.12735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates</span></div><div class="casAuthors">Henderson, S. J.; Konkar, A.; Hornigold, D. C.; Trevaskis, J. L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Loefmark, R.; Naylor, J.; Rossi, A.; Bednarek, M. A.; Bhagroo, N.; Salari, H.; Will, S.; Oldham, S.; Hansen, G.; Feigh, M.; Klein, T.; Grimsby, J.; Maguire, S.; Jermutus, L.; Rondinone, C. M.; Coghlan, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1176-1190</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To characterize the pharmacol. of MEDI0382, a peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors.  Materials and methods : MEDI0382 was evaluated in vitro for its ability to stimulate cAMP accumulation in cell lines expressing transfected recombinant or endogenous GLP-1 or glucagon receptors, to potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic β-cell lines and stimulate hepatic glucose output (HGO) by primary hepatocytes.  The ability of MEDI0382 to reduce body wt. and improve energy balance (i.e. food intake and energy expenditure), as well as control blood glucose, was evaluated in mouse models of obesity and healthy cynomolgus monkeys following single and repeated daily s.c. administration for up to 2 mo.  Results : MEDI0382 potently activated rodent, cynomolgus and human GLP-1 and glucagon receptors and exhibited a fivefold bias for activation of GLP-1 receptor vs. the glucagon receptor.  MEDI0382 produced superior wt. loss and comparable glucose lowering to the GLP-1 peptide analog liraglutide when administered daily at comparable doses in DIO mice.  The addnl. fat mass redn. elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor.  Notably, the significant wt. loss elicited by MEDI0382 in DIO mice was recapitulated in cynomolgus monkeys.  Conclusions : Repeated administration of MEDI0382 elicits profound wt. loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels.  The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving wt. and glucose control in overweight or obese Type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Lj1dV4AsLVg90H21EOLACvtfcHk0lhb5VAKbYBMnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGgsbnN&md5=e0af76d2553a265b6367aab1cc46df6f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fdom.12735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12735%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DS.%2BJ.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DHornigold%26aufirst%3DD.%2BC.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DJackson%26aufirst%3DR.%26aulast%3DFritsch%2BFredin%26aufirst%3DM.%26aulast%3DJansson-L%25C3%25B6fmark%26aufirst%3DR.%26aulast%3DNaylor%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26aulast%3DBhagroo%26aufirst%3DN.%26aulast%3DSalari%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DOldham%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DG.%26aulast%3DFeigh%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DGrimsby%26aufirst%3DJ.%26aulast%3DMaguire%26aufirst%3DS.%26aulast%3DJermutus%26aufirst%3DL.%26aulast%3DRondinone%26aufirst%3DC.%2BM.%26aulast%3DCoghlan%26aufirst%3DM.%2BP.%26atitle%3DRobust%2520Anti-Obesity%2520and%2520Metabolic%2520Effects%2520of%2520a%2520Dual%2520GLP-1%252FGlucagon%2520Receptor%2520Peptide%2520Agonist%2520in%2520Rodents%2520and%2520Non-Human%2520Primates%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D1176%26doi%3D10.1111%2Fdom.12735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>Pegapamodutide, C16H27N3O7S, PubChem. <a href="https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties" class="extLink">https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties</a> (accessed Mar 21,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pegapamodutide%2C+C16H27N3O7S%2C+PubChem.+https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fcompound%2F121494121%23section%3DChemical-and-Physical-Properties+%28accessed+Mar+21%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Transition Therapeutics Inc.</span><a href="http://www.transitiontherapeutics.com/technology/tt401.php" class="extLink">http://www.transitiontherapeutics.com/technology/tt401.php</a> (accessed Mar 21,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Transition+Therapeutics+Inc.http%3A%2F%2Fwww.transitiontherapeutics.com%2Ftechnology%2Ftt401.php+%28accessed+Mar+21%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&issue=1&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2eZTremBuH1yBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26issue%3D1%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Eng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raufman, J. P.</span><span> </span><span class="NLM_article-title">Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma Suspectum Venom. Further Evidence for an Exendin Receptor on Dispersed Acini from Guinea Pig Pancreas</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">7402</span><span class="NLM_x">–</span> <span class="NLM_lpage">7405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1313797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK38XktVantbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=7402-7405&issue=11&author=J.+Engauthor=W.+A.+Kleinmanauthor=L.+Singhauthor=G.+Singhauthor=J.+P.+Raufman&title=Isolation+and+Characterization+of+Exendin-4%2C+an+Exendin-3+Analogue%2C+from+Heloderma+Suspectum+Venom.+Further+Evidence+for+an+Exendin+Receptor+on+Dispersed+Acini+from+Guinea+Pig+Pancreas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and characterization of exendin-4, an exendin-3 analog, from Heloderma suspectum venom.  Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas</span></div><div class="casAuthors">Eng, John; Kleinman, Wayne A.; Singh, Latika; Singh, Gurcharn; Raufman, Jean Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7402-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">An amino acid sequencing assay for peptides contg. an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom.  Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical.  The structural differences make exendin-4 distinct from exendin-3 in its bioactivity.  In dispersed acini from guinea pig pancreas, natural and synthetic exendin-4 stimulate a monophasic increase in cAMP beginning at 100 pM that plateaus at 10 nM.  The exendin-4-induced increase in cAMP is inhibited progressively by increasing concns. of the exendin receptor antagonist, exendin-(9-39) amide.  Unlike exendin-3, exendin-4 does not stimulate a second rise in acinar cAMP at concns. >100 nM, does not stimulate amylase release, and does not inhibit the binding of radiolabeled vasoactive intestinal peptide to acini.  This indicates that in dispersed pancreatic acini, exendin-4 interacts only with the recently described exendin receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGIkNL-1j-OLVg90H21EOLACvtfcHk0lgeKRzee5z7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVantbw%253D&md5=30a9fa4a1a4f1b307babeb02750af81e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DKleinman%26aufirst%3DW.%2BA.%26aulast%3DSingh%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DRaufman%26aufirst%3DJ.%2BP.%26atitle%3DIsolation%2520and%2520Characterization%2520of%2520Exendin-4%252C%2520an%2520Exendin-3%2520Analogue%252C%2520from%2520Heloderma%2520Suspectum%2520Venom.%2520Further%2520Evidence%2520for%2520an%2520Exendin%2520Receptor%2520on%2520Dispersed%2520Acini%2520from%2520Guinea%2520Pig%2520Pancreas%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D11%26spage%3D7402%26epage%3D7405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gentilella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, C. M.</span><span> </span><span class="NLM_article-title">Exenatide: A Review from Pharmacology to Clinical Practice</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1111/j.1463-1326.2008.01018.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1463-1326.2008.01018.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19383034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnslKrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=544-556&issue=6&author=R.+Gentilellaauthor=C.+Bianchiauthor=A.+Rossiauthor=C.+M.+Rotella&title=Exenatide%3A+A+Review+from+Pharmacology+to+Clinical+Practice&doi=10.1111%2Fj.1463-1326.2008.01018.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Exenatide: a review from pharmacology to clinical practice</span></div><div class="casAuthors">Gentilella, R.; Bianchi, C.; Rossi, A.; Rotella, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-556</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Background: Exenatide is an incretin mimetic that activates glucagon-like-peptide-1 receptors.  It blunts the postprandial rise of plasma glucose by increasing glucose-dependent insulin secretion, suppressing inappropriately high glucagon secretion and delaying gastric emptying.  Methods: In seven clin. trials performed in 2845 adult patients with type 2 diabetes mellitus who were inadequately controlled by a sulfonylurea and/or metformin (glycosylated Hb, HbA1c ≤11%), or by thiazolidinediones (with or without metformin) and treated for periods from 16 wk to 3 years, exenatide (5 μg b.i.d. s.c. for the first 4 wk of treatment and 10 μg b.i.d. s.c. thereafter) reduced HbA1c, fasting and postprandial glucose, and body wt. dose dependently, and was similar to insulin glargine and biphasic insulin aspart in reducing HbA1c.  Body wt. diminished with exenatide, whereas it increased with both insulin prepns.  Pos. effects on the lipid profile and a redn. in C-reactive protein were also recorded with exenatide.  Treatment extensions up to 3 years showed that benefits were maintained in the long term.  Adverse events were usually mild to moderate in intensity, and generally the frequency decreased with continued therapy.  The most common was nausea (whose incidence may be reduced by gradual dose escalation from 5 μg b.i.d. to 10 μg b.i.d.), vomiting, diarrhoea, headache and hypoglycemia (almost exclusively in patients treated with a sulfonylurea).  Results and conclusions: Exenatide is a new, promising therapeutic option for type 2 diabetic patients inadequately controlled by oral agents, before insulin therapy, offering the added benefits of body wt. redn. and tight postprandial glucose control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpY_wods_kbVg90H21EOLACvtfcHk0lgeKRzee5z7Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnslKrtLc%253D&md5=654e14d148130da5589b20d28e8b08e0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2008.01018.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2008.01018.x%26sid%3Dliteratum%253Aachs%26aulast%3DGentilella%26aufirst%3DR.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRotella%26aufirst%3DC.%2BM.%26atitle%3DExenatide%253A%2520A%2520Review%2520from%2520Pharmacology%2520to%2520Clinical%2520Practice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2009%26volume%3D11%26issue%3D6%26spage%3D544%26epage%3D556%26doi%3D10.1111%2Fj.1463-1326.2008.01018.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Norris, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakurta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K. S.</span><span> </span><span class="NLM_article-title">Exenatide Efficacy and Safety: A Systematic Review</span> <span class="citation_source-journal">Diabetic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span><span class="refDoi"> DOI: 10.1111/j.1464-5491.2009.02790.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1464-5491.2009.02790.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19719703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=837-846&issue=9&author=S.+L.+Norrisauthor=N.+Leeauthor=S.+Thakurtaauthor=B.+K.+S.+Chan&title=Exenatide+Efficacy+and+Safety%3A+A+Systematic+Review&doi=10.1111%2Fj.1464-5491.2009.02790.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Exenatide efficacy and safety: a systematic review</span></div><div class="casAuthors">Norris, S. L.; Lee, N.; Thakurta, S.; Chan, B. K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetic Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-846</span>CODEN:
                <span class="NLM_cas:coden">DIMEEV</span>;
        ISSN:<span class="NLM_cas:issn">0742-3071</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Objective: To examine the efficacy, effectiveness and side effects of exenatide when compared with oral glucose-lowering agents or insulin therapy.  Research design and methods: Relevant citations were identified from searches of multiple bibliog. databases supplemented with searches of the US Food and Drug Administration website and other sources.  A qual. synthesis was performed, with a random effects meta-anal. when appropriate.  Results: We identified 17 studies.  In placebo-controlled trials of subjects with poorly controlled diabetes (with both groups receiving various oral glucose-lowering agents), exenatide 10 μg twice daily improved glycated Hb (HbA1c) by approx. 1.0% over 30 wk [pooled est. -0.97%, 95% confidence interval (CI), -1.16 to -0.79%, P < 0.0001] and exenatide treatment over 16-30 wk was assocd. with wt. loss of 1.0-2.5 kg.  Exenatide appeared to confer a similar benefit to various insulin regimes for glycemic control at follow-up between 16 and 52 wk (pooled est. HbA1c -0.04%, 95% CI, -0.14 to 0.06%, P = 0.41), but was advantageous over insulin with respect to wt. loss (3-6 kg loss at up to 52 wk of follow-up).  Nausea was the most common adverse event in placebo- and active-controlled trials.  Rates of hypoglycemia were similar in exenatide and insulin groups, but were higher with exenatide 10 μg twice daily compared with placebo and hypoglycemia was most frequent when a sulfonylurea was administered.  Conclusions: In subjects with poorly controlled diabetes, exenatide was assocd. with a redn. in HbA1c that was similar to introducing another oral agent or insulin.  Wt. loss may be an advantage with exenatide.  Long-term studies in diverse and unselected populations are needed to clarify the benefit vs. harm profile of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplZdRe2LxeZrVg90H21EOLACvtfcHk0lg96buGf4WdXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gnu7jI&md5=67e66917de24465a7ab4bfad9406df86</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-5491.2009.02790.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-5491.2009.02790.x%26sid%3Dliteratum%253Aachs%26aulast%3DNorris%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DThakurta%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DB.%2BK.%2BS.%26atitle%3DExenatide%2520Efficacy%2520and%2520Safety%253A%2520A%2520Systematic%2520Review%26jtitle%3DDiabetic%2520Med.%26date%3D2009%26volume%3D26%26issue%3D9%26spage%3D837%26epage%3D846%26doi%3D10.1111%2Fj.1464-5491.2009.02790.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Bunck, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliasson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaginian, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskinen, M.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yki-Jarvinen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamant, M.</span><span> </span><span class="NLM_article-title">Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2047</span><span class="refDoi"> DOI: 10.2337/dc11-0291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.2337%2Fdc11-0291" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=2041-2047&issue=9&author=M.+C.+Bunckauthor=A.+Cornerauthor=B.+Eliassonauthor=R.+J.+Heineauthor=R.+M.+Shaginianauthor=M.-R.+Taskinenauthor=U.+Smithauthor=H.+Yki-Jarvinenauthor=M.+Diamant&title=Effects+of+Exenatide+on+Measures+of+-Cell+Function+After+3+Years+in+Metformin-Treated+Patients+With+Type+2+Diabetes&doi=10.2337%2Fdc11-0291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2337%2Fdc11-0291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-0291%26sid%3Dliteratum%253Aachs%26aulast%3DBunck%26aufirst%3DM.%2BC.%26aulast%3DCorner%26aufirst%3DA.%26aulast%3DEliasson%26aufirst%3DB.%26aulast%3DHeine%26aufirst%3DR.%2BJ.%26aulast%3DShaginian%26aufirst%3DR.%2BM.%26aulast%3DTaskinen%26aufirst%3DM.-R.%26aulast%3DSmith%26aufirst%3DU.%26aulast%3DYki-Jarvinen%26aufirst%3DH.%26aulast%3DDiamant%26aufirst%3DM.%26atitle%3DEffects%2520of%2520Exenatide%2520on%2520Measures%2520of%2520-Cell%2520Function%2520After%25203%2520Years%2520in%2520Metformin-Treated%2520Patients%2520With%2520Type%25202%2520Diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2011%26volume%3D34%26issue%3D9%26spage%3D2041%26epage%3D2047%26doi%3D10.2337%2Fdc11-0291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dritselis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Liraglutide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1038/nrd3148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnrd3148" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=267-268&issue=4&author=D.+J.+Druckerauthor=A.+Dritselisauthor=P.+Kirkpatrick&title=Liraglutide&doi=10.1038%2Fnrd3148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3148%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDritselis%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DLiraglutide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D4%26spage%3D267%26epage%3D268%26doi%3D10.1038%2Fnrd3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Buse, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sesti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zychma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blonde, L.</span><span> </span><span class="NLM_article-title">Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x"> (</span><span class="NLM_issue">9683</span><span class="NLM_x">) </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/S0140-6736(09)60659-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2FS0140-6736%2809%2960659-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19515413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=39-47&issue=9683&author=J.+B.+Buseauthor=J.+Rosenstockauthor=G.+Sestiauthor=W.+E.+Schmidtauthor=E.+Montanyaauthor=J.+H.+Brettauthor=M.+Zychmaauthor=L.+Blonde&title=Liraglutide+Once+a+Day+versus+Exenatide+Twice+a+Day+for+Type+2+Diabetes%3A+A+26-Week+Randomised%2C+Parallel-Group%2C+Multinational%2C+Open-Label+Trial+%28LEAD-6%29&doi=10.1016%2FS0140-6736%2809%2960659-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)</span></div><div class="casAuthors">Buse, John B.; Rosenstock, Julio; Sesti, Giorgio; Schmidt, Wolfgang E.; Montanya, Eduard; Brett, Jason H.; Zychma, Marcin; Blonde, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9683</span>),
    <span class="NLM_cas:pages">39-47</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Unlike most antihyperglycemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote wt. loss.  We compared the efficacy and safety of liraglutide, a human GLP-1 analog, with exenatide, an exendin-based GLP-1 receptor agonist.  Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulfonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive addnl. liraglutide 1.8 mg once a day (n = 233) or exenatide 10 μg twice a day (n = 231) in a 26-wk open-label, parallel-group, multinational (15 countries) study.  The primary outcome was change in glycosylated Hb (HbA1c).  Efficacy analyses were by intention to treat.  The trial is registered with, no.  Mean baseline HbA1c for the study population was 8.2%.  Liraglutide reduced mean HbA1c significantly more than did exenatide (-1.12% [SE 0.08] vs -0.79% [0.08]; estd. treatment difference -0.33; 95% CI -0.47 to -0.18; p < 0.0001) and more patients achieved a HbA1c value of less than 7% (54%vs 43%, resp.; odds ratio 2.02; 95% CI 1.31 to 3.11; p = 0.0015).  Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mmol/L [SE 0.20] vs -0.60 mmol/L [0.20]; estd. treatment difference -1.01 mmol/L; 95% CI -1.37 to -0.65; p < 0.0001) but postprandial glucose control was less effective after breakfast and dinner.  Both drugs promoted similar wt. losses (liraglutide -3.24 kg vs exenatide -2.87 kg).  Both drugs were well tolerated, but nausea was less persistent (estd. treatment rate ratio 0.448, p < 0.0001) and minor hypoglycemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per yr; rate ratio 0.55; 95% CI 0.34 to 0.88; p = 0.0131; 25.5%vs 33.6% had minor hypoglycemia).  Two patients taking both exenatide and a sulfonylurea had a major hypoglycemic episode.  Liraglutide once a day provided significantly greater improvements in glycemic control than did exenatide twice a day, and was generally better tolerated.  The results suggest that liraglutide might be a treatment option for type 2 diabetes, esp. when wt. loss and risk of hypoglycemia are major considerations.  Funding: Novo Nordisk A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsh9qykvg7dLVg90H21EOLACvtfcHk0lg96buGf4WdXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgtb4%253D&md5=ac520ef9465d51345328acc40c5b6a1d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2960659-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252960659-0%26sid%3Dliteratum%253Aachs%26aulast%3DBuse%26aufirst%3DJ.%2BB.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DSesti%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DMontanya%26aufirst%3DE.%26aulast%3DBrett%26aufirst%3DJ.%2BH.%26aulast%3DZychma%26aufirst%3DM.%26aulast%3DBlonde%26aufirst%3DL.%26atitle%3DLiraglutide%2520Once%2520a%2520Day%2520versus%2520Exenatide%2520Twice%2520a%2520Day%2520for%2520Type%25202%2520Diabetes%253A%2520A%252026-Week%2520Randomised%252C%2520Parallel-Group%252C%2520Multinational%252C%2520Open-Label%2520Trial%2520%2528LEAD-6%2529%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26issue%3D9683%26spage%3D39%26epage%3D47%26doi%3D10.1016%2FS0140-6736%2809%2960659-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Neidigh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesinmeyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Designing a 20-Residue Protein</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1038/nsb798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnsb798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=11979279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=425-430&issue=6&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=N.+H.+Andersen&title=Designing+a+20-Residue+Protein&doi=10.1038%2Fnsb798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Designing a 20-residue protein</span></div><div class="casAuthors">Neidigh, Jonathan W.; Fesinmeyer, R. Matthew; Andersen, Niels H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">425-430</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Truncation and mutation of a poorly folded 39-residue peptide has produced 20-residue constructs that are >95% folded in water at physiol. pH.  These constructs optimize a novel fold, designated as the 'Trp-cage' motif, and are significantly more stable than any other miniprotein reported to date.  Folding is cooperative and hydrophobically driven by the encapsulation of a Trp side chain in a sheath of Pro rings.  As the smallest protein-like construct, Trp-cage miniproteins should provide a testing ground for both exptl. studies and computational simulations of protein folding and unfolding pathways.  Pro-Trp interactions may be a particularly effective strategy for the a priori design of self-folding peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLL9DJ-UavV7Vg90H21EOLACvtfcHk0lj694CWwhYREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFOms7g%253D&md5=4f82538a45b96f90d6e0e7a366a4f412</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsb798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb798%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DDesigning%2520a%252020-Residue%2520Protein%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26issue%3D6%26spage%3D425%26epage%3D430%26doi%3D10.1038%2Fnsb798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Neidigh, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesinmeyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickett, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Exendin-4 and Glucagon-like-Peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">13188</span><span class="NLM_x">–</span> <span class="NLM_lpage">13200</span><span class="refDoi"> DOI: 10.1021/bi010902s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi010902s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=13188-13200&issue=44&author=J.+W.+Neidighauthor=R.+M.+Fesinmeyerauthor=K.+S.+Prickettauthor=N.+H.+Andersen&title=Exendin-4+and+Glucagon-like-Peptide-1%3A+NMR+Structural+Comparisons+in+the+Solution+and+Micelle-Associated+States&doi=10.1021%2Fbi010902s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 and Glucagon-like-peptide-1: NMR Structural Comparisons in the Solution and Micelle-Associated States</span></div><div class="casAuthors">Neidigh, Jonathan W.; Fesinmeyer, R. Matthew; Prickett, Kathryn S.; Andersen, Niels H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13188-13200</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exendin-4, a 39 amino acid peptide originally isolated from the oral secretions of the lizard Heloderma suspectum, has been shown to share certain activities with glucagon-like-peptide-1 (GLP-1), a 30 amino acid peptide.  We have detd. the structuring preferences of exendin-4 and GLP-1 by NMR in both the soln. and dodecylphosphocholine (DPC) micelle-assocd. states.  Based on both chem. shift deviations and the pattern of intermediate range NOEs, both peptides display significant helicity from residue 7 to residue 28 with greater fraying at the N-terminus.  Thornton and Gorenstein [(1994) Biochem. 33, 3532-3539] reported that the presence of a flexible, helix-destabilizing, glycine at residue 16 in GLP-1 was an important feature for membrane and receptor binding. Exendin-4 has a helix-favoring glutamate as residue 16.  In the micelle-assocd. state, NMR data indicate that GLP-1 is less helical than exendin-4 due to the presence of Gly16; chem. shift deviations along the peptide sequence suggest that Gly16 serves as an N-cap for a second, more persistent, helix.  In 30 vol-% trifluoroethanol (TFE), a single continuous helix is evident in a significant fraction of the GLP-1 conformers present. Exendin-4 has a more regular and less fluxional helix in both media and displays stable tertiary structure in the soln. state.  In the micelle-bound state of exendin-4, a single helix (residues 11-27) is obsd. with residues 31-39 completely disordered and undergoing rapid segmental motion.  In aq. fluoroalc. or aq. glycol, the Leu21-Pro38 span of exendin-4 forms a compact tertiary fold (the Trp-cage) which shields the side chain of Trp25 from solvent exposure and produces ring current shifts as large as 3 ppm.  This tertiary structure is partially populated in water and fully populated in aq. TFE.  The Leu21-Pro38 segment of exendin-4 may be the smallest protein-like folding unit obsd. to date.  When the Trp-cage forms, fraying of the exendin-4 helix occurs exclusively from the N-terminus; backbone NHs for the C-terminal residues of the helix display H/D exchange protection factors as large as 105 at 9 °C.  In contrast, no tertiary structure is evident when exendin-4 binds to DPC micelles.  An energetically favorable insertion of the tryptophan ring into the DPC micelle is suggested as the basis for this change.  With the exception of exendin-4 in media contg. fluoro alc. cosolvents, NMR structure ensembles generated from the NOE data do not fully reflect the conformational averaging present in these systems.  Secondary structure definition from chem. shift deviations may be the most appropriate treatment for peptides that lack tertiary structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wHXw0VmZgrVg90H21EOLACvtfcHk0lj694CWwhYREg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFagt7s%253D&md5=ab4a09dd8ee0e83395452cccc42af447</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi010902s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi010902s%26sid%3Dliteratum%253Aachs%26aulast%3DNeidigh%26aufirst%3DJ.%2BW.%26aulast%3DFesinmeyer%26aufirst%3DR.%2BM.%26aulast%3DPrickett%26aufirst%3DK.%2BS.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExendin-4%2520and%2520Glucagon-like-Peptide-1%253A%2520NMR%2520Structural%2520Comparisons%2520in%2520the%2520Solution%2520and%2520Micelle-Associated%2520States%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26issue%3D44%26spage%3D13188%26epage%3D13200%26doi%3D10.1021%2Fbi010902s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Chabenne, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Optimization of the Native Glucagon Sequence for Medicinal Purposes</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1322</span><span class="NLM_x">–</span> <span class="NLM_lpage">1331</span><span class="refDoi"> DOI: 10.1177/193229681000400605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1177%2F193229681000400605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=21129326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1322-1331&issue=6&author=J.+R.+Chabenneauthor=M.+A.+DiMarchiauthor=V.+M.+Gelfanovauthor=R.+D.+DiMarchi&title=Optimization+of+the+Native+Glucagon+Sequence+for+Medicinal+Purposes&doi=10.1177%2F193229681000400605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the native glucagon sequence for medicinal purposes</span></div><div class="casAuthors">Chabenne Joseph R; DiMarchi Maria A; Gelfanov Vasily M; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes science and technology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1322-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glucagon is a life-saving medication used in the treatment of hypoglycemia.  It possesses poor solubility in aqueous buffers at or near physiological pH values.  At low and high pH, at which the peptide can be formulated to concentrations of a milligram or more per milliliter, the chemical integrity of the hormone is limited, as evidenced by the formation of multiple degradation-related peptides.  Consequently, the commercial preparation is provided as a lyophilized solid with an acidic diluent and directions for rendering it soluble at the time of use.  Any unused material is recommended for disposal immediately after initial use.  METHODS:  A set of glucagon analogs was prepared by solid-phase peptide synthesis to explore the identification of a glucagon analog with enhanced solubility and chemical stability at physiological pH.  The physical properties of the peptide analogs were studied by solubility determination, high-performance chromatography, and mass spectral analysis.  The biochemical properties were determined in engineered human embryonic kidney cell line 293 (HEK293) cells that overexpressed either the human glucagon or glucagon-like peptide-1 (GLP-1) receptors linked to a luciferase reporter gene.  RESULTS:  We observed the previously characterized formation of glucagon degradation products upon incubation of the peptide in dilute acid for extended periods or elevated temperature.  Lowering the isoelectric point of the hormone through the substitution of asparagine-28 with aspartic acid significantly increased the solubility at physiological pH.  Similarly, the C-terminal extension (Cex) of the hormone with an exendin-based, 10-residue, C-terminal sequence yielded a peptide of dramatically enhanced solubility.  These two glucagon analogs, D28 and Cex, maintained high potency and selectivity for the glucagon receptor relative to GLP-1 receptor.  CONCLUSIONS:  Glucagon presents unique structural challenges to the identification of an analog of high biological activity and selectivity that also possesses sufficient aqueous solubility and stability such that it might be developed as a ready-to-use medicine.  The glucagon analogs D28 and Cex demonstrated all of the chemical, physical, and biochemical properties supportive of further study as potential clinical candidates for treatment of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCyyMqEaCIRWfpMXQLRstfW6udTcc2ebjp7wi1hAdmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FhvVGnug%253D%253D&md5=9a27028640295b5f4a6c2bd040bcd120</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F193229681000400605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F193229681000400605%26sid%3Dliteratum%253Aachs%26aulast%3DChabenne%26aufirst%3DJ.%2BR.%26aulast%3DDiMarchi%26aufirst%3DM.%2BA.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOptimization%2520of%2520the%2520Native%2520Glucagon%2520Sequence%2520for%2520Medicinal%2520Purposes%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2010%26volume%3D4%26issue%3D6%26spage%3D1322%26epage%3D1331%26doi%3D10.1177%2F193229681000400605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Runge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Ligand-Bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">11340</span><span class="NLM_x">–</span> <span class="NLM_lpage">11347</span><span class="refDoi"> DOI: 10.1074/jbc.M708740200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M708740200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=18287102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11340-11347&issue=17&author=S.+Rungeauthor=H.+Th%C3%B8gersenauthor=K.+Madsenauthor=J.+Lauauthor=R.+Rudolph&title=Crystal+Structure+of+the+Ligand-Bound+Glucagon-like+Peptide-1+Receptor+Extracellular+Domain&doi=10.1074%2Fjbc.M708740200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain</span></div><div class="casAuthors">Runge, Steffen; Thogersen, Henning; Madsen, Kjeld; Lau, Jesper; Rudolph, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11340-11347</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide hormone glucagon-like peptide-1 (GLP-1).  GLP-1 is involved in glucose homeostasis, and activation of GLP-1R in the plasma membrane of pancreatic β-cells potentiates glucose-dependent insulin secretion.  The N-terminal extracellular domain (nGLP-1R) is an important ligand binding domain that binds GLP-1 and the homologous peptide Exendin-4 with differential affinity.  Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp cage", which is absent in GLP-1.  The Trp cage was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4.  However, the mol. details that govern ligand binding and specificity of nGLP-1R remain undefined.  Here the authors report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9-39) solved by the multiwavelength anomalous dispersion method to 2.2Å resoln.  The structure reveals that Exendin-4(9-39) is an amphipathic α-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R.  The Trp cage of Exendin-4 is not involved in binding to nGLP-1R.  The hydrophobic binding site of nGLP-1R is defined by discontinuous segments including primarily a well defined α-helix in the N terminus of nGLP-1R and a loop between two antiparallel β-strands.  The structure provides for the first time detailed mol. insight into ligand binding of the human GLP-1 receptor, an established target for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquCFNrYkVbPLVg90H21EOLACvtfcHk0lj9H-w82S4wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtr4%253D&md5=43529117c437b477afb23e0ba196b1b1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708740200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708740200%26sid%3Dliteratum%253Aachs%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Ligand-Bound%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Extracellular%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D17%26spage%3D11340%26epage%3D11347%26doi%3D10.1074%2Fjbc.M708740200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Underwood, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garibay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastrup, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedtz-Runge, S.</span><span> </span><span class="NLM_article-title">Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span><span class="refDoi"> DOI: 10.1074/jbc.M109.033829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M109.033829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=19861722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SqtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=723-730&issue=1&author=C.+R.+Underwoodauthor=P.+Garibayauthor=L.+B.+Knudsenauthor=S.+Hastrupauthor=G.+H.+Petersauthor=R.+Rudolphauthor=S.+Reedtz-Runge&title=Crystal+Structure+of+Glucagon-like+Peptide-1+in+Complex+with+the+Extracellular+Domain+of+the+Glucagon-like+Peptide-1+Receptor&doi=10.1074%2Fjbc.M109.033829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor</span></div><div class="casAuthors">Underwood, Christina Rye; Garibay, Patrick; Knudsen, Lotte Bjerre; Hastrup, Sven; Peters, Guenther H.; Rudolph, Rainer; Reedtz-Runge, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">723-730</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to food intake.  Activation of the GLP-1 receptor potentiates the synthesis and release of insulin from pancreatic β-cells in a glucose-dependent manner.  The GLP-1 receptor belongs to class B of the G-protein-coupled receptors, a subfamily characterized by a large N-terminal extracellular ligand binding domain.  Exendin-4 and GLP-1 are 50% identical, and exendin-4 is a full agonist with similar affinity and potency for the GLP-1 receptor.  We recently solved the crystal structure of the GLP-1 receptor extracellular domain in complex with the competitive antagonist exendin-4(9-39).  Interestingly, the isolated extracellular domain binds exendin-4 with much higher affinity than the endogenous agonist GLP-1.  Here, we have solved the crystal structure of the extracellular domain in complex with GLP-1 to 2.1 Åresoln.  The structure shows that important hydrophobic ligand-receptor interactions are conserved in agonist- and antagonist-bound forms of the extracellular domain, but certain residues in the ligand-binding site adopt a GLP-1-specific conformation.  GLP-1 is a kinked but continuous α-helix from Thr13 to Val33 when bound to the extracellular domain.  We supplemented the crystal structure with site-directed mutagenesis to link the structural information of the isolated extracellular domain with the binding properties of the full-length receptor.  The data support the existence of differences in the binding modes of GLP-1 and exendin-4 on the full-length GLP-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpex-ZPbuqSCrVg90H21EOLACvtfcHk0lj9H-w82S4wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SqtrrM&md5=59f7b2cee843c4299acab5900036172c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.033829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.033829%26sid%3Dliteratum%253Aachs%26aulast%3DUnderwood%26aufirst%3DC.%2BR.%26aulast%3DGaribay%26aufirst%3DP.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DHastrup%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DG.%2BH.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26atitle%3DCrystal%2520Structure%2520of%2520Glucagon-like%2520Peptide-1%2520in%2520Complex%2520with%2520the%2520Extracellular%2520Domain%2520of%2520the%2520Glucagon-like%2520Peptide-1%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26issue%3D1%26spage%3D723%26epage%3D730%26doi%3D10.1074%2Fjbc.M109.033829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Simonsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, C. F.</span><span> </span><span class="NLM_article-title">The C-Terminal Extension of Exendin-4 Provides Additional Metabolic Stability When Added to GLP-1, While There Is Minimal Effect of Truncating Exendin-4 in Anaesthetized Pigs</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.regpep.2012.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.regpep.2012.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=23318502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2jsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2013&pages=17-21&author=L.+Simonsenauthor=J.+J.+Holstauthor=K.+Madsenauthor=C.+F.+Deacon&title=The+C-Terminal+Extension+of+Exendin-4+Provides+Additional+Metabolic+Stability+When+Added+to+GLP-1%2C+While+There+Is+Minimal+Effect+of+Truncating+Exendin-4+in+Anaesthetized+Pigs&doi=10.1016%2Fj.regpep.2012.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anesthetized pigs</span></div><div class="casAuthors">Simonsen, L.; Holst, J. J.; Madsen, K.; Deacon, C. F.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-21</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The most striking sequence difference between glucagon-like peptide-1 (GLP-1) and the longer-acting GLP-1 receptor agonist, exendin-4 (Ex-4), is the nine-amino acid C-terminal extension of Ex-4.  The authors investigated the contribution of this extension to the survival time of Ex-4.  The authors assessed the overall metab. of GLP-1, Ex-4, a C-terminally extended GLP-1 peptide (GLP-1 + Ex(31-39); GLP-Ex), and a C-terminally truncated exendin peptide (Ex(1-30)) in anesthetized, catheterized pigs, with focus on the extn. across the kidneys and a peripheral tissue (a hindleg, representing muscle, adipose- and connective tissue).  Peptide anal. was carried out with assays against the mid-region of the peptides, whereby the role of dipeptidyl peptidase-4 (DPP-4) mediated N-terminal degrdn. could be disregarded.  The half-life of GLP-1 was significantly increased when the C-terminal extension of Ex-4 was added (GLP-1 4.8±3.3 min; GLP-Ex 19.5±3.3 min).  In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1 min; Ex(1-30) 28.4±1.7 min).  Ex-4 and Ex(1-30) were cleared solely by the kidneys at rates corresponding to the glomerular filtration rate (GFR), while GLP-1 and GLP-Ex were cleared by both the kidneys and peripheral tissues.  Both extn. rates were, however, significantly reduced with GLP-Ex compared to GLP-1.  The renal clearance rate of GLP-1 greatly exceeded GFR, while GLP-Ex was cleared at a rate resembling GFR.  In conclusion, the C-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addn. of this sequence to GLP-1 significantly reduces its clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmxwbNCyPNG7Vg90H21EOLACvtfcHk0lj9H-w82S4wkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2jsbw%253D&md5=a67fdc8032ef2a9ba23ac87e1f4c4484</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2012.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2012.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DSimonsen%26aufirst%3DL.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26atitle%3DThe%2520C-Terminal%2520Extension%2520of%2520Exendin-4%2520Provides%2520Additional%2520Metabolic%2520Stability%2520When%2520Added%2520to%2520GLP-1%252C%2520While%2520There%2520Is%2520Minimal%2520Effect%2520of%2520Truncating%2520Exendin-4%2520in%2520Anaesthetized%2520Pigs%26jtitle%3DRegul.%2520Pept.%26date%3D2013%26volume%3D181%26spage%3D17%26epage%3D21%26doi%3D10.1016%2Fj.regpep.2012.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Hudson, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, N. H.</span><span> </span><span class="NLM_article-title">Exenatide: NMR/CD Evaluation of the Medium Dependence of Conformation and Aggregation State</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1002/bip.20126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fbip.20126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=298-308&issue=4&author=F.+M.+Hudsonauthor=N.+H.+Andersen&title=Exenatide%3A+NMR%2FCD+Evaluation+of+the+Medium+Dependence+of+Conformation+and+Aggregation+State&doi=10.1002%2Fbip.20126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fbip.20126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20126%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DF.%2BM.%26aulast%3DAndersen%26aufirst%3DN.%2BH.%26atitle%3DExenatide%253A%2520NMR%252FCD%2520Evaluation%2520of%2520the%2520Medium%2520Dependence%2520of%2520Conformation%2520and%2520Aggregation%2520State%26jtitle%3DBiopolymers%26date%3D2004%26volume%3D76%26issue%3D4%26spage%3D298%26epage%3D308%26doi%3D10.1002%2Fbip.20126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madjidi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estevez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotzel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, B. B.</span><span> </span><span class="NLM_article-title">Molecular Basis for Negative Regulation of the Glucagon Receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">36</span><span class="NLM_x">) </span> <span class="NLM_fpage">14393</span><span class="NLM_x">–</span> <span class="NLM_lpage">14398</span><span class="refDoi"> DOI: 10.1073/pnas.1206734109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1073%2Fpnas.1206734109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=14393-14398&issue=36&author=C.+M.+Kothauthor=J.+M.+Murrayauthor=S.+Mukundauthor=A.+Madjidiauthor=A.+Minnauthor=H.+J.+Clarkeauthor=T.+Wongauthor=V.+Chiangauthor=E.+Luisauthor=A.+Estevezauthor=J.+Rondonauthor=Y.+Zhangauthor=I.+Hotzelauthor=B.+B.+Allan&title=Molecular+Basis+for+Negative+Regulation+of+the+Glucagon+Receptor&doi=10.1073%2Fpnas.1206734109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1206734109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1206734109%26sid%3Dliteratum%253Aachs%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DMadjidi%26aufirst%3DA.%26aulast%3DMinn%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DV.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DRondon%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHotzel%26aufirst%3DI.%26aulast%3DAllan%26aufirst%3DB.%2BB.%26atitle%3DMolecular%2520Basis%2520for%2520Negative%2520Regulation%2520of%2520the%2520Glucagon%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D36%26spage%3D14393%26epage%3D14398%26doi%3D10.1073%2Fpnas.1206734109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Sasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamiak, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T.</span><span> </span><span class="NLM_article-title">X-Ray Analysis of Glucagon and Its Relationship to Receptor Binding</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x"> (</span><span class="NLM_issue">5529</span><span class="NLM_x">) </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span><span class="refDoi"> DOI: 10.1038/257751a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2F257751a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=171582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaE28XislWjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1975&pages=751-757&issue=5529&author=K.+Sasakiauthor=S.+Dockerillauthor=D.+A.+Adamiakauthor=I.+J.+Tickleauthor=T.+Blundell&title=X-Ray+Analysis+of+Glucagon+and+Its+Relationship+to+Receptor+Binding&doi=10.1038%2F257751a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray analysis of glucagon and its relation to receptor binding</span></div><div class="casAuthors">Sasaki, Kyoyu; Dockerill, Susan; Adamiak, Dorota A.; Tickle, Ian J.; Blundell, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5529</span>),
    <span class="NLM_cas:pages">751-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-ray anal. of glucagon showed that in crystals the polypeptide adopted a mainly helical conformation, which was stabilized by hydrophobic interactions between mols. related by 3-fold symmetry.  A model is presented in which the glucagon mol. exists in dil. solns. as an equil. population of conformers with little retention of structure, and in which the helical conformation is stabilized by hydrophobic interactions either as an oligomer or as a complex with the receptor.  The relevance of the structure, which is compared with that of insulin, to storage in α cells is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfDTG1R-OBDLVg90H21EOLACvtfcHk0ljN8B02rOY7sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XislWjtw%253D%253D&md5=37d49f9d5ff7703acd7d3f3f41d88548</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2F257751a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F257751a0%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DDockerill%26aufirst%3DS.%26aulast%3DAdamiak%26aufirst%3DD.%2BA.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DBlundell%26aufirst%3DT.%26atitle%3DX-Ray%2520Analysis%2520of%2520Glucagon%2520and%2520Its%2520Relationship%2520to%2520Receptor%2520Binding%26jtitle%3DNature%26date%3D1975%26volume%3D257%26issue%3D5529%26spage%3D751%26epage%3D757%26doi%3D10.1038%2F257751a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Siu, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Graaf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the Human Glucagon Class B G-Protein-Coupled Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">499</span><span class="NLM_x"> (</span><span class="NLM_issue">7459</span><span class="NLM_x">) </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span><span class="refDoi"> DOI: 10.1038/nature12393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1038%2Fnature12393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=23863937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2013&pages=444-449&issue=7459&author=F.+Y.+Siuauthor=M.+Heauthor=C.+de+Graafauthor=G.+W.+Hanauthor=D.+Yangauthor=Z.+Zhangauthor=C.+Zhouauthor=Q.+Xuauthor=D.+Wackerauthor=J.+S.+Josephauthor=W.+Liuauthor=J.+Lauauthor=V.+Cherezovauthor=V.+Katritchauthor=M.-W.+Wangauthor=R.+C.+Stevens&title=Structure+of+the+Human+Glucagon+Class+B+G-Protein-Coupled+Receptor&doi=10.1038%2Fnature12393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human glucagon class B G-protein-coupled receptor</span></div><div class="casAuthors">Siu, Fai Yiu; He, Min; de Graaf, Chris; Han, Gye Won; Yang, Dehua; Zhang, Zhiyun; Zhou, Caihong; Xu, Qingping; Wacker, Daniel; Joseph, Jeremiah S.; Liu, Wei; Lau, Jesper; Cherezov, Vadim; Katritch, Vsevolod; Wang, Ming-Wei; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">7459</span>),
    <span class="NLM_cas:pages">444-449</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Binding of the glucagon peptide to the glucagon receptor (GCGR) triggers the release of glucose from the liver during fasting; thus GCGR plays an important role in glucose homeostasis.  Here we report the crystal structure of the seven transmembrane helical domain of human GCGR at 3.4 Å resoln., complemented by extensive site-specific mutagenesis, and a hybrid model of glucagon bound to GCGR to understand the mol. recognition of the receptor for its native ligand.  Beyond the shared seven transmembrane fold, the GCGR transmembrane domain deviates from class A G-protein-coupled receptors with a large ligand-binding pocket and the first transmembrane helix having a 'stalk' region that extends three alpha-helical turns above the plane of the membrane.  The stalk positions the extracellular domain (∼12 kilodaltons) relative to the membrane to form the glucagon-binding site that captures the peptide and facilitates the insertion of glucagon's amino terminus into the seven transmembrane domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXzQjGi9t48rVg90H21EOLACvtfcHk0ljN8B02rOY7sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWktbzN&md5=ba4801075b7fc13454710def7f083710</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature12393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12393%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DF.%2BY.%26aulast%3DHe%26aufirst%3DM.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DM.-W.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Glucagon%2520Class%2520B%2520G-Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2013%26volume%3D499%26issue%3D7459%26spage%3D444%26epage%3D449%26doi%3D10.1038%2Fnature12393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huusfeldt, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, F. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agersø, H.</span><span> </span><span class="NLM_article-title">Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1664</span><span class="NLM_x">–</span> <span class="NLM_lpage">1669</span><span class="refDoi"> DOI: 10.1021/jm9909645</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9909645" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1664-1669&issue=9&author=L.+B.+Knudsenauthor=P.+F.+Nielsenauthor=P.+O.+Huusfeldtauthor=N.+L.+Johansenauthor=K.+Madsenauthor=F.+Z.+Pedersenauthor=H.+Th%C3%B8gersenauthor=M.+Wilkenauthor=H.+Agers%C3%B8&title=Potent+Derivatives+of+Glucagon-like+Peptide-1+with+Pharmacokinetic+Properties+Suitable+for+Once+Daily+Administration&doi=10.1021%2Fjm9909645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration</span></div><div class="casAuthors">Knudsen, Lotte B.; Nielsen, Per F.; Huusfeldt, Per O.; Johansen, Nils L.; Madsen, Kjeld; Pedersen, Freddy Z.; Thogersen, Henning; Wilken, Michael; Agerso, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1664-1669</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of very potent derivs. of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described.  The compds. were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC50) of 55 pM for the cloned human GLP-1 receptor.  Many of the compds. had similar or even higher potencies, despite quite large substituents.  All compds. derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients.  A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency.  Derivatization with two fatty acid substituents led to a considerable loss of potency.  A structure-activity relationship on derivatization of specific amino acids generally was obtained.  It was found that the longer the fatty acid, the more potency was lost.  Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_iyZt3E6tG7Vg90H21EOLACvtfcHk0liY7u1f6txlQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKksLg%253D&md5=d050c27dd6aea795191798254e2bf080</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm9909645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9909645%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DHuusfeldt%26aufirst%3DP.%2BO.%26aulast%3DJohansen%26aufirst%3DN.%2BL.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DPedersen%26aufirst%3DF.%2BZ.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DM.%26aulast%3DAgers%25C3%25B8%26aufirst%3DH.%26atitle%3DPotent%2520Derivatives%2520of%2520Glucagon-like%2520Peptide-1%2520with%2520Pharmacokinetic%2520Properties%2520Suitable%2520for%2520Once%2520Daily%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D9%26spage%3D1664%26epage%3D1669%26doi%3D10.1021%2Fjm9909645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agersoe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thøgersen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, N. L.</span><span> </span><span class="NLM_article-title">Structure–Activity and Protraction Relationship of Long-Acting Glucagon-like Peptide-1 Derivatives: Importance of Fatty Acid Length, Polarity, and Bulkiness</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">6126</span><span class="NLM_x">–</span> <span class="NLM_lpage">6132</span><span class="refDoi"> DOI: 10.1021/jm070861j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070861j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6126-6132&issue=24&author=K.+Madsenauthor=L.+B.+Knudsenauthor=H.+Agersoeauthor=P.+F.+Nielsenauthor=H.+Th%C3%B8gersenauthor=M.+Wilkenauthor=N.+L.+Johansen&title=Structure%E2%80%93Activity+and+Protraction+Relationship+of+Long-Acting+Glucagon-like+Peptide-1+Derivatives%3A+Importance+of+Fatty+Acid+Length%2C+Polarity%2C+and+Bulkiness&doi=10.1021%2Fjm070861j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm070861j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070861j%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DAgersoe%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DP.%2BF.%26aulast%3DTh%25C3%25B8gersen%26aufirst%3DH.%26aulast%3DWilken%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DN.%2BL.%26atitle%3DStructure%25E2%2580%2593Activity%2520and%2520Protraction%2520Relationship%2520of%2520Long-Acting%2520Glucagon-like%2520Peptide-1%2520Derivatives%253A%2520Importance%2520of%2520Fatty%2520Acid%2520Length%252C%2520Polarity%252C%2520and%2520Bulkiness%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D24%26spage%3D6126%26epage%3D6132%26doi%3D10.1021%2Fjm070861j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Ward, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Peptide Lipidation Stabilizes Structure to Enhance Biological Function</span> <span class="citation_source-journal">Mol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1016/j.molmet.2013.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.molmet.2013.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=24327962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=468-479&issue=4&author=B.+P.+Wardauthor=N.+L.+Ottawayauthor=D.+Perez-Tilveauthor=D.+Maauthor=V.+M.+Gelfanovauthor=M.+H.+Tsch%C3%B6pauthor=R.+D.+DiMarchi&title=Peptide+Lipidation+Stabilizes+Structure+to+Enhance+Biological+Function&doi=10.1016%2Fj.molmet.2013.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide lipidation stabilizes structure to enhance biological function</span></div><div class="casAuthors">Ward, Brian P.; Ottaway, Nickki L.; Perez-Tilve, Diego; Ma, Dejian; Gelfanov, Vasily M.; Tschop, Matthias H.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-479</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Medicines that decrease body wt. and restore nutrient tolerance could improve human diabetes and obesity treatment outcomes.  We developed lipid-acylated glucagon analogs that are co-agonists for the glucagon and glucagon-like peptide 1 receptors, and stimulate wt. loss and plasma glucose lowering in pre-diabetic obese mice.  Our studies identified lipid acylation (lipidation) can increase and balance in vitro potencies of select glucagon analogs for the two aforementioned receptors in a lipidation site-dependent manner.  A general capacity for lipidation to enhance the secondary structure of glucagon analogs was recognized, and the energetics of this effect quantified.  The mol. structure of a lipid-acylated glucagon analog in water was also characterized.  These results support that lipidation can modify biol. activity through thermodynamically-favorable intramol. interactions which stabilize structure.  This establishes use of lipidation to achieve specific pharmacol. and implicates similar endogenous post-translational modifications as physiol. tools capable of refining biol. action in means previously underappreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nclxtgAVyLVg90H21EOLACvtfcHk0liY7u1f6txlQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgt77K&md5=021ed975227b94ca2d47394d22e19d1a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2013.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2013.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BP.%26aulast%3DOttaway%26aufirst%3DN.%2BL.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DGelfanov%26aufirst%3DV.%2BM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520Lipidation%2520Stabilizes%2520Structure%2520to%2520Enhance%2520Biological%2520Function%26jtitle%3DMol.%2520Metab.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D468%26epage%3D479%26doi%3D10.1016%2Fj.molmet.2013.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Amon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolios, N.</span><span> </span><span class="NLM_article-title">Lipidation and Glycosylation of a T Cell Antigen Receptor (TCR) Transmembrane Hydrophobic Peptide Dramatically Enhances in Vitro and in Vivo Function</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1763</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2006.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bbamcr.2006.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=16782215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWhsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1763&publication_year=2006&pages=879-888&issue=8&author=M.+A.+Amonauthor=M.+Aliauthor=V.+Benderauthor=Y.-N.+Chanauthor=I.+Tothauthor=N.+Manolios&title=Lipidation+and+Glycosylation+of+a+T+Cell+Antigen+Receptor+%28TCR%29+Transmembrane+Hydrophobic+Peptide+Dramatically+Enhances+in+Vitro+and+in+Vivo+Function&doi=10.1016%2Fj.bbamcr.2006.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function</span></div><div class="casAuthors">Amon, Michael A.; Ali, Marina; Bender, Vera; Chan, Yiu-Ngok; Toth, Istvan; Manolios, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1763</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">879-888</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A T cell antigen receptor (TCR) transmembrane sequence derived peptide (CP) has been shown to inhibit T cell activation both in vitro and in vivo at the membrane level of the receptor signal transduction.  To examine the effect of sugar or lipid conjugations on CP function, we linked CP to 1-aminoglucosesuccinate (GS), N-myristate (MYR), mono-di-tripalmitate (LP1, LP2, or LP3), and a lipoamino acid (LA) and examd. the effects of these compds. on T cell activation in vitro and by using a rat model of adjuvant-induced arthritis, in vivo.  In vitro, antigen presentation results demonstrated that lipid conjugation enhanced CP's ability to lower IL-2 prodn. from 56.99% ± 15.69 S.D. obsd. with CP, to 12.08% ± 3.34 S.D. obsd. with LA.  The sugar conjugate GS resulted in only a mild loss of in vitro activity compared to CP (82.95% ± 14.96 S.D.).  In vivo, lipid conjugation retarded the progression of adjuvant-induced arthritis by approx. 50%, whereas the sugar conjugated CP, GS, almost completely inhibited the progression of arthritis.  This study demonstrates that hydrophobic peptide activity is markedly enhanced in vitro and in vivo by conjugation to lipids or sugars.  This may have practical applications in drug delivery and bioavailability of hydrophobic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp65WRA7ptptbVg90H21EOLACvtfcHk0liY7u1f6txlQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWhsb4%253D&md5=919a3ab54dc57740d55fcf203abdede2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2006.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2006.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DAmon%26aufirst%3DM.%2BA.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DY.-N.%26aulast%3DToth%26aufirst%3DI.%26aulast%3DManolios%26aufirst%3DN.%26atitle%3DLipidation%2520and%2520Glycosylation%2520of%2520a%2520T%2520Cell%2520Antigen%2520Receptor%2520%2528TCR%2529%2520Transmembrane%2520Hydrophobic%2520Peptide%2520Dramatically%2520Enhances%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Function%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2006%26volume%3D1763%26issue%3D8%26spage%3D879%26epage%3D888%26doi%3D10.1016%2Fj.bbamcr.2006.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Sal-Man, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shai, Y.</span><span> </span><span class="NLM_article-title">The Identification of a Minimal Dimerization Motif QXXS That Enables Homo- and Hetero-Association of Transmembrane Helices in Vivo</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x"> (</span><span class="NLM_issue">29</span><span class="NLM_x">) </span> <span class="NLM_fpage">27449</span><span class="NLM_x">–</span> <span class="NLM_lpage">27457</span><span class="refDoi"> DOI: 10.1074/jbc.M503095200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1074%2Fjbc.M503095200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=27449-27457&issue=29&author=N.+Sal-Manauthor=D.+Gerberauthor=Y.+Shai&title=The+Identification+of+a+Minimal+Dimerization+Motif+QXXS+That+Enables+Homo-+and+Hetero-Association+of+Transmembrane+Helices+in+Vivo&doi=10.1074%2Fjbc.M503095200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M503095200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M503095200%26sid%3Dliteratum%253Aachs%26aulast%3DSal-Man%26aufirst%3DN.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DShai%26aufirst%3DY.%26atitle%3DThe%2520Identification%2520of%2520a%2520Minimal%2520Dimerization%2520Motif%2520QXXS%2520That%2520Enables%2520Homo-%2520and%2520Hetero-Association%2520of%2520Transmembrane%2520Helices%2520in%2520Vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D29%26spage%3D27449%26epage%3D27457%26doi%3D10.1074%2Fjbc.M503095200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Majerle, A.</span><span> </span><span class="NLM_article-title">Enhancement of Antibacterial and Lipopolysaccharide Binding Activities of a Human Lactoferrin Peptide Fragment by the Addition of Acyl Chain</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span><span class="refDoi"> DOI: 10.1093/jac/dkg219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1093%2Fjac%2Fdkg219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=12697647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=1159-1165&issue=5&author=A.+Majerle&title=Enhancement+of+Antibacterial+and+Lipopolysaccharide+Binding+Activities+of+a+Human+Lactoferrin+Peptide+Fragment+by+the+Addition+of+Acyl+Chain&doi=10.1093%2Fjac%2Fdkg219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain</span></div><div class="casAuthors">Majerle, Andreja; Kidric, Jurka; Jerala, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1159-1165</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cationic antibacterial peptides are potentially therapeutic in the treatment of sepsis, because of their amalgamated antibacterial and lipopolysaccharide-binding activities.  We prepd. acyl analogs of the peptide fragment of human lactoferrin, which originally had weak antibacterial activity.  It was found that 12 carbon units constitute the optimal acyl chain length, enhancing the antibacterial activity and binding of lipopolysaccharide by up to two orders of magnitude.  Lactoferrin-based lipopeptides approached the activity of polymyxin B, a lipopeptide of natural origin, but were also active against Gram-pos. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnoQ3lM7zAjbVg90H21EOLACvtfcHk0liVEuxqEtk5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVKlsbg%253D&md5=68abef2b99fb137c2d455f053aab5222</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg219%26sid%3Dliteratum%253Aachs%26aulast%3DMajerle%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520Antibacterial%2520and%2520Lipopolysaccharide%2520Binding%2520Activities%2520of%2520a%2520Human%2520Lactoferrin%2520Peptide%2520Fragment%2520by%2520the%2520Addition%2520of%2520Acyl%2520Chain%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26issue%3D5%26spage%3D1159%26epage%3D1165%26doi%3D10.1093%2Fjac%2Fdkg219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Stoffel, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macrae, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Premont, R. T.</span><span> </span><span class="NLM_article-title">Palmitoylation Increases the Kinase Activity of the G Protein-Coupled Receptor Kinase, GRK6</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x"> (</span><span class="NLM_issue">46</span><span class="NLM_x">) </span> <span class="NLM_fpage">16053</span><span class="NLM_x">–</span> <span class="NLM_lpage">16059</span><span class="refDoi"> DOI: 10.1021/bi981432d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981432d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=16053-16059&issue=46&author=R.+H.+Stoffelauthor=J.+Ingleseauthor=A.+D.+Macraeauthor=R.+J.+Lefkowitzauthor=R.+T.+Premont&title=Palmitoylation+Increases+the+Kinase+Activity+of+the+G+Protein-Coupled+Receptor+Kinase%2C+GRK6&doi=10.1021%2Fbi981432d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fbi981432d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981432d%26sid%3Dliteratum%253Aachs%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DMacrae%26aufirst%3DA.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26atitle%3DPalmitoylation%2520Increases%2520the%2520Kinase%2520Activity%2520of%2520the%2520G%2520Protein-Coupled%2520Receptor%2520Kinase%252C%2520GRK6%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26issue%3D46%26spage%3D16053%26epage%3D16059%26doi%3D10.1021%2Fbi981432d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Staes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Absil, P.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lins, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasseur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deleu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecouturier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fievez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">des Rieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mingeot-Leclercq, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raussens, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Préat, V.</span><span> </span><span class="NLM_article-title">Acylated and Unacylated Ghrelin Binding to Membranes and to Ghrelin Receptor: Towards a Better Understanding of the Underlying Mechanisms</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1798</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2102</span><span class="NLM_x">–</span> <span class="NLM_lpage">2113</span><span class="refDoi"> DOI: 10.1016/j.bbamem.2010.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2Fj.bbamem.2010.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=20637180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=2102-2113&issue=11&author=E.+Staesauthor=P.-A.+Absilauthor=L.+Linsauthor=R.+Brasseurauthor=M.+Deleuauthor=N.+Lecouturierauthor=V.+Fievezauthor=A.+des+Rieuxauthor=M.-P.+Mingeot-Leclercqauthor=V.+Raussensauthor=V.+Pr%C3%A9at&title=Acylated+and+Unacylated+Ghrelin+Binding+to+Membranes+and+to+Ghrelin+Receptor%3A+Towards+a+Better+Understanding+of+the+Underlying+Mechanisms&doi=10.1016%2Fj.bbamem.2010.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acylated and unacylated ghrelin binding to membranes and to ghrelin receptor: Towards a better understanding of the underlying mechanisms</span></div><div class="casAuthors">Staes, Edith; Absil, Pierre-Antoine; Lins, Laurence; Brasseur, Robert; Deleu, Magali; Lecouturier, Nathalie; Fievez, Virginie; des Rieux, Anne; Mingeot-Leclercq, Marie-Paule; Raussens, Vincent; Preat, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2102-2113</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The O-octanoylation of human ghrelin is a natural post-translational modification that enhances its binding to model membranes and could potentially play a central role in ghrelin biol. activities.  Here, we aimed to clarify the mechanisms that drive ghrelin to the membrane and hence to its receptor that mediates most of its endocrinol. effects.  As the acylation enhances ghrelin lipophilicity and that ghrelin contains many basic residues, we examd. the electrostatic attraction and/or hydrophobic interactions with membranes.  Using various liposomes and buffer conditions in binding, zeta potential and isothermal titrn. calorimetry studies, we found that whereas acylated and unacylated ghrelin were both electrostatically attracted towards the membrane, only acylated ghrelin penetrated into the headgroup and the lipid backbone regions of neg. charged membranes.  The O-acylation induced a 120-fold increase in ghrelin local concn. in the membrane.  However, acylated ghrelin did not deeply penetrate the membrane nor did it perturb its organization.  Conformational studies by CD and attenuated total reflection Fourier transformed IR as well as in silico modeling revealed that both forms of ghrelin mainly adopted the same structure in aq., micellar and bilayer environments even though acylated ghrelin structure is slightly more α-helical in a lipid bilayer environment.  Altogether our results suggest that membrane acts as a "catalyst" in acylated ghrelin binding to the ghrelin receptor and hence could explain why acylated and unacylated ghrelin are both full agonists of this receptor but in the nanomolar and micromolar range, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIf2UPZ5hvLLVg90H21EOLACvtfcHk0liVEuxqEtk5Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvE&md5=e7709c8683413d25a2adf016ef47d6df</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DStaes%26aufirst%3DE.%26aulast%3DAbsil%26aufirst%3DP.-A.%26aulast%3DLins%26aufirst%3DL.%26aulast%3DBrasseur%26aufirst%3DR.%26aulast%3DDeleu%26aufirst%3DM.%26aulast%3DLecouturier%26aufirst%3DN.%26aulast%3DFievez%26aufirst%3DV.%26aulast%3Ddes%2BRieux%26aufirst%3DA.%26aulast%3DMingeot-Leclercq%26aufirst%3DM.-P.%26aulast%3DRaussens%26aufirst%3DV.%26aulast%3DPr%25C3%25A9at%26aufirst%3DV.%26atitle%3DAcylated%2520and%2520Unacylated%2520Ghrelin%2520Binding%2520to%2520Membranes%2520and%2520to%2520Ghrelin%2520Receptor%253A%2520Towards%2520a%2520Better%2520Understanding%2520of%2520the%2520Underlying%2520Mechanisms%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26issue%3D11%26spage%3D2102%26epage%3D2113%26doi%3D10.1016%2Fj.bbamem.2010.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Elvert, R.; Herling, A.; Weiss, T.; Bossart, M.; Zhang, B.; Wenski, P.; Wandschneider, J.; Kleutsch, S.; Butty, U.; Kannt, A.; Wagner, M.; Haack, T.; Evers, A.; Dudda, A.; Larsen; Philip, J.</span><span> </span><span class="NLM_article-title">Running on Mixed Fuel: Dual Agonistic Approach of GLP-1 and GCG Receptors Leads to Beneficial Impact on Body Weight and Blood Glucose Control. A Comparative Study between Mice and Non-Human Primates</span>. Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Elvert%2C+R.%3B+Herling%2C+A.%3B+Weiss%2C+T.%3B+Bossart%2C+M.%3B+Zhang%2C+B.%3B+Wenski%2C+P.%3B+Wandschneider%2C+J.%3B+Kleutsch%2C+S.%3B+Butty%2C+U.%3B+Kannt%2C+A.%3B+Wagner%2C+M.%3B+Haack%2C+T.%3B+Evers%2C+A.%3B+Dudda%2C+A.%3B+Larsen%3B+Philip%2C+J.+Running+on+Mixed+Fuel%3A+Dual+Agonistic+Approach+of+GLP-1+and+GCG+Receptors+Leads+to+Beneficial+Impact+on+Body+Weight+and+Blood+Glucose+Control.+A+Comparative+Study+between+Mice+and+Non-Human+Primates.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DElvert%26aufirst%3DR.%26atitle%3DRunning%2520on%2520Mixed%2520Fuel%253A%2520Dual%2520Agonistic%2520Approach%2520of%2520GLP-1%2520and%2520GCG%2520Receptors%2520Leads%2520to%2520Beneficial%2520Impact%2520on%2520Body%2520Weight%2520and%2520Blood%2520Glucose%2520Control.%2520A%2520Comparative%2520Study%2520between%2520Mice%2520and%2520Non-Human%2520Primates" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschöp, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocai, A.</span><span> </span><span class="NLM_article-title">Optimization of Co-Agonism at GLP-1 and Glucagon Receptors to Safely Maximize Weight Reduction in DIO-Rodents</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1002/bip.22072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fbip.22072" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=443-450&issue=5&author=J.+W.+Dayauthor=V.+Gelfanovauthor=D.+Smileyauthor=P.+E.+Carringtonauthor=G.+Eiermannauthor=G.+Chicchiauthor=M.+D.+Erionauthor=J.+Giddaauthor=N.+A.+Thornberryauthor=M.+H.+Tsch%C3%B6pauthor=D.+J.+Marshauthor=R.+SinhaRoyauthor=R.+DiMarchiauthor=A.+Pocai&title=Optimization+of+Co-Agonism+at+GLP-1+and+Glucagon+Receptors+to+Safely+Maximize+Weight+Reduction+in+DIO-Rodents&doi=10.1002%2Fbip.22072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbip.22072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22072%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DChicchi%26aufirst%3DG.%26aulast%3DErion%26aufirst%3DM.%2BD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DPocai%26aufirst%3DA.%26atitle%3DOptimization%2520of%2520Co-Agonism%2520at%2520GLP-1%2520and%2520Glucagon%2520Receptors%2520to%2520Safely%2520Maximize%2520Weight%2520Reduction%2520in%2520DIO-Rodents%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26issue%3D5%26spage%3D443%26epage%3D450%26doi%3D10.1002%2Fbip.22072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pincus, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honig, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">A Hierarchical Approach to All-Atom Protein Loop Prediction</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1002/prot.10613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1002%2Fprot.10613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=15048827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=351-367&issue=2&author=M.+P.+Jacobsonauthor=D.+L.+Pincusauthor=C.+S.+Rappauthor=T.+J.+F.+Dayauthor=B.+Honigauthor=D.+E.+Shawauthor=R.+A.+Friesner&title=A+Hierarchical+Approach+to+All-Atom+Protein+Loop+Prediction&doi=10.1002%2Fprot.10613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A hierarchical approach to all-atom protein loop prediction</span></div><div class="casAuthors">Jacobson, Matthew P.; Pincus, David L.; Rapp, Chaya S.; Day, Tyler J. F.; Honig, Barry; Shaw, David E.; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-367</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The application of all-atom force fields (and explicit or implicit solvent models) to protein homol.-modeling tasks such as side-chain and loop prediction remains challenging both because of the expense of the individual energy calcns. and because of the difficulty of sampling the rugged all-atom energy surface.  Here the authors address this challenge for the problem of loop prediction through the development of numerous new algorithms, with an emphasis on multiscale and hierarchical techniques.  As a first step in evaluating the performance of the authors' loop prediction algorithm, the authors have applied it to the problem of reconstructing loops in native structures; the authors also explicitly include crystal packing to provide a fair comparison with crystal structures.  In brief, large nos. of loops are generated by using a dihedral angle-based buildup procedure followed by iterative cycles of clustering, side-chain optimization, and complete energy minimization of selected loop structures.  The authors evaluate this method by the largest test set yet used for validation of a loop prediction method, with a total of 833 loops ranging from 4 to 12 residues in length.  Av./median backbone root-mean-square deviations (RMSDs) to the native structures (superimposing the body of the protein, not the loop itself) are 0.42/0.24 Å for 5 residue loops, 1.00/0.44 Å for 8 residue loops, and 2.47/1.83 Å for 11 residue loops.  Median RMSDs are substantially lower than the avs. because of a small no. of outliers; the causes of these failures are examd. in some detail, and many can be attributed to errors in assignment of protonation states of titratable residues, omission of ligands from the simulation, and, in a few cases, probable errors in the exptl. detd. structures.  When these obvious problems in the data sets are filtered out, av. RMSDs to the native structures improve to 0.43 Å for 5 residue loops, 0.84 Å for 8 residue loops, and 1.63 Å for 11 residue loops.  In the vast majority of cases, the method locates energy min. that are lower than or equal to that of the minimized native loop, thus indicating that sampling rarely limits prediction accuracy.  The overall results are, to the authors' knowledge, the best reported to date, and the authors attribute this success to the combination of an accurate all-atom energy function, efficient methods for loop buildup and side-chain optimization, and, esp. for the longer loops, the hierarchical refinement protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHqYMnqaWXvLVg90H21EOLACvtfcHk0lhQ1L9TDlkgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKhsrc%253D&md5=e0eff655eeefb30ea00ae041ea9099c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fprot.10613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10613%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DPincus%26aufirst%3DD.%2BL.%26aulast%3DRapp%26aufirst%3DC.%2BS.%26aulast%3DDay%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DHonig%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DA%2520Hierarchical%2520Approach%2520to%2520All-Atom%2520Protein%2520Loop%2520Prediction%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D55%26issue%3D2%26spage%3D351%26epage%3D367%26doi%3D10.1002%2Fprot.10613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">King, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, G. B.</span><span> </span><span class="NLM_article-title">A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1111/j.1399-3011.1990.tb00976.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1111%2Fj.1399-3011.1990.tb00976.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=2279849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=255-266&issue=3&author=D.+S.+Kingauthor=C.+G.+Fieldsauthor=G.+B.+Fields&title=A+Cleavage+Method+Which+Minimizes+Side+Reactions+Following+Fmoc+Solid+Phase+Peptide+Synthesis&doi=10.1111%2Fj.1399-3011.1990.tb00976.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">King, David S.; Fields, Cynthia G.; Fields, Gregg B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-66</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">The success of solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl (Fmoc) amino acids is often limited by deleterious side reactions which occur during CF3CO2H (TFA) peptide-resin cleavage and side-chain deprotection.  The majority of these side reactions modify susceptible residues, such as Trp, Tyr, Met, and Cys, with TFA-liberated side-chain protecting groups and linkers.  The relative effectiveness of various scavengers in suppressing these side reactions was studied.  The cleavage mixt. 82.5% TFA : 5% H2O : 5% thioanisole : 2.5% 1,2-ethanedithiol (reagent K) was maximally efficient in inhibiting a great variety of side reactions.  Synthesis and cleavage of 10 peptides, each contg. 20-50 residues, demonstrated the complementarity of Fmoc chem. with reagent K for efficient synthesis of complex peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwcooNm7oD7Vg90H21EOLACvtfcHk0lhQ1L9TDlkgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVGktg%253D%253D&md5=ecf761fc6877559af82062c6345306ab</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00976.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00976.x%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DD.%2BS.%26aulast%3DFields%26aufirst%3DC.%2BG.%26aulast%3DFields%26aufirst%3DG.%2BB.%26atitle%3DA%2520Cleavage%2520Method%2520Which%2520Minimizes%2520Side%2520Reactions%2520Following%2520Fmoc%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26issue%3D3%26spage%3D255%26epage%3D266%26doi%3D10.1111%2Fj.1399-3011.1990.tb00976.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Chhabra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hothi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bycroft, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span> </span><span class="NLM_article-title">An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1606</span><span class="refDoi"> DOI: 10.1016/S0040-4039(97)10828-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;key=10.1016%2FS0040-4039%2897%2910828-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1603-1606&issue=12&author=S.+R.+Chhabraauthor=B.+Hothiauthor=D.+J.+Evansauthor=P.+D.+Whiteauthor=B.+W.+Bycroftauthor=W.+C.+Chan&title=An+Appraisal+of+New+Variants+of+Dde+Amine+Protecting+Group+for+Solid+Phase+Peptide+Synthesis&doi=10.1016%2FS0040-4039%2897%2910828-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2910828-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252910828-0%26sid%3Dliteratum%253Aachs%26aulast%3DChhabra%26aufirst%3DS.%2BR.%26aulast%3DHothi%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26aulast%3DBycroft%26aufirst%3DB.%2BW.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Appraisal%2520of%2520New%2520Variants%2520of%2520Dde%2520Amine%2520Protecting%2520Group%2520for%2520Solid%2520Phase%2520Peptide%2520Synthesis%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26issue%3D12%26spage%3D1603%26epage%3D1606%26doi%3D10.1016%2FS0040-4039%2897%2910828-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1jrj','PDB','1jrj'); return false;">PDB: 1jrj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1gcn" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1gcn','PDB','1gcn'); return false;">PDB: 1gcn</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c59','PDB','3c59'); return false;">PDB: 3c59</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ers','PDB','4ers'); return false;">PDB: 4ers</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3iol" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3iol','PDB','3iol'); return false;">PDB: 3iol</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c5t" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3c5t','PDB','3c5t'); return false;">PDB: 3c5t</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIQ','PDB','5NIQ'); return false;">PDB: 5NIQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00174">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74182"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00174">10.1021/acs.jmedchem.7b00174</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data with RP-HPLC retention times and molecular masses of the synthesized peptides, <sup>1</sup>H chemical shifts of peptide <b>14</b>, distance constraints used for the MD simulation obtained from NOESY spectra, and tabular results of pharmacokinetic data not shown in the manuscript (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00174/suppl_file/jm7b00174_si_001.pdf">jm7b00174_si_001.pdf (256.72 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for peptide <b>14</b> can be accessed using PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIQ">5NIQ</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00174%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-10%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00174" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679978b25afa3c8e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
